



PMI-0105

**PMI-0105 - Single-Dose Oral (Gavage) Toxicity
Study in Mice with a 14-Day Observation Period**

Final Report

DATA REQUIREMENT(S): European Community Guidelines for the Assessment of
Additives in Feeding Stuffs
US FDA Redbook 2000
US EPA Health Effects Test Guidelines
US EPA Microbial Pesticide Test Guidelines

AUTHOR(S): Chandrashekhar K. Korgaonkar, PhD, DABT

STUDY COMPLETION DATE: 3 April 2009

PERFORMING LABORATORY: WIL Research Laboratories, LLC
1407 George Road
Ashland, OH 44805-8946 USA

LABORATORY PROJECT ID: Study Number: WIL-639011

SPONSOR: Syngenta Crop Protection, Inc.
410 Swing Road
Greensboro, NC 27409 USA

STATEMENTS OF DATA CONFIDENTIALITY CLAIMS

This page intentionally left blank.

GOOD LABORATORY PRACTICE COMPLIANCE STATEMENT

This study, designated WIL-639011, was conducted in compliance with the United States Environmental Protection Agency (EPA) Good Laboratory Practice Standards (40 CFR Part 160), 16 October 1989 pursuant to the Federal Insecticide, Fungicide and Rodenticide Act, the standard operating procedures of WIL Research Laboratories, LLC, and the protocol as approved by the sponsor.


The protocol was designed to be in general accordance with the requirements for safety studies as defined by the following regulatory authorities:

The European Community (Guidelines for the Assessment of Additives in Feeding Stuff)

The United States of America Food and Drug Administration (Redbook 2000 Toxicological Principles for the Safety of Food Ingredients)

The United States of America Environmental Protection Agency (Health Effects Test Guidelines)

The United States of America Environmental Protection Agency (Microbial Pesticide Test Guidelines)



April 3, 2009

Chandrashekhar K. Korgaonkar, PhD, DABT **Date**
Study Director
Staff Toxicologist

Performing Laboratory:

WIL Research Laboratories, LLC
1407 George Road
Ashland, OH 44805-8946 USA

FLAGGING STATEMENT

This page intentionally left blank.

QUALITY ASSURANCE STATEMENT

Phases Inspected

<u>Date(s) of Inspection(s)</u>	<u>Phase Inspected</u>	<u>Date(s) Findings Reported to Study Director</u>	<u>Date(s) Findings Reported to Management</u>	<u>Auditor(s)</u>
12-Dec-2007	Test Substance Preparation	12-Dec-2007	17-Jan-2008	M.Stauffer
12-Dec-2007	Test Substance Administration	12-Dec-2007	17-Jan-2008	M.Salyers
17-Mar-2008	Study Records (I-1)	17-Mar-2008	24-Apr-2008	P.Brant
17-Mar-2008	Study Records (Rx-1)	17-Mar-2008	24-Apr-2008	P.Brant
17-Mar-2008	Study Records (C-1)	17-Mar-2008	24-Apr-2008	P.Brant
17-Mar-2008	Study Records (N-1)	17-Mar-2008	24-Apr-2008	P.Brant
17-Mar-2008	Study Records (H-1)	17-Mar-2008	24-Apr-2008	P.Brant
17-Mar-2008	Study Records (P-1)	17-Mar-2008	24-Apr-2008	P.Brant
17-Mar-2008 18-Mar-2008	Draft Pathology Report	18-Mar-2008	24-Apr-2008	P.Brant
17-Mar-2008 18-Mar-2008	Draft Report, excluding Pathology appendix	18-Mar-2008	24-Apr-2008	P.Brant

This study was inspected in accordance with the U.S. EPA Good Laboratory Practice Standards (40 CFR Part 160), the standard operating procedures of WIL Research Laboratories, LLC and the sponsor's protocol and protocol amendments, with the following exceptions. The data located in Appendix 1 (Certificate of Analysis) were the responsibility of the sponsor. Quality Assurance findings, derived from the inspections during the conduct of the study and from the inspections of the raw data and draft report, are documented and have been reported to the study director. A status report is submitted to management monthly.

This report accurately reflects the data generated during the study. The methods and procedures used in the study were those specified in the protocol, its amendments and the standard operating procedures of WIL Research Laboratories, LLC.


The raw data, the retention sample and the final report will be stored in the Archives at WIL Research Laboratories, LLC.

Quality Assurance Approval

Report Audited By:

Patricia A. Brant, RQAP-GLP, Senior Compliance Specialist*

Report Released By:

 3 Apr 2009
Heather L. Johnson, BS, RQAP-GLP Date
Manager, Quality Assurance

* = No longer employed by WIL Research Laboratories, LLC

KEY STUDY PERSONNEL AND REPORT SUBMISSION

Report Submitted By:



Chandrashekhar K. Korgaonkar, PhD, DABT
Staff Toxicologist, Toxicology
Study Director

3 April 2009

Date

Report Prepared By:




Troy M. Harter, BS
Associate Study Analyst

3 April 2009

Date

Report Reviewed By:



Christopher P. Chengelis, PhD, DABT
Vice President and
Chief Scientific Officer

3 April 2009


Date



Jozef J.W.M. Mertens, PhD, DABT
Director, Toxicology

3 April 2009

Date



Robert A. Wally, BS, RAC
Manager, Reporting and
Regulatory Technical Services

3 April 2009

Date

GENERAL INFORMATION

Contributors

The following contributed to this report in the capacities indicated:

Name	Title
Chandrashekhar K. Korgaonkar, PhD, DABT	Study Director
Susan C. Haley, BS	Manager, Clinical Pathology
Sally A. Keets, AS	Senior Operations Manager, Vivarium
Carol A. Kopp, BS, LAT	Manager, Gross Pathology and Developmental Toxicology Laboratory
Teresa D. Morris, BS	Senior Operations Manager, Toxicology
Theresa M. Rafeld, CPhT	Group Manager, Formulations Laboratory
Michael A. Safron, AS, HT (ASCP) ^{CM}	Manager, Histology
Bennett J. Varsho, MPH, DABT	Operations Manager, Developmental and Reproductive Toxicology and the Formulations Laboratory
Alaina Sauvé, MS	Sponsor Representative

Study dates

26 November 2007	Study director authorization to receive animals
27 November 2007	Experimental starting date (animal receipt)
3 December 2007	Study initiation date (protocol signed by study director)
12 December 2007	Experimental start date (administration of single oral dose; study day 0)
26 December 2007	Scheduled necropsy (study day 14)
7 February 2008	Experimental termination date (last histopathological examination)

Deviations from the guidelines

None

Deviations from the protocol

This study was conducted in accordance with the protocol and protocol amendments, except for the following.

- **Protocol Section 4.1.6** states the storage conditions for the test substance as frozen at approximately -20°C, desiccated. However, from 28 November 2007 to 12 December 2007, the test substance was only stored frozen (not desiccated). The test substance containers were moved to the desiccator in the freezer on 12 December 2007.
- **Protocol Section 8.5.2** states that serum chemistry parameters will be prioritized in a specific order. On 26 December 2007 (study day 14), the priority order for serum chemistry analysis was not followed for male no. 1641 (2000 mg/kg group). Gamma glutamyltransferase was tested prior to cholesterol, triglycerides, albumin, total protein, phosphorous, calcium and creatine kinase for this mouse.

These deviations did not negatively impact the quality or integrity of the data nor the outcome of the study.

Data Retention and Retention of Samples

The sponsor has title to all documentation records, raw data, specimens or other work product generated during the performance of the study. All work product generated by WIL Research Laboratories, LLC, including raw paper data and specimens, are retained in the Archives at WIL Research Laboratories, LLC, as specified in the study protocol.

Reserve samples of the test substance (if appropriate), pertinent electronic storage media and the original final report are retained in the Archives at WIL Research Laboratories, LLC in compliance with regulatory requirements.

TABLE OF CONTENTS

STATEMENTS OF DATA CONFIDENTIALITY CLAIMS	2
GOOD LABORATORY PRACTICE COMPLIANCE STATEMENT	3
FLAGGING STATEMENT	4
QUALITY ASSURANCE STATEMENT	5
KEY STUDY PERSONNEL AND REPORT SUBMISSION	7
GENERAL INFORMATION	8
TABLE OF CONTENTS	10
1.0 EXECUTIVE SUMMARY	13
1.1 Study design	13
1.2 Results	13
1.3 Conclusion	14
2.0 INTRODUCTION	15
2.1 Purpose	15
2.2 Regulatory guidelines	15
2.3 General Information	15
3.0 MATERIALS AND METHODS	16
3.1 Test substance	16
3.1.1 Vehicle identification and preparation	16
3.1.2 Preparation of test substance dosing formulation	16
3.1.3 Sampling and analyses	17
3.2 Experimental design	17
3.2.1 Test system	17
3.2.2 Organization of test groups, dose levels and treatment regimen	17
3.2.3 Animal receipt and acclimation/pretest period	18
3.2.4 Animal housing	18
3.2.5 Diet, drinking water and maintenance	18

3.2.6	Environmental conditions.....	19
3.2.7	Assignment of animals to treatment groups	19
3.3	<i>Ante mortem</i> investigations	19
3.3.1	Clinical observations and survival.....	19
3.3.2	Body weights	20
3.3.3	Food consumption	20
3.3.4	Clinical Pathology	20
3.3.4.1	Hematology	21
3.3.4.2	Serum Chemistry	21
3.4	<i>Post mortem</i> investigations.....	22
3.4.1	Macroscopic examination.....	22
3.4.2	Organ weights.....	23
3.4.3	Slide preparation and microscopic examination.....	24
3.5	Data evaluation.....	24
4.0	RESULTS AND DISCUSSION	25
4.1	Clinical observations and survival.....	25
4.2	Body weights	25
4.3	Food consumption	25
4.4	Clinical pathology.....	26
4.4.1	Hematology	26
4.4.2	Serum Chemistry	26
4.5	Anatomic pathology	27
4.5.1	Macroscopic examination.....	27
4.5.2	Organ weights.....	27
4.5.3	Microscopic examination	28
5.0	CONCLUSIONS	29
6.0	REFERENCES	30

TABLES SECTION	31
TABLE 1	Summary of Survival and Disposition 32
TABLE 2	Summary of Clinical Findings: Total Occurrence/No. of Animals (Detailed Physical Examinations/Dispositions) 34
TABLE 3	Summary of Clinical Findings: Total Occurrence/No. of Animals (Dosing Day Observations) 36
TABLE 4	Summary of Clinical Findings: Total Occurrence/No. of Animals (Daily Observations – Nondosing Days)..... 38
TABLE 5	Summary of Body Weights [g]..... 40
TABLE 6	Summary of Body Weight Changes [g] 50
TABLE 7	Summary of Cumulative Body Weight Changes [g]..... 58
TABLE 8	Summary of Food Consumption [g/animal/day] 64
TABLE 9	Summary of Hematology Values 70
TABLE 10	Summary of Serum Chemistry Values 82
TABLE 11	Summary of Macroscopic Findings..... 87
TABLE 12	Summary of Organ Weights and Relative Organ Weights 89
TABLE 13	Summary of Microscopic Findings 101
FIGURES SECTION	118
FIGURE 1	Summary of Body Weights [g] (Males) 119
FIGURE 2	Summary of Body Weights [g] (Females)..... 120
APPENDICES SECTION	121
APPENDIX 1	Certificate of Analysis 122
APPENDIX 2	Pretest Clinical Observations 124
APPENDIX 3	Animal Room Environmental Conditions 127
APPENDIX 4	Unscheduled Clinical Observations 132
APPENDIX 5	Clinical Pathology Method, Procedures and References..... 134
APPENDIX 6	Pathology Report (WIL Research Laboratories, LLC) 139
APPENDIX 7	Individual Animal Data 157

1.0 EXECUTIVE SUMMARY

1.1 Study design

Test substance PMI-0105, containing the active ingredient phosphomannose isomerase protein (89.5% purity w/w), was administered as a single oral gavage dose to groups of five male and five female Crl:CD-1(ICR) mice at 0 or 2000 mg active ingredient/ kg body weight. Deionized water was used as the vehicle and administered to the control group. The dosing formulations were administered at a dose volume of 10 mL/kg. All animals were euthanized after a 14-day observation period following dosing.

All animals were observed twice daily for mortality and moribundity. Clinical examinations were performed at the time of dosing, approximately 1-2 hours post-dosing and approximately 4-5 hours post-dosing on the day of dose administration (study day 0) and once daily on non-dosing days (study days 1-13). Detailed physical examinations were performed weekly. Individual body weights and food consumption were recorded daily during the study. Clinical pathology evaluations (hematology and serum chemistry) were performed on all animals prior to the scheduled necropsy. Complete necropsies were conducted on all animals, and selected organs were weighed at the scheduled necropsy. Selected tissues were examined microscopically from all animals.

1.2 Results

All animals survived the 14-day observation period following dosing, up until the scheduled necropsy. There were no test substance-related clinical observations. There were no test substance-related effects on body weight or weight gain, food consumption or hematology parameters. There were no macroscopic or microscopic findings that were attributable to the test substance.

Higher urea nitrogen levels (males only), slightly higher alkaline phosphatase levels (males only) and slightly higher alanine aminotransferase levels (females only) were noted in the 2000 mg/kg group compared with the control group, and were considered test substance-related. However, these changes in serum chemistry parameters were considered non-adverse as there were no histopathological correlates and the group mean values were within WIL Historical control ranges (Version 2.5), except for one male mouse which had urea nitrogen levels exceeding the historical control range.

Statistically significantly lower testicular and epididymal weights in males and slightly higher adrenal weights in females were noted in the 2000 mg/kg group compared with the control group, and were considered test substance-related. However, there were no distinct microscopic changes in these organs, and the organ weights were within the WIL Historical control ranges (Version 2.6), suggesting that organ weight alterations probably represented physiologic responses of a non-adverse nature.

1.3 Conclusion

Test substance PMI-0105, containing the active ingredient phosphomannose isomerase protein (89.5% purity w/w), administered as a single oral gavage dose at 0 or 2000 mg active ingredient/ kg body weight followed by a 14-day observation period was well tolerated in male and female CD1 mice. All mice survived without clinical signs of physical impairment or physiologic dysfunction. There were no test substance-related clinical observations. There were no test substance-related effects on body weight or weight gain, food consumption or hematology parameters. There were no macroscopic or microscopic findings that were attributable to the test substance.

Test substance-related changes included slight, but statistically significant, alterations in serum urea nitrogen and alkaline phosphatase in males and alanine aminotransferase in females, along with lower testicular/epididymidal weight in males and higher adrenal weights in females. These changes were considered physiologic responses of a non-adverse nature as there were no histopathological correlates and the group mean values were within WIL Historical control ranges (Version 2.5 for clinical pathology, Version 2.6 for organ weights).

Collectively, clinical and anatomical pathology findings indicated that, under the conditions of this study, a specific target organ toxicity was not identified. The changes observed represented minor perturbations without meaningful toxicologic consequences.

2.0 INTRODUCTION

2.1 Purpose

The objective of this study was to evaluate the potential toxicity of PMI-0105, containing the active ingredient phosphomannose isomerase protein (PMI), when administered as a single dose orally by gavage to male and female mice, followed by a 14-day observation period to assess the persistence, reversibility, or delayed occurrence of any toxic effects.

2.2 Regulatory guidelines

The study procedures described in this report are adapted from the following guidelines:

The European Community (Guidelines for the Assessment of Additives in Feeding Stuffs)

The United States of America Food and Drug Administration (Redbook 2000 Toxicological Principles for the Safety of Food Ingredients)

The United States of America Environmental Protection Agency (Health Effects Test Guidelines)

The United States of America Environmental Protection Agency (Microbial Pesticide Test Guidelines)

2.3 General Information

This report presents the data from “PMI-0105: Single-Dose Oral (Gavage) Toxicity Study in Mice with a 14-Day Observation Period”. Due to software spacing constraints, the study title appears as “A Single Oral Dose of PMI-0105 with a 14 Day Recovery in Mice” on the report tables.

The following computer protocols were used for data collection during the study:

Computer Protocol	Type of Data Collected
WIL 639011	Main study data
WIL-639011R	Nondosing day clinical data
WIL-639011P	Pretest data
WIL-639011U	Unscheduled clinical observations

3.0 MATERIALS AND METHODS

3.1 Test substance

The test substance, PMI-0105, was received from Syngenta Biotechnology Inc., (Research Triangle Park, North Carolina), on 28 November 2007, as follows:

<u>Identification</u>	<u>Quantity Received</u>	<u>Physical Description</u>
PMI-0105 Exp. Date: November 2015 [WIL log no. 7776A]	4 vials	White lyophilized powder

Documentation regarding the purity and stability of the test substance is on file with the sponsor and WIL Research Laboratories LLC. A Certificate of Analysis for the test substance is presented in Appendix 1. The purity of the active ingredient PMI in the test substance was 89.5% w/w. The test substance was stored frozen at approximately -20°C, desiccated and was considered stable under these conditions. A reserve sample of the test substance (approximately 10 mg) was collected on 10 December 2007, and stored in the Archives of WIL Research Laboratories, LLC.

3.1.1 Vehicle identification and preparation

The vehicle used in preparation of the test substance formulations and for administration to the control group was deionized water (prepared on-site). A sufficient amount of deionized water was dispensed into a glass container and mixed with a magnetic stirrer throughout use. The vehicle was prepared on the day of dosing (study day 0) and stored at room temperature.

3.1.2 Preparation of test substance dosing formulation

Dosing formulation was prepared at the concentration indicated in the following table:

<u>Group Number</u>	<u>Test Substance</u>	<u>Dose Level (mg/kg)^a</u>	<u>Dose Concentration (mg/mL)^a</u>
2	PMI-0105	2000	200

^a = Dose level and dose concentration refer to concentration of active ingredient (adjusted by a factor of 1.117 to account for active ingredient purity in the test substance). Therefore, the dose level of the test substance was 2234 mg/kg and the concentration of the test substance in the dosing formulation was 223.4 mg/mL.

The appropriate amount of the test substance for the formulation was weighed into a tared, calibrated storage container. Vehicle was added to the container to bring the formulation

nearly to the calibration mark. Using a magnetic stirrer, the formulation was mixed slowly to wet the test substance. Vehicle was then added to the container to bring the formulation to the calibration mark. The formulation was stirred slowly for at least 2 hours until uniform.

The vehicle and test substance formulation were prepared on the day of dosing and were stored at room temperature.

3.1.3 Sampling and analyses

Analyses of dosing formulations were not conducted.

3.2 Experimental design

3.2.1 Test system

CrI:CD-1(ICR) mice from Charles River Laboratories, Inc., Raleigh, North Carolina were used as the test system in this study. This species and strain of animal is recognized as appropriate for short-term toxicity studies. The mouse was used because it is a universally used model for evaluating toxicity of various classes of chemicals and is a widely used species for which significant historical control data are available in the literature and at WIL Research Laboratories, LLC. The animals were approximately 9 weeks old at the initiation of dose administration.

3.2.2 Organization of test groups, dose levels and treatment regimen

The vehicle and test substance formulations were administered as a single oral dose by gavage using syringes of appropriate volume equipped with flexible Teflon[®]-shafted, stainless steel ball-tipped dosing cannula (Natume, Japan). The dose volume for all groups was 10 mL/kg. Individual doses were based on the study day 0 individual body weights collected after a 3-hour fasting period to provide the correct mg/kg dose.

The following table represents the study group assignment:

<u>Group Number</u>	<u>Group Name</u>	<u>Dose Level (mg/kg/day)^b</u>	<u>Dose Volume (mL/kg)</u>	<u>Number of Animals^c</u>	
				<u>Males</u>	<u>Females</u>
1	Control ^a	0	0	5	5
2	PMI-0105	2000	200	5	5

^a = The control group was administered deionized water (the vehicle).

^b = Formulations were adjusted by a factor of 1.117 to account for test substance purity. Therefore, the dose level of the test substance was 2234 mg/kg and the concentration of the test substance in the dosing formulation was 223.4 mg/mL.

^c = All animals/sex/group were euthanized following 14 days of observation.

The single dose level of 2000 mg/kg was selected because it represents a limit dose for this type of study (see for example, OECD 2001; US EPA 2002).

The selected route of administration for this study was oral (gavage) since the oral route represents a likely route of human exposure and other mammalian exposure. The number of animals selected for this study was sufficient to provide adequate statistical evaluation of the data and was the minimum required to achieve the objectives of the study.

3.2.3 Animal receipt and acclimation/pretest period

Fifteen male and 15 female Crl:CD-1 (ICR) mice were received in good health on 27 November 2007, from Charles River Laboratories, Inc., Raleigh, North Carolina. The animals were approximately 7 weeks (50 days) old at receipt. Each animal was examined by a qualified technician on the day of receipt and weighed 3 days later. Each animal was uniquely identified by tail tattoo displaying the permanent identification number. All animals were housed for a 15-day acclimation/pretest period. During this period, each animal was observed twice daily for mortality and changes in general appearance or behavior.

Pretest data collection began on 30 November 2007. Individual body weights were recorded and detailed physical examinations were performed periodically during the pretest period. Food consumption data were also recorded for pretest animals prior to the initiation of dose administration. Pretest clinical observations are presented in Appendix 2. The pretest data for the other parameters are included in the summary tables (Tables 5, 6, and 8) and Appendix 7.

3.2.4 Animal housing

Upon arrival, all animals were housed 3 per cage by sex for 3 days. Thereafter, all animals were housed individually in clean, stainless steel, wire mesh cages suspended above cage board. Animals were maintained in accordance with the Guide for the Care and Use of Laboratory Animals (National Research Council, 1996). The animal facilities at WIL Research Laboratories, LLC are accredited by the Association for Assessment and Accreditation of Laboratory Animal Care International (AAALAC International).

3.2.5 Diet, drinking water and maintenance

The basal diet used in this study, PMI (Purina Mills, Inc.) Nutrition International, LLC, Certified Rodent LabDiet[®] 5002 (meal), is a certified feed with appropriate analyses performed by the manufacturer and provided to WIL Research Laboratories, LLC. Reverse osmosis treated (on site) drinking water, delivered by an automatic watering system, and the basal diet were provided ad libitum during the observation period. On study day 0, the diet was removed approximately 3 hours prior to dosing and was returned approximately 1-2 hours post-dosing, after the completion of the 1-2 hour post-dosing clinical observation. Municipal water supplying the facility was analyzed for contaminants according to the

standard operating procedures. The results of the diet and water analyses are maintained at WIL Research Laboratories, LLC. No contaminants were present in animal feed or water at concentrations sufficient to interfere with the objectives of this study.

3.2.6 Environmental conditions

All animals were housed throughout the acclimation period and during the study in an environmentally controlled room. The room temperature and humidity controls were set to maintain daily averages of $71 \pm 5^\circ\text{F}$ ($22 \pm 3^\circ\text{C}$) and $50 \pm 20\%$ relative humidity. Room temperature and relative humidity were controlled and monitored using the Metasys[®] DDC Electronic Environmental control system. These data were recorded approximately hourly and are summarized in Appendix 3. Actual mean daily temperature ranged from 66.2°F to 70.1°F (19.0°C to 21.2°C) and mean daily relative humidity ranged from 34.6% to 46.9% during the study. Fluorescent lighting provided illumination for a 12 hour light (0600 hours to 1800 hours)/12 hour dark photoperiod. The 12 hour light/12 hour dark photoperiod was interrupted as necessary to allow for the performance of protocol specified activities. Air handling units were set to provide a minimum of 10 fresh air changes per hour.

3.2.7 Assignment of animals to treatment groups

On 10 December 2007 (2 days prior to the day of dosing), all available mice were weighed and examined in detail for physical abnormalities. These data were collected using the WIL Toxicology Data Management System (WTDMS[™]) and reviewed by the study director. The animals judged suitable for assignment to the study were selected for use in a computerized randomization procedure. A printout containing the animal numbers, corresponding body weights and individual group assignments was generated based on body weight stratification in a block design. The animals were then arranged into groups according to the printout. Individual body weights at randomization were within $\pm 20\%$ of the mean for each sex. Each group consisted of 5 males and 5 females, Individual body weights ranged from 28.7 g to 34.1 g for males and from 22.8 g to 24.2 g for females.

3.3 *Ante mortem* investigations

3.3.1 Clinical observations and survival

All animals were observed twice daily, once in the morning and once in the afternoon, for mortality and moribundity.

Clinical examinations were performed at the time of dose administration, approximately 1 to 2 hours following dose administration and approximately 4 to 5 hours following dose administration. During the recovery period, the animals were observed once daily. The absence or presence of findings was recorded for individual animals at the scheduled intervals. Detailed physical examinations were conducted on all animals weekly, beginning 1 week prior to test substance administration and prior to the scheduled necropsy. Daily observations during the nondosing period were not conducted on days that the detailed

physical examinations were performed. A separate computer protocol was used to record any observations noted outside of the above-specified intervals. These unscheduled clinical observations are presented in Appendix 4.

3.3.2 Body weights

Individual body weights were recorded weekly during the pretest period, at randomization, just prior to dosing (after 3 hours of fasting) and daily during the observation period. Mean body weights and mean body weight changes were calculated for the corresponding intervals.

3.3.3 Food consumption

Individual food consumption was recorded weekly during the pretest period (study days -8 to -2) and daily during the study. Food intake was calculated as g/animal/day for the corresponding body weight intervals. When food consumption could not be measured for a given interval (due to spillage, weighing error, obvious erroneous value, etc.), the appropriate interval was footnoted as "NA" (Not Applicable) on the individual tables.

3.3.4 Clinical Pathology

Blood samples for clinical pathology evaluation (hematology and serum chemistry) were collected from all animals prior to the scheduled necropsy (study day 14). Blood was collected from the retro-orbital sinus of animals anesthetized by inhalation of isoflurane. Blood was collected into tubes containing potassium EDTA (hematology) or no anticoagulant (serum chemistry). Clinical pathology methods, procedures and references are presented in Appendix 5. Interpretation of the clinical pathology data was performed by Ellen L. Ziemer, DVM, PhD, DACVIM, DACVP (Appendix 6). The following parameters were evaluated:

3.3.4.1 Hematology

Total leukocyte count (White Cells)	Differential leukocyte count -
Erythrocyte count (Red Cells)	Percent and absolute
Hemoglobin	-Neutrophil
Hematocrit	-Lymphocyte
Mean corpuscular volume (MCV)	-Monocyte
Mean corpuscular hemoglobin	-Eosinophil
(MCH)	-Basophil
Mean corpuscular hemoglobin	-Large unstained cell
concentration (MCHC)	Red cell morphology
Platelet count (Platelet)	(RBC Morphology) ^a
Reticulocyte count	
Percent (Reticulocyte)	
Absolute (Retic Absolute)	

() - Designates tabular abbreviation used in data tables

^a - Presented on individual tables if a manual differential was performed, and the manual data were accepted and reported instead of the automated differential data

3.3.4.2 Serum Chemistry

Albumin	Aspartate aminotransferase
Total protein	(AspartatTransfer)
Globulin [by calculation]	Gamma glutamyltransferase
Albumin/globulin ratio (A/G Ratio)	(GlutamylTransfer)
[by calculation]	Glucose
Total bilirubin (Total Bili)	Total cholesterol (Cholesterol)
Urea nitrogen	Calcium
Creatinine	Chloride
Creatinine kinase	Phosphorus
Alkaline phosphatase	Potassium
(AlkalinePhos'tse)	Sodium
Alanine aminotransferase	Triglycerides (Triglyceride)
(Alanine Transfer)	

() - Designates tabular abbreviation used in data tables

The analysis of serum chemistry parameters was prioritized as follows, in the case of insufficient blood volume:

- Alkaline phosphatase, alanine aminotransferase, aspartate aminotransferase
- Creatinine, urea
- Glucose, cholesterol, triglycerides
- Albumin, total protein
- Phosphorous, calcium
- Creatinine kinase, gamma glutamyltransferase, total bilirubin
- Sodium, potassium, chloride

3.4 *Post mortem* investigations

3.4.1 Macroscopic examination

A complete necropsy was conducted on all animals. Animals were euthanized by carbon dioxide anesthesia and exsanguinated. The necropsies included, but were not limited to, examination of the external surface, all orifices, and the cranial, thoracic, abdominal and pelvic cavities, including viscera. The following tissues and organs were collected and placed in 10% neutral buffered formalin (except as noted):

Adrenals (2)	Lymph nodes
Aorta	Mandibular
Bone with marrow	Mesenteric
Femur with joint	Ovaries (2) with oviducts ^d (females)
Sternum	Pancreas
Bone marrow smear ^a	Peripheral nerve (sciatic)
Brain	Peyer's patches
Cerebrum (2 levels)	Pituitary
Cerebellum with medulla/pons	Prostate (males)
Cervix (females)	Salivary glands [mandibular (2)]
Epididymides (2) ^b (males)	Seminal vesicles (2) (males)
Eyes with optic nerve (2) ^c	Skeletal muscle (rectus femoris)
Gallbladder	Skin with mammary gland ^e
Gastrointestinal tract	Spinal cord (cervical, thoracic, lumbar)
Esophagus	Spleen
Stomach	Testes (2) ^b (males)
Duodenum	Thymus
Jejunum	Thyroid [with parathyroids, if present (2)] ^d
Ileum	Trachea
Cecum	Urinary bladder
Colon	Uterus (females)
Rectum	Vagina (females)
Heart	Gross lesions (when possible)
Kidneys (2)	
Liver	
Lungs (fixed by inflation with fixative)	

- ^a - Bone marrow smears were obtained at scheduled necropsy, but not placed in formalin; slides were examined only if scientifically warranted.
- ^b - Fixed in Bouin's solution
- ^c - Fixed in Davidson's solution
- ^d - Parathyroids and oviducts were examined histologically if in the plane of section and in all cases when a gross lesion was present
- ^e - For females; a corresponding section of skin was collected from the same anatomic area for males

3.4.2 Organ weights

The following organs were weighed from all animals at the scheduled necropsy:

Adrenals	Liver (with gall bladder)
Brain	Ovaries with oviducts (females)
Epididymides (males)	Spleen
Heart	Testes (males)
Kidneys	

Paired organs were weighed together. Organ-to-final-body-weight and organ-to-brain-weight ratios were calculated.

3.4.3 Slide preparation and microscopic examination

After fixation, protocol specified tissues were trimmed according to standard operating procedures and the protocol. Trimmed tissues were processed into paraffin blocks, sectioned at 4 to 8 microns, mounted on glass microscope slides and stained with hematoxylin and eosin.

Microscopic examination was performed on all tissues listed in Section 3.4.1 from all animals at the scheduled necropsy. Missing tissues were identified as not found at necropsy, lost at necropsy, lost during processing or other designations as appropriate. Tissues may appear on the report tables as not examined due to the tissue not being in the plane of section, not present at trimming, etc. Microscopic examination was performed by Richard Bruner, DVM, DACVP, WIL Research Laboratories, LLC (Appendix 6).

3.5 Data evaluation

All statistical tests were performed using appropriate computing devices or programs. Analyses were conducted using two-tailed tests (except as noted otherwise) for minimum significance levels of 1% and 5%, comparing each test substance-treated group to the control group by sex. Each mean was presented with the standard deviation (S.D.), standard error (S.E.) and the number of animals (N) used to calculate the mean. In addition, percent difference from the control group is presented for body weights, clinical pathology parameters and organ weights. Statistical analyses were not conducted if the number of animals was 2 or less. Due to the different rounding conventions inherent in the types of software used, the means and standard deviations on the summary and individual tables may differ by ± 1 in the last significant figure.

Body weight, body weight change, food consumption, continuous clinical pathology and organ weight data were subjected to a parametric one way analysis of variance (ANOVA) (Snedecor and Cochran, 1980) to determine intergroup differences. If the ANOVA revealed statistically significant ($p < 0.05$) intergroup variance, Dunnett's test (Dunnett, 1964) was used to compare the test substance treated groups to the control group.

4.0 RESULTS AND DISCUSSION

All summary data tables are presented in a separate Table Section. All individual data tables are presented in Appendix 7 of the report.

4.1 Clinical observations and survival

Summary Data: Tables 1, 2, 3, 4

Individual Data: Tables A1, A2, A3, A4, A5

Unscheduled Clinical Observations: Appendix 4

All animals survived to the scheduled necropsy. There were no test substance-related clinical observations. The observation of wet and/or dry yellow material near the urogenital area was noted in select males and females of both the 2000 mg/kg and control groups. All clinical findings in the test substance treated groups were noted with similar incidence in the control group, were limited to single animals and/or were common findings for laboratory mice of this age and strain.

4.2 Body weights

Summary Data: Tables 5, 6, 7; Figures 1, 2

Individual Data: Tables A6, A7, A8

Body weights and body weight gains were unaffected by test substance administration. A statistically significantly higher body weight gain was noted for the 2000 mg/kg group males on study day 1-2 compared with the control group males. This difference in body weight gain was considered incidental and not related to test substance administration because the magnitude of the change was very small (0.0 vs. 0.7 grams gained for the control and test substance treated males, respectively). Furthermore, no statistically significant changes in body weight gain for either males or females were noted for any of the other study intervals.

4.3 Food consumption

Summary Data: Table 8

Individual Data: Table A9

Food consumption was unaffected by test substance administration. Statistically significantly lower food consumption was noted for the 2000 mg/kg males on study day 5-6 compared with the control males. This difference in food consumption was considered incidental and not related to test substance administration because the magnitude of the change was small (7.2 vs. 5.8 grams consumed for the controls and test substance treated males, respectively) and no statistically significant changes in food consumption were noted for any of the other study intervals.

4.4 Clinical pathology

4.4.1 Hematology

Summary Data: Table 9

Individual Data: Table A10

Pathology Report: Appendix 6

There were no statistically significant differences for any of the hematology parameters when the control and test substance treated groups were compared.

4.4.2 Serum Chemistry

Summary Data: Table 10

Individual Data: Table A11

Pathology Report: Appendix 6

Due to insufficient serum sample, albumin, total protein, globulin, A/G ratio, total bilirubin, glutamyltransferase, cholesterol, calcium, chloride, phosphorus, potassium, sodium, creatinine kinase and triglyceride measurements were not carried out for every study animal.

There were no adverse effects on mice for any of the evaluated serum chemistry parameters.

Statistically significantly higher urea nitrogen (males only), alkaline phosphatase (males only) and alanine aminotransferase levels (females only) were noted in the 2000 mg/kg group compared with controls, and were considered test substance-related.

The changes in the urea nitrogen levels were not considered adverse as the changes were of low magnitude and mean levels were within WIL Historical Control Range (Version 2.5) except for 1 male. In addition, this difference was not noted in the 2000 mg/kg group females where mean urea nitrogen values were slightly (but not statistically significantly) lower than the control group. There were no histopathological correlates in the kidney.

The changes in the alkaline phosphatase (ALP) and alanine aminotransferase (ALT) levels were not considered adverse as the changes were of low magnitude and the group mean and individual animal values for ALP and ALT for the 2000 mg/kg group males and females were all within WIL Historical control ranges (Version 2.5). There were no histopathological correlates in the liver.

Comparison of Serum Chemistry Parameters That Varied Significantly from the Control Group with WIL Historical control ranges (Version 2.5, Age 9-12 weeks)			
	2000 mg/kg	Historical Control Data	
	Mean	Mean	Reference Range
Males			
Urea nitrogen (mg/dL)	27.5*	23.3	17.4-30.3
Alkaline phosphatase (U/L)	92*	86	49-141
Females			
Alanine Aminotransferase (U/L)	41*	48	24-122

4.5 Anatomic pathology

4.5.1 Macroscopic examination

Summary Data: Table 11

Individual Data: Table A12

Pathology Report: Appendix 6

There were no test substance-related macroscopic findings at the scheduled necropsy. All macroscopic findings noted were considered to be spontaneous and/or incidental in nature and unrelated to test substance administration.

4.5.2 Organ weights

Summary Data: Table 12

Individual Data: Tables A13, A14, A15

Pathology Report: Appendix 6

For males, the mean absolute, relative-to-body, and relative-to-brain weights for the testes and the epididymides were statistically significantly lower than for the 2000 mg/kg group when compared with the weights of the control group, and were considered test substance-related. However, there were no distinct histologic correlates for weight changes in either organ, and all organ weight differences were within WIL Historical control ranges (Version 2.6).

For females, the mean absolute, relative-to-body, and relative-to-brain adrenal weights were statistically significantly higher for the 2000 mg/kg group when compared with the weights of the control group, and were considered test substance-related. However, there were no distinct histopathological correlates, and an opposite trend was noted in the 2000 mg/kg

group males, where adrenal weights were slightly lower (but not statistically significant) than the control group.

Comparison of Mean Organ Weights That Varied Significantly from the Control Group with WIL Historical control ranges (Version 2.6, Age 9-12 weeks)			
	2000 mg/kg	Historical Control Data	
	Mean	Mean	Range (Mean \pm 2 S.D.)
Testes			
Absolute [g]	0.1915**	0.22	0.16-0.29
Relative-to-Body [g/100 g FBW]	0.570**	0.682	0.509-0.854
Relative-to-Brain [g/100 g brain]	39.493**	45.545	32.145-58.945
Epididymides			
Absolute [g]	0.0839**	0.09	0.05-0.13
Relative-to-Body [g/100 g FBW]	0.249**	0.275	0.177-0.374
Relative-to-Brain [g/100 g brain]	17.330**	18.337	10.577-26.097
Adrenal Gland (Female)			
Absolute [g]	0.0125*	0.0111	0.0065-0.0156
Relative-to-Body [g/100 g FBW]	0.049*	0.042	0.024-0.059
Relative-to-Brain [g/100 g brain]	2.539*	2.296	1.319-3.273

* = Significantly different from the control group at 0.05 using Dunnett's test

** = Significantly different from the control group at 0.01 using Dunnett's test

4.5.3 Microscopic examination

Summary Data: Table 11 and 13

Individual Data: Table A12

Pathology Report: Appendix 6

There were no test substance-related microscopic findings.

One 2000 mg/kg group female (no. 1667) displayed minimal cytoplasmic vacuolation of renal tubular cells within the outer stripe of the outer medulla. Although this singular finding was most consistent with tissue processing artifact, a test substance relationship could not be entirely ruled out.

All additional microscopic findings were consistent with common, spontaneous alterations in laboratory mice, or changes associated with some aspect of experimental manipulation other than administration of the test substance.

5.0 CONCLUSIONS

Test substance PMI-0105, containing the active ingredient phosphomannose isomerase protein (89.5% purity w/w), administered as a single oral gavage dose at 0 or 2000 mg active ingredient/ kg body weight followed by a 14-day observation period was well tolerated in male and female CD1 mice. All mice survived without clinical signs of distress or impairment. There were no test substance-related clinical observations. There were no test substance-related effects on body weight or weight gain, food consumption or hematology parameters. There were no macroscopic or microscopic findings that were attributable to the test substance.

Test substance-related changes included slight, but statistically significant, alterations in serum urea nitrogen and alkaline phosphatase in males and alanine aminotransferase in females, along with lower testicular/epididymidal weight in males and higher adrenal weight in females. These changes were considered physiologic responses of a non-adverse nature as there were no correlating histopathological correlates and the group mean values were within WIL Historical control ranges (Version 2.5 for clinical pathology, Version 2.6 for organ weights).

Collectively, clinical and anatomical pathology findings indicated that, under the conditions of this study, a specific target organ toxicity was not identified. The changes observed represented minor perturbations without meaningful toxicologic consequences.

6.0 REFERENCES

Dunnett, C.W. (1964) New tables for multiple comparisons with a control. *Biometrics*, 20, 482-491.

National Research Council. (1996) *Guide for the Care and Use of Laboratory Animals*, Institute of Laboratory Animal Resources, Commission on Life Sciences; National Academy Press: Washington, DC.

OECD (2001) OECD Guideline Test Guideline 420 Acute Oral Toxicity: Fixed Dose Procedure. http://iccvam.niehs.nih.gov/SuppDocs/FedDocs/OECD/OECD_GL420.pdf.

Snedecor, G.W.; Cochran, W.G. (1980) One Way Classifications; Analysis of Variance. In *Statistical Methods*, 7th ed.; The Iowa State University Press: Ames, IA; pp 215-237.

US EPA (2002) Health Effects Test Guidelines – OPPTS 870.1100 – Acute Oral Toxicity. http://www.epa.gov/opptsfrs/publications/OPPTS_Harmonized/870_Health_Effects_Test_Guidelines/Series/Revised_870r-1100.pdf

TABLES SECTION

PROJECT NO.:WIL-639011
 SPONSOR:SYNGENTA

TABLE 1
 A SINGLE ORAL DOSE OF PMI-0105 WITH A 14-DAY RECOVERY IN MICE
 SUMMARY OF SURVIVAL AND DISPOSITION

GROUP :		1		2		MALES			
DAY	LIVE	FD	EE	SE	LIVE	FD	EE	SE	
0	5	0	0	0	5	0	0	0	
1	5	0	0	0	5	0	0	0	
2	5	0	0	0	5	0	0	0	
3	5	0	0	0	5	0	0	0	
4	5	0	0	0	5	0	0	0	
5	5	0	0	0	5	0	0	0	
6	5	0	0	0	5	0	0	0	
7	5	0	0	0	5	0	0	0	
8	5	0	0	0	5	0	0	0	
9	5	0	0	0	5	0	0	0	
10	5	0	0	0	5	0	0	0	
11	5	0	0	0	5	0	0	0	
12	5	0	0	0	5	0	0	0	
13	5	0	0	0	5	0	0	0	
14	0	0	0	5	0	0	0	5	

DAY = DAY OF STUDY FD = FOUND DEAD EE = EUTHANIZED IN EXTREMIS SE = SCHEDULED EUTHANASIA

1- 0 MG/KG 2- 2000 MG/KG

PROJECT NO.:WIL-639011
 SPONSOR:SYNGENTA

TABLE 1
 A SINGLE ORAL DOSE OF PMI-0105 WITH A 14-DAY RECOVERY IN MICE
 SUMMARY OF SURVIVAL AND DISPOSITION

GROUP :		1				2			
DAY	LIVE	FD	EE	SE	LIVE	FD	EE	SE	
0	5	0	0	0	5	0	0	0	
1	5	0	0	0	5	0	0	0	
2	5	0	0	0	5	0	0	0	
3	5	0	0	0	5	0	0	0	
4	5	0	0	0	5	0	0	0	
5	5	0	0	0	5	0	0	0	
6	5	0	0	0	5	0	0	0	
7	5	0	0	0	5	0	0	0	
8	5	0	0	0	5	0	0	0	
9	5	0	0	0	5	0	0	0	
10	5	0	0	0	5	0	0	0	
11	5	0	0	0	5	0	0	0	
12	5	0	0	0	5	0	0	0	
13	5	0	0	0	5	0	0	0	
14	0	0	0	5	0	0	0	5	

DAY = DAY OF STUDY FD = FOUND DEAD EE = EUTHANIZED IN EXTREMIS SE = SCHEDULED EUTHANASIA

1- 0 MG/KG 2- 2000 MG/KG

PSURVv4.09
 02/26/2008
 R:03/20/2009

PROJECT NO.:WIL-639011
 SPONSOR:SYNGENTA

TABLE 2 (DETAILED PHYSICAL EXAMINATIONS/DISPOSITIONS)
 A SINGLE ORAL DOSE OF PMI-0105 WITH A 14-DAY RECOVERY IN MICE
 SUMMARY OF CLINICAL FINDINGS: TOTAL OCCURRENCE/NO. OF ANIMALS

PAGE 1

----- M A L E -----

TABLE RANGE: GROUP:	DAY 000 TO DAY 014		
		1	2
NORMAL			
-NO SIGNIFICANT CLINICAL OBSERVATIONS	12/ 5		15/ 5
DISPOSITION			
-PRIMARY NECROPSY (DAY 14)	5/ 5		5/ 5
EYES/EARS/NOSE			
-ABNORMAL PUPIL POSITION RIGHT EYE	2/ 1		0/ 0
BODY/INTEG III			
-DRIED YELLOW MATERIAL UROGENITAL AREA	1/ 1		0/ 0
1- 0 MG/KG	2- 2000 MG/KG		

PROJECT NO.:WIL-639011
 SPONSOR:SYNGENTA

TABLE 2 (DETAILED PHYSICAL EXAMINATIONS/DISPOSITIONS)
 A SINGLE ORAL DOSE OF PMI-0105 WITH A 14-DAY RECOVERY IN MICE
 SUMMARY OF CLINICAL FINDINGS: TOTAL OCCURRENCE/NO. OF ANIMALS

PAGE 2

----- F E M A L E -----

TABLE RANGE: GROUP:	DAY 000 TO DAY 014	1	2
NORMAL			
-NO SIGNIFICANT CLINICAL OBSERVATIONS	13/ 5		15/ 5
DISPOSITION			
-PRIMARY NECROPSY (DAY 14)	5/ 5		5/ 5
CARDIO-PULMONARY			
-EXTREMITIES PALE	1/ 1		0/ 0
-BODY PALE	1/ 1		0/ 0
-RALES	1/ 1		0/ 0
EXCRETA			
-DEFECATION DECREASED	1/ 1		0/ 0
-FECES SMALLER THAN NORMAL	1/ 1		0/ 0
1- 0 MG/KG	2- 2000 MG/KG		

PCSUv4.07
 02/26/2008
 R:03/20/2009

PROJECT NO.:WIL-639011
 SPONSOR:SYNGENTA

TABLE 3 (DOSING DAY OBSERVATIONS)
 A SINGLE ORAL DOSE OF PMI-0105 WITH A 14-DAY RECOVERY IN MICE
 SUMMARY OF POST-DOSE FINDINGS: TOTAL OCCURRENCE/NO. OF ANIMALS

----- M A L E -----

 TABLE RANGE: DAY 0
 GROUP: 1 2

NORMAL

TIME OF DOSE		
-NO SIGNIFICANT CLINICAL OBSERVATIONS	5/5	5/5
1-2 HOURS POST-DOSING		
-NO SIGNIFICANT CLINICAL OBSERVATIONS	5/5	5/5
4-5 HOURS POST-DOSING		
-NO SIGNIFICANT CLINICAL OBSERVATIONS	5/5	5/5

 1- 0 MG/KG 2- 2000 MG/KG

PROJECT NO.:WIL-639011
 SPONSOR:SYNGENTA

TABLE 3 (DOSING DAY OBSERVATIONS)
 A SINGLE ORAL DOSE OF PMI-0105 WITH A 14-DAY RECOVERY IN MICE
 SUMMARY OF POST-DOSE FINDINGS: TOTAL OCCURRENCE/NO. OF ANIMALS

PAGE 2

----- F E M A L E -----

 TABLE RANGE: DAY 0
 GROUP: 1 2

NORMAL

TIME OF DOSE
 -NO SIGNIFICANT CLINICAL OBSERVATIONS 5/5 5/5
 1-2 HOURS POST-DOSING
 -NO SIGNIFICANT CLINICAL OBSERVATIONS 5/5 5/5
 4-5 HOURS POST-DOSING
 -NO SIGNIFICANT CLINICAL OBSERVATIONS 5/5 5/5

1- 0 MG/KG 2- 2000 MG/KG

PPDTSUv1.39
 02/26/2008
 R:03/20/2009

PROJECT NO.:WIL-639011R
 SPONSOR:SYNGENTA

TABLE 4 (DAILY OBSERVATIONS - NONDOSING DAYS)
 A SINGLE ORAL DOSE OF PMI-0105 WITH A 14-DAY RECOVERY IN MICE
 SUMMARY OF CLINICAL FINDINGS: TOTAL OCCURRENCE/NO. OF ANIMALS

PAGE 1

----- M A L E -----

TABLE RANGE:		DAY 001 TO DAY 013	
GROUP:		1	2
NORMAL			
-NO SIGNIFICANT CLINICAL OBSERVATIONS		51/ 5	47/ 5
BODY/INTEG III			
-WET YELLOW MATERIAL UROGENITAL AREA		4/ 2	3/ 2
-WET YELLOW MATERIAL VENTRAL TRUNK		1/ 1	0/ 0
-DRIED YELLOW MATERIAL UROGENITAL AREA		5/ 2	10/ 4
-DRIED YELLOW MATERIAL VENTRAL TRUNK		0/ 0	1/ 1
-DRIED YELLOW MATERIAL ANOGENITAL AREA		0/ 0	2/ 1
1-	0 MG/KG	2-	2000 MG/KG

PROJECT NO.:WIL-639011R
 SPONSOR:SYNGENTA

TABLE 4 (DAILY OBSERVATIONS - NONDOSING DAYS)
 A SINGLE ORAL DOSE OF PMI-0105 WITH A 14-DAY RECOVERY IN MICE
 SUMMARY OF CLINICAL FINDINGS: TOTAL OCCURRENCE/NO. OF ANIMALS

PAGE 2

----- F E M A L E -----

TABLE RANGE:	DAY 001 TO DAY 013		
GROUP:		1	2

NORMAL			
-NO SIGNIFICANT CLINICAL OBSERVATIONS		57/ 5	59/ 5
BODY/INTEG III			
-WET YELLOW MATERIAL UROGENITAL AREA		0/ 0	1/ 1
-DRIED YELLOW MATERIAL UROGENITAL AREA		1/ 1	0/ 0
-DRIED YELLOW MATERIAL ANOGENITAL AREA		2/ 1	0/ 0

1- 0 MG/KG	2- 2000 MG/KG		

PCSUv4.07
 02/26/2008
 R:03/20/2009

PROJECT NO.: WIL-639011
SPONSOR: SYNGENTA

TABLE 5
A SINGLE ORAL DOSE OF PMI-0105 WITH A 14-DAY RECOVERY IN MICE
SUMMARY OF BODY WEIGHTS [G]

PAGE 1

GROUP:		MALES	
		0 MG/KG	2000 MG/KG
DAY -12	MEAN	29.6	29.4
% DIFFERENCE			-0.7
	S.D.	1.46	1.16
	S.E.	0.65	0.52
	N	5	5
-8	MEAN	31.1	30.0
% DIFFERENCE			-3.5
	S.D.	0.97	0.65
	S.E.	0.43	0.29
	N	5	5
-2	MEAN	32.3	32.2
% DIFFERENCE			-0.3
	S.D.	1.27	1.13
	S.E.	0.57	0.51
	N	5	5
0	MEAN	32.3	31.3
% DIFFERENCE			-3.1
	S.D.	1.27	1.64
	S.E.	0.57	0.73
	N	5	5

None significantly different from control group

PROJECT NO.: WIL-639011
 SPONSOR: SYNGENTA

TABLE 5
 A SINGLE ORAL DOSE OF PMI-0105 WITH A 14-DAY RECOVERY IN MICE
 SUMMARY OF BODY WEIGHTS [G]

GROUP:		0 MG/KG	MALES	2000 MG/KG
DAY	1			
	MEAN	33.6		32.3
%	DIFFERENCE			-3.9
	S.D.	0.80		1.38
	S.E.	0.36		0.62
	N	5		5
	2			
	MEAN	33.6		33.0
%	DIFFERENCE			-1.8
	S.D.	1.01		1.53
	S.E.	0.45		0.69
	N	5		5
	3			
	MEAN	33.2		32.5
%	DIFFERENCE			-2.1
	S.D.	1.03		1.90
	S.E.	0.46		0.85
	N	5		5
	4			
	MEAN	34.1		32.8
%	DIFFERENCE			-3.8
	S.D.	1.28		1.66
	S.E.	0.57		0.74
	N	5		5

None significantly different from control group

PROJECT NO.:WIL-639011
 SPONSOR:SYNGENTA

TABLE 5
 A SINGLE ORAL DOSE OF PMI-0105 WITH A 14-DAY RECOVERY IN MICE
 SUMMARY OF BODY WEIGHTS [G]

GROUP :		MALES	
		0 MG/KG	2000 MG/KG
DAY	5		
	MEAN	34.3	32.8
%	DIFFERENCE		-4.4
	S.D.	1.38	1.76
	S.E.	0.62	0.79
	N	5	5
	6		
	MEAN	34.4	33.1
%	DIFFERENCE		-3.8
	S.D.	1.47	1.62
	S.E.	0.66	0.73
	N	5	5
	7		
	MEAN	34.3	33.0
%	DIFFERENCE		-3.8
	S.D.	1.50	1.49
	S.E.	0.67	0.67
	N	5	5
	8		
	MEAN	35.1	33.8
%	DIFFERENCE		-3.7
	S.D.	1.37	1.90
	S.E.	0.61	0.85
	N	5	5

None significantly different from control group

PROJECT NO.: WIL-639011
SPONSOR: SYNGENTATABLE 5
A SINGLE ORAL DOSE OF PMI-0105 WITH A 14-DAY RECOVERY IN MICE
SUMMARY OF BODY WEIGHTS [G]

PAGE 4

GROUP:		MALES	
		0 MG/KG	2000 MG/KG
DAY	9		
	MEAN	34.9	33.5
%	DIFFERENCE		-4.0
	S.D.	1.30	1.80
	S.E.	0.58	0.80
	N	5	5
	10		
	MEAN	35.2	33.6
%	DIFFERENCE		-4.5
	S.D.	1.57	1.93
	S.E.	0.70	0.86
	N	5	5
	11		
	MEAN	35.4	33.7
%	DIFFERENCE		-4.8
	S.D.	1.57	1.97
	S.E.	0.70	0.88
	N	5	5
	12		
	MEAN	35.1	33.4
%	DIFFERENCE		-4.8
	S.D.	1.63	1.68
	S.E.	0.73	0.75
	N	5	5

None significantly different from control group

PROJECT NO.:WIL-639011
 SPONSOR:SYNGENTA

TABLE 5
 A SINGLE ORAL DOSE OF PMI-0105 WITH A 14-DAY RECOVERY IN MICE
 SUMMARY OF BODY WEIGHTS [G]

GROUP:		MALES	
		0 MG/KG	2000 MG/KG
DAY	13		
	MEAN	35.4	34.1
%	DIFFERENCE		-3.7
	S.D.	1.26	1.97
	S.E.	0.56	0.88
	N	5	5
	14		
	MEAN	34.9	33.8
%	DIFFERENCE		-3.2
	S.D.	1.25	1.87
	S.E.	0.56	0.84
	N	5	5

None significantly different from control group

PROJECT NO.: WIL-639011
SPONSOR: SYNGENTATABLE 5
A SINGLE ORAL DOSE OF PMI-0105 WITH A 14-DAY RECOVERY IN MICE
SUMMARY OF BODY WEIGHTS [G]

PAGE 6

GROUP:		FEMALES	
		0 MG/KG	2000 MG/KG
DAY -12	MEAN	21.9	22.7*
% DIFFERENCE			3.7
	S.D.	0.62	0.40
	S.E.	0.28	0.18
	N	5	5
-8	MEAN	23.2	23.1
% DIFFERENCE			-0.4
	S.D.	0.26	0.42
	S.E.	0.12	0.19
	N	5	5
-2	MEAN	24.2	24.1
% DIFFERENCE			-0.4
	S.D.	0.77	1.04
	S.E.	0.34	0.47
	N	5	5
0	MEAN	23.5	23.1
% DIFFERENCE			-1.7
	S.D.	0.57	0.24
	S.E.	0.25	0.11
	N	5	5

* = Significantly different from the control group at 0.05 using Dunnett's test

PROJECT NO.:WIL-639011
 SPONSOR:SYNGENTA

TABLE 5
 A SINGLE ORAL DOSE OF PMI-0105 WITH A 14-DAY RECOVERY IN MICE
 SUMMARY OF BODY WEIGHTS [G]

GROUP:		FEMALES	
		0 MG/KG	2000 MG/KG
DAY	1		
	MEAN	23.5	24.1
%	DIFFERENCE		2.6
	S.D.	1.55	0.77
	S.E.	0.69	0.35
	N	5	5
	2		
	MEAN	23.3	24.4
%	DIFFERENCE		4.7
	S.D.	2.26	1.10
	S.E.	1.01	0.49
	N	5	5
	3		
	MEAN	23.3	24.4
%	DIFFERENCE		4.7
	S.D.	2.36	0.95
	S.E.	1.05	0.43
	N	5	5
	4		
	MEAN	23.8	24.6
%	DIFFERENCE		3.4
	S.D.	2.78	0.56
	S.E.	1.24	0.25
	N	5	5

None significantly different from control group

PROJECT NO.:WIL-639011
 SPONSOR:SYNGENTA

TABLE 5
 A SINGLE ORAL DOSE OF PMI-0105 WITH A 14-DAY RECOVERY IN MICE
 SUMMARY OF BODY WEIGHTS [G]

GROUP:		FEMALES	
		0 MG/KG	2000 MG/KG
DAY	5		
	MEAN	23.8	24.4
%	DIFFERENCE		2.5
	S.D.	2.38	0.88
	S.E.	1.07	0.39
	N	5	5
	6		
	MEAN	24.0	24.8
%	DIFFERENCE		3.3
	S.D.	2.64	0.90
	S.E.	1.18	0.40
	N	5	5
	7		
	MEAN	24.0	24.8
%	DIFFERENCE		3.3
	S.D.	2.44	1.03
	S.E.	1.09	0.46
	N	5	5
	8		
	MEAN	24.6	25.1
%	DIFFERENCE		2.0
	S.D.	2.95	0.76
	S.E.	1.32	0.34
	N	5	5

None significantly different from control group

PROJECT NO.:WIL-639011
 SPONSOR:SYNGENTA

TABLE 5
 A SINGLE ORAL DOSE OF PMI-0105 WITH A 14-DAY RECOVERY IN MICE
 SUMMARY OF BODY WEIGHTS [G]

GROUP:		FEMALES	
		0 MG/KG	2000 MG/KG
DAY	9		
	MEAN	24.2	25.1
%	DIFFERENCE		3.7
	S.D.	2.55	0.91
	S.E.	1.14	0.41
	N	5	5
	10		
	MEAN	24.7	25.2
%	DIFFERENCE		2.0
	S.D.	2.68	1.21
	S.E.	1.20	0.54
	N	5	5
	11		
	MEAN	24.6	25.6
%	DIFFERENCE		4.1
	S.D.	2.74	1.42
	S.E.	1.22	0.63
	N	5	5
	12		
	MEAN	24.7	25.4
%	DIFFERENCE		2.8
	S.D.	2.69	1.31
	S.E.	1.20	0.58
	N	5	5

None significantly different from control group

PROJECT NO.:WIL-639011
 SPONSOR:SYNGENTA

TABLE 5
 A SINGLE ORAL DOSE OF PMI-0105 WITH A 14-DAY RECOVERY IN MICE
 SUMMARY OF BODY WEIGHTS [G]

GROUP:		0 MG/KG	FEMALES	2000 MG/KG
DAY	13			
	MEAN	25.2		25.8
%	DIFFERENCE			2.4
	S.D.	2.35		1.35
	S.E.	1.05		0.60
	N	5		5
	14			
	MEAN	25.1		25.7
%	DIFFERENCE			2.4
	S.D.	1.88		1.25
	S.E.	0.84		0.56
	N	5		5

None significantly different from control group

PBFSTv5.28
 02/26/2008
 R:03/20/2009

PROJECT NO.:WIL-639011
 SPONSOR:SYNGENTA

TABLE 6
 A SINGLE ORAL DOSE OF PMI-0105 WITH A 14-DAY RECOVERY IN MICE
 SUMMARY OF BODY WEIGHT CHANGES [G]

GROUP :		MALES	
		0 MG/KG	2000 MG/KG
DAY -12 TO	-8		
	MEAN	1.5	0.6
	S.D.	0.63	1.02
	S.E.	0.28	0.46
	N	5	5
-8 TO	-2		
	MEAN	1.2	2.2
	S.D.	0.54	0.96
	S.E.	0.24	0.43
	N	5	5
-2 TO	0		
	MEAN	0.0	-0.9
	S.D.	0.61	0.88
	S.E.	0.27	0.40
	N	5	5
0 TO	1		
	MEAN	1.3	1.0
	S.D.	0.74	0.60
	S.E.	0.33	0.27
	N	5	5
1 TO	2		
	MEAN	0.0	0.7*
	S.D.	0.50	0.33
	S.E.	0.22	0.15
	N	5	5

* = Significantly different from the control group at 0.05 using Dunnett's test

PROJECT NO.:WIL-639011
 SPONSOR:SYNGENTA

TABLE 6
 A SINGLE ORAL DOSE OF PMI-0105 WITH A 14-DAY RECOVERY IN MICE
 SUMMARY OF BODY WEIGHT CHANGES [G]

GROUP :		MALES	
DAY	2 TO 3	0 MG/KG	2000 MG/KG
	MEAN	-0.3	-0.5
	S.D.	0.34	0.60
	S.E.	0.15	0.27
	N	5	5
	3 TO 4		
	MEAN	0.8	0.3
	S.D.	0.30	0.50
	S.E.	0.13	0.22
	N	5	5
	4 TO 5		
	MEAN	0.2	0.0
	S.D.	0.30	0.16
	S.E.	0.13	0.07
	N	5	5
	5 TO 6		
	MEAN	0.1	0.3
	S.D.	0.35	0.24
	S.E.	0.16	0.11
	N	5	5
	6 TO 7		
	MEAN	-0.1	-0.1
	S.D.	0.54	0.19
	S.E.	0.24	0.09
	N	5	5

None significantly different from control group

PROJECT NO.:WIL-639011
 SPONSOR:SYNGENTA

TABLE 6
 A SINGLE ORAL DOSE OF PMI-0105 WITH A 14-DAY RECOVERY IN MICE
 SUMMARY OF BODY WEIGHT CHANGES [G]

GROUP :		MALES	
DAY	7 TO 8	0 MG/KG	2000 MG/KG
	MEAN	0.8	0.8
	S.D.	0.48	0.51
	S.E.	0.22	0.23
	N	5	5
	8 TO 9		
	MEAN	-0.2	-0.3
	S.D.	0.19	0.25
	S.E.	0.09	0.11
	N	5	5
	9 TO 10		
	MEAN	0.3	0.1
	S.D.	0.42	0.21
	S.E.	0.19	0.09
	N	5	5
	10 TO 11		
	MEAN	0.2	0.1
	S.D.	0.08	0.27
	S.E.	0.04	0.12
	N	5	5
	11 TO 12		
	MEAN	-0.3	-0.3
	S.D.	0.24	0.61
	S.E.	0.11	0.27
	N	5	5

None significantly different from control group

PROJECT NO.:WIL-639011
 SPONSOR:SYNGENTA

TABLE 6
 A SINGLE ORAL DOSE OF PMI-0105 WITH A 14-DAY RECOVERY IN MICE
 SUMMARY OF BODY WEIGHT CHANGES [G]

GROUP:		MALES	
DAY		0 MG/KG	2000 MG/KG
12 TO	13		
	MEAN	0.3	0.7
	S.D.	0.64	0.43
	S.E.	0.29	0.19
	N	5	5
13 TO	14		
	MEAN	-0.5	-0.3
	S.D.	0.45	0.28
	S.E.	0.20	0.12
	N	5	5

None significantly different from control group

PROJECT NO.:WIL-639011
 SPONSOR:SYNGENTA

TABLE 6
 A SINGLE ORAL DOSE OF PMI-0105 WITH A 14-DAY RECOVERY IN MICE
 SUMMARY OF BODY WEIGHT CHANGES [G]

GROUP:		FEMALES	
		0 MG/KG	2000 MG/KG
DAY -12 TO	-8		
	MEAN	1.3	0.4**
	S.D.	0.45	0.22
	S.E.	0.20	0.10
	N	5	5
-8 TO	-2		
	MEAN	1.0	1.0
	S.D.	0.63	0.76
	S.E.	0.28	0.34
	N	5	5
-2 TO	0		
	MEAN	-0.7	-1.0
	S.D.	0.36	0.88
	S.E.	0.16	0.40
	N	5	5
0 TO	1		
	MEAN	0.0	1.0
	S.D.	1.34	0.63
	S.E.	0.60	0.28
	N	5	5
1 TO	2		
	MEAN	-0.2	0.4
	S.D.	0.73	0.48
	S.E.	0.33	0.22
	N	5	5

** = Significantly different from the control group at 0.01 using Dunnett's test

PROJECT NO.:WIL-639011
 SPONSOR:SYNGENTA

TABLE 6
 A SINGLE ORAL DOSE OF PMI-0105 WITH A 14-DAY RECOVERY IN MICE
 SUMMARY OF BODY WEIGHT CHANGES [G]

GROUP :		FEMALES	
DAY	2 TO 3	0 MG/KG	2000 MG/KG
	MEAN	0.0	-0.1
	S.D.	0.17	0.34
	S.E.	0.07	0.15
	N	5	5
	3 TO 4		
	MEAN	0.4	0.2
	S.D.	0.51	0.72
	S.E.	0.23	0.32
	N	5	5
	4 TO 5		
	MEAN	0.0	-0.2
	S.D.	0.61	0.49
	S.E.	0.27	0.22
	N	5	5
	5 TO 6		
	MEAN	0.2	0.4
	S.D.	0.39	0.39
	S.E.	0.18	0.17
	N	5	5
	6 TO 7		
	MEAN	0.0	0.0
	S.D.	0.54	0.52
	S.E.	0.24	0.23
	N	5	5

None significantly different from control group

PROJECT NO.:WIL-639011
 SPONSOR:SYNGENTA

TABLE 6
 A SINGLE ORAL DOSE OF PMI-0105 WITH A 14-DAY RECOVERY IN MICE
 SUMMARY OF BODY WEIGHT CHANGES [G]

GROUP :		FEMALES	
DAY	7 TO 8	0 MG/KG	2000 MG/KG
	MEAN	0.6	0.3
	S.D.	0.58	0.57
	S.E.	0.26	0.25
	N	5	5
	8 TO 9		
	MEAN	-0.4	0.0
	S.D.	0.63	0.34
	S.E.	0.28	0.15
	N	5	5
	9 TO 10		
	MEAN	0.5	0.1
	S.D.	0.48	0.44
	S.E.	0.22	0.20
	N	5	5
	10 TO 11		
	MEAN	-0.1	0.4
	S.D.	0.44	0.33
	S.E.	0.20	0.15
	N	5	5
	11 TO 12		
	MEAN	0.1	-0.2
	S.D.	0.28	0.52
	S.E.	0.13	0.23
	N	5	5

None significantly different from control group

PROJECT NO.:WIL-639011
 SPONSOR:SYNGENTA

TABLE 6
 A SINGLE ORAL DOSE OF PMI-0105 WITH A 14-DAY RECOVERY IN MICE
 SUMMARY OF BODY WEIGHT CHANGES [G]

GROUP:		FEMALES	
		0 MG/KG	2000 MG/KG
DAY 12 TO 13			
	MEAN	0.5	0.4
	S.D.	0.55	0.33
	S.E.	0.25	0.15
	N	5	5
13 TO 14			
	MEAN	-0.1	-0.1
	S.D.	0.58	0.39
	S.E.	0.26	0.17
	N	5	5

None significantly different from control group

PBFSTv5.28
 02/26/2008
 R:03/20/2009

PROJECT NO.:WIL-639011
 SPONSOR:SYNGENTA

TABLE 7
 A SINGLE ORAL DOSE OF PMI-0105 WITH A 14-DAY RECOVERY IN MICE
 SUMMARY OF CUMULATIVE BODY WEIGHT CHANGES [G]

GROUP :		MALES	
DAY	0 TO	0 MG/KG	2000 MG/KG
	1		
	MEAN	1.3	1.0
	S.D.	0.74	0.60
	S.E.	0.33	0.27
	N	5	5
	2		
	MEAN	1.3	1.7
	S.D.	0.38	0.59
	S.E.	0.17	0.27
	N	5	5
	3		
	MEAN	0.9	1.2
	S.D.	0.30	0.43
	S.E.	0.14	0.19
	N	5	5
	4		
	MEAN	1.8	1.5
	S.D.	0.23	0.35
	S.E.	0.10	0.16
	N	5	5
	5		
	MEAN	2.0	1.5
	S.D.	0.47	0.32
	S.E.	0.21	0.14
	N	5	5

None significantly different from control group

PROJECT NO.:WIL-639011
 SPONSOR:SYNGENTA

TABLE 7
 A SINGLE ORAL DOSE OF PMI-0105 WITH A 14-DAY RECOVERY IN MICE
 SUMMARY OF CUMULATIVE BODY WEIGHT CHANGES [G]

GROUP :		MALES	
DAY		0 MG/KG	2000 MG/KG
0 TO	6		
	MEAN	2.1	1.8
	S.D.	0.75	0.45
	S.E.	0.33	0.20
	N	5	5
0 TO	7		
	MEAN	2.0	1.7
	S.D.	0.60	0.56
	S.E.	0.27	0.25
	N	5	5
0 TO	8		
	MEAN	2.8	2.5
	S.D.	0.59	0.94
	S.E.	0.26	0.42
	N	5	5
0 TO	9		
	MEAN	2.6	2.2
	S.D.	0.68	0.74
	S.E.	0.31	0.33
	N	5	5
0 TO	10		
	MEAN	2.9	2.3
	S.D.	0.82	0.75
	S.E.	0.36	0.33
	N	5	5

None significantly different from control group

PROJECT NO.:WIL-639011
 SPONSOR:SYNGENTA

TABLE 7
 A SINGLE ORAL DOSE OF PMI-0105 WITH A 14-DAY RECOVERY IN MICE
 SUMMARY OF CUMULATIVE BODY WEIGHT CHANGES [G]

GROUP:		MALES	
DAY		0 MG/KG	2000 MG/KG
0 TO	11		
	MEAN	3.1	2.4
	S.D.	0.87	0.74
	S.E.	0.39	0.33
	N	5	5
0 TO	12		
	MEAN	2.8	2.1
	S.D.	0.74	0.90
	S.E.	0.33	0.40
	N	5	5
0 TO	13		
	MEAN	3.1	2.8
	S.D.	0.99	0.80
	S.E.	0.44	0.36
	N	5	5
0 TO	14		
	MEAN	2.6	2.5
	S.D.	0.81	0.58
	S.E.	0.36	0.26
	N	5	5

None significantly different from control group

PROJECT NO.:WIL-639011
 SPONSOR:SYNGENTA

TABLE 7
 A SINGLE ORAL DOSE OF PMI-0105 WITH A 14-DAY RECOVERY IN MICE
 SUMMARY OF CUMULATIVE BODY WEIGHT CHANGES [G]

GROUP:		FEMALES	
DAY	0 TO	0 MG/KG	2000 MG/KG
	1		
	MEAN	0.0	1.0
	S.D.	1.34	0.63
	S.E.	0.60	0.28
	N	5	5
	2		
	MEAN	-0.2	1.4
	S.D.	1.99	0.92
	S.E.	0.89	0.41
	N	5	5
	3		
	MEAN	-0.2	1.3
	S.D.	2.07	0.74
	S.E.	0.93	0.33
	N	5	5
	4		
	MEAN	0.3	1.5
	S.D.	2.51	0.41
	S.E.	1.12	0.18
	N	5	5
	5		
	MEAN	0.3	1.3
	S.D.	2.17	0.76
	S.E.	0.97	0.34
	N	5	5

None significantly different from control group

PROJECT NO.:WIL-639011
 SPONSOR:SYNGENTA

TABLE 7
 A SINGLE ORAL DOSE OF PMI-0105 WITH A 14-DAY RECOVERY IN MICE
 SUMMARY OF CUMULATIVE BODY WEIGHT CHANGES [G]

GROUP:		FEMALES	
DAY	0 TO	0 MG/KG	2000 MG/KG
	6		
	MEAN	0.5	1.7
	S.D.	2.39	0.71
	S.E.	1.07	0.32
	N	5	5
	7		
	MEAN	0.5	1.7
	S.D.	2.18	0.81
	S.E.	0.97	0.36
	N	5	5
	8		
	MEAN	1.1	2.0
	S.D.	2.70	0.55
	S.E.	1.21	0.25
	N	5	5
	9		
	MEAN	0.7	2.1
	S.D.	2.31	0.74
	S.E.	1.03	0.33
	N	5	5
	10		
	MEAN	1.2	2.1
	S.D.	2.48	1.05
	S.E.	1.11	0.47
	N	5	5

None significantly different from control group

PROJECT NO.:WIL-639011
 SPONSOR:SYNGENTA

TABLE 7
 A SINGLE ORAL DOSE OF PMI-0105 WITH A 14-DAY RECOVERY IN MICE
 SUMMARY OF CUMULATIVE BODY WEIGHT CHANGES [G]

GROUP:		FEMALES	
DAY	0 TO	0 MG/KG	2000 MG/KG
	11		
	MEAN	1.1	2.5
	S.D.	2.57	1.24
	S.E.	1.15	0.55
	N	5	5
	12		
	MEAN	1.2	2.3
	S.D.	2.47	1.13
	S.E.	1.11	0.51
	N	5	5
	13		
	MEAN	1.7	2.8
	S.D.	2.19	1.15
	S.E.	0.98	0.52
	N	5	5
	14		
	MEAN	1.6	2.7
	S.D.	1.71	1.08
	S.E.	0.76	0.48
	N	5	5

None significantly different from control group

PBFSTv5.28
 02/26/2008
 R:03/20/2009

PROJECT NO.:WIL-639011
 SPONSOR:SYNGENTA

TABLE 8
 A SINGLE ORAL DOSE OF PMI-0105 WITH A 14-DAY RECOVERY IN MICE
 SUMMARY OF FOOD CONSUMPTION [G/ANIMAL/DAY]

GROUP :		MALES	
		0 MG/KG	2000 MG/KG
DAY	-8 TO -2		
	MEAN	7.3	8.2
	S.D.	1.43	1.46
	S.E.	0.64	0.65
	N	5	5
	0 TO 1		
	MEAN	6.7	5.1
	S.D.	1.88	0.52
	S.E.	0.84	0.23
	N	5	5
	1 TO 2		
	MEAN	6.5	5.6
	S.D.	0.77	0.77
	S.E.	0.38	0.34
	N	4	5
	2 TO 3		
	MEAN	7.1	6.7
	S.D.	0.85	1.34
	S.E.	0.43	0.60
	N	4	5
	3 TO 4		
	MEAN	7.5	8.9
	S.D.	1.06	1.41
	S.E.	0.61	1.00
	N	3	2

None significantly different from control group

PROJECT NO.:WIL-639011
 SPONSOR:SYNGENTA

TABLE 8
 A SINGLE ORAL DOSE OF PMI-0105 WITH A 14-DAY RECOVERY IN MICE
 SUMMARY OF FOOD CONSUMPTION [G/ANIMAL/DAY]

GROUP :			MALES	
DAY	4 TO	5	0 MG/KG	2000 MG/KG
		MEAN	7.0	7.2
		S.D.	1.65	1.79
		S.E.	0.83	0.89
		N	4	4
	5 TO	6		
		MEAN	7.2	5.8**
		S.D.	0.84	0.39
		S.E.	0.37	0.18
		N	5	5
	6 TO	7		
		MEAN	7.1	6.4
		S.D.	0.68	0.42
		S.E.	0.31	0.19
		N	5	5
	7 TO	8		
		MEAN	6.5	5.8
		S.D.	1.27	1.03
		S.E.	0.57	0.46
		N	5	5
	8 TO	9		
		MEAN	6.7	6.0
		S.D.	0.54	1.12
		S.E.	0.27	0.50
		N	4	5

** = Significantly different from the control group at 0.01 using Dunnett's test

PROJECT NO.:WIL-639011
 SPONSOR:SYNGENTA

TABLE 8
 A SINGLE ORAL DOSE OF PMI-0105 WITH A 14-DAY RECOVERY IN MICE
 SUMMARY OF FOOD CONSUMPTION [G/ANIMAL/DAY]

GROUP :		MALES	
DAY		0 MG/KG	2000 MG/KG
9 TO 10	MEAN	6.3	6.1
	S.D.	0.72	0.42
	S.E.	0.42	0.19
	N	3	5
10 TO 11	MEAN	5.7	6.0
	S.D.	1.13	0.46
	S.E.	0.56	0.20
	N	4	5
11 TO 12	MEAN	6.8	6.9
	S.D.	1.08	1.23
	S.E.	0.48	0.55
	N	5	5
12 TO 13	MEAN	5.0	6.0
	S.D.	2.04	0.49
	S.E.	1.02	0.22
	N	4	5
13 TO 14	MEAN	4.6	6.5
	S.D.	2.69	0.57
	S.E.	1.20	0.25
	N	5	5

None significantly different from control group

PROJECT NO.:WIL-639011
 SPONSOR:SYNGENTA

TABLE 8
 A SINGLE ORAL DOSE OF PMI-0105 WITH A 14-DAY RECOVERY IN MICE
 SUMMARY OF FOOD CONSUMPTION [G/ANIMAL/DAY]

GROUP :		FEMALES	
		0 MG/KG	2000 MG/KG
DAY	-8 TO -2		
	MEAN	6.8	6.4
	S.D.	1.08	1.50
	S.E.	0.48	0.67
	N	5	5
	0 TO 1		
	MEAN	3.8	5.6
	S.D.	2.14	1.50
	S.E.	0.96	0.67
	N	5	5
	1 TO 2		
	MEAN	5.0	5.6
	S.D.	1.17	1.29
	S.E.	0.52	0.65
	N	5	4
	2 TO 3		
	MEAN	5.2	5.9
	S.D.	0.95	1.67
	S.E.	0.47	0.75
	N	4	5
	3 TO 4		
	MEAN	8.7	7.0
	S.D.	1.44	3.25
	S.E.	0.83	2.30
	N	3	2

None significantly different from control group

PROJECT NO.:WIL-639011
 SPONSOR:SYNGENTA

TABLE 8
 A SINGLE ORAL DOSE OF PMI-0105 WITH A 14-DAY RECOVERY IN MICE
 SUMMARY OF FOOD CONSUMPTION [G/ANIMAL/DAY]

GROUP :			FEMALES	
DAY	4 TO	5	0 MG/KG	2000 MG/KG
		MEAN	6.7	4.8
		S.D.	0.51	4.71
		S.E.	0.25	2.72
		N	4	3
	5 TO	6		
		MEAN	6.3	5.9
		S.D.	1.11	0.77
		S.E.	0.56	0.34
		N	4	5
	6 TO	7		
		MEAN	6.4	6.6
		S.D.	0.33	1.30
		S.E.	0.17	0.65
		N	4	4
	7 TO	8		
		MEAN	5.5	5.6
		S.D.	0.98	0.79
		S.E.	0.44	0.39
		N	5	4
	8 TO	9		
		MEAN	6.7	6.3
		S.D.	0.65	1.95
		S.E.	0.29	0.98
		N	5	4

None significantly different from control group

PROJECT NO.:WIL-639011
 SPONSOR:SYNGENTA

TABLE 8
 A SINGLE ORAL DOSE OF PMI-0105 WITH A 14-DAY RECOVERY IN MICE
 SUMMARY OF FOOD CONSUMPTION [G/ANIMAL/DAY]

GROUP :		0 MG/KG	FEMALES	2000 MG/KG
DAY	9 TO 10			
	MEAN	6.2		5.4
	S.D.	1.07		0.71
	S.E.	0.48		0.41
	N	5		3
	10 TO 11			
	MEAN	6.0		6.6
	S.D.	1.68		1.12
	S.E.	0.75		0.56
	N	5		4
	11 TO 12			
	MEAN	5.7		6.0
	S.D.	1.31		0.96
	S.E.	0.58		0.48
	N	5		4
	12 TO 13			
	MEAN	5.9		5.6
	S.D.	1.24		0.39
	S.E.	0.56		0.19
	N	5		4
	13 TO 14			
	MEAN	6.0		5.0
	S.D.	1.20		1.48
	S.E.	0.54		0.66
	N	5		5

None significantly different from control group

PBFStv5.28
 02/26/2008
 R:03/20/2009

PROJECT NO.:WIL-639011
 SPONSOR:SYNGENTA

TABLE 9
 A SINGLE ORAL DOSE OF PMI-0105 WITH A 14-DAY RECOVERY IN MICE
 SUMMARY OF HEMATOLOGY VALUES

ANALYSIS		GROUP:		MALES	
		0 MG/KG		2000 MG/KG	

WHITE CELLS (thous/uL)					
DAY 14	MEAN	2.93		3.52	
	% DIFFERENCE			20.1	
	S.D.	0.865		0.987	
	S.E.	0.387		0.441	
	N	5		5	
RED CELLS (mil/uL)					
DAY 14	MEAN	8.96		9.02	
	% DIFFERENCE			0.7	
	S.D.	0.510		0.296	
	S.E.	0.228		0.132	
	N	5		5	
HEMOGLOBIN (g/dL)					
DAY 14	MEAN	15.0		14.7	
	% DIFFERENCE			-2.0	
	S.D.	1.20		0.41	
	S.E.	0.54		0.18	
	N	5		5	
HEMATOCRIT (%)					
DAY 14	MEAN	42.1		41.2	
	% DIFFERENCE			-2.1	
	S.D.	3.31		1.24	
	S.E.	1.48		0.55	
	N	5		5	

thous/uL = THOUSANDS/MICROLITER, mil/uL = MILLIONS/MICROLITER, fL = FEMTOLITERS, pg = PICOGRAMS, g/dL = GRAMS/DECILITER

None significantly different from control group

PROJECT NO.:WIL-639011
 SPONSOR:SYNGENTA

TABLE 9
 A SINGLE ORAL DOSE OF PMI-0105 WITH A 14-DAY RECOVERY IN MICE
 SUMMARY OF HEMATOLOGY VALUES

ANALYSIS		GROUP:	MALES	
			0 MG/KG	2000 MG/KG

MCV (fL)				
DAY 14	MEAN		47.0	45.7
	% DIFFERENCE			-2.8
	S.D.		1.31	1.39
	S.E.		0.59	0.62
	N		5	5
MCH (pg)				
DAY 14	MEAN		16.7	16.3
	% DIFFERENCE			-2.4
	S.D.		0.62	0.38
	S.E.		0.28	0.17
	N		5	5
MCHC (g/dL)				
DAY 14	MEAN		35.6	35.7
	% DIFFERENCE			0.3
	S.D.		0.77	0.33
	S.E.		0.35	0.15
	N		5	5
PLATELET (thous/uL)				
DAY 14	MEAN		1053.	1101.
	% DIFFERENCE			4.6
	S.D.		67.4	169.8
	S.E.		30.1	75.9
	N		5	5

thous/uL = THOUSANDS/MICROLITER, mil/uL = MILLIONS/MICROLITER, fL = FEMTOLITERS, pg = PICOGRAMS, g/dL = GRAMS/DECILITER

None significantly different from control group

PROJECT NO.:WIL-639011
SPONSOR:SYNGENTA

TABLE 9
A SINGLE ORAL DOSE OF PMI-0105 WITH A 14-DAY RECOVERY IN MICE
SUMMARY OF HEMATOLOGY VALUES

PAGE 3

ANALYSIS		GROUP:		MALES	
		0 MG/KG		2000 MG/KG	
RETICULOCYTE (%)					
DAY 14	MEAN	2.5		2.6	
	% DIFFERENCE			4.0	
	S.D.	0.15		0.27	
	S.E.	0.07		0.12	
	N	5		5	
RETIC ABSOLUTE (thous/uL)					
DAY 14	MEAN	225.3		236.4	
	% DIFFERENCE			4.9	
	S.D.	19.63		19.40	
	S.E.	8.78		8.67	
	N	5		5	
NEUTROPHIL (%)					
DAY 14	MEAN	15.1		14.7	
	% DIFFERENCE			-2.6	
	S.D.	2.67		2.79	
	S.E.	1.19		1.25	
	N	5		5	
LYMPHOCYTE (%)					
DAY 14	MEAN	79.3		80.4	
	% DIFFERENCE			1.4	
	S.D.	2.59		3.21	
	S.E.	1.16		1.44	
	N	5		5	

thous/uL = THOUSANDS/MICROLITER, mil/uL = MILLIONS/MICROLITER, fL = FEMTOLITERS, pg = PICOGRAMS, g/dL = GRAMS/DECILITER

None significantly different from control group

PROJECT NO.:WIL-639011
 SPONSOR:SYNGENTA

TABLE 9
 A SINGLE ORAL DOSE OF PMI-0105 WITH A 14-DAY RECOVERY IN MICE
 SUMMARY OF HEMATOLOGY VALUES

ANALYSIS		GROUP:	MALES	
			0 MG/KG	2000 MG/KG

MONOCYTE (%)				
DAY 14	MEAN		1.2	1.8
	% DIFFERENCE			50.0
	S.D.		0.33	1.32
	S.E.		0.15	0.59
	N		5	5
EOSINOPHIL (%)				
DAY 14	MEAN		3.8	2.4
	% DIFFERENCE			-36.8
	S.D.		0.64	1.70
	S.E.		0.29	0.76
	N		5	5
BASOPHIL (%)				
DAY 14	MEAN		0.4	0.4
	% DIFFERENCE			0.0
	S.D.		0.19	0.26
	S.E.		0.08	0.12
	N		5	5
LG UNSTAIN CELL (%)				
DAY 14	MEAN		0.3	0.3
	% DIFFERENCE			0.0
	S.D.		0.16	0.21
	S.E.		0.07	0.09
	N		5	5

thous/uL = THOUSANDS/MICROLITER, mil/uL = MILLIONS/MICROLITER, fL = FEMTOLITERS, pg = PICOGRAMS, g/dL = GRAMS/DECILITER

None significantly different from control group

PROJECT NO.:WIL-639011
 SPONSOR:SYNGENTA

TABLE 9
 A SINGLE ORAL DOSE OF PMI-0105 WITH A 14-DAY RECOVERY IN MICE
 SUMMARY OF HEMATOLOGY VALUES

ANALYSIS		GROUP:		MALES	
		0 MG/KG		2000 MG/KG	
NEU ABSOLUTE (thous/uL)					
DAY 14	MEAN	0.44		0.52	
	% DIFFERENCE			18.2	
	S.D.	0.144		0.172	
	S.E.	0.065		0.077	
	N	5		5	
LYMPH ABSOLUTE (thous/uL)					
DAY 14	MEAN	2.33		2.84	
	% DIFFERENCE			21.9	
	S.D.	0.696		0.852	
	S.E.	0.311		0.381	
	N	5		5	
MONO ABSOLUTE (thous/uL)					
DAY 14	MEAN	0.03		0.06	
	% DIFFERENCE			100.0	
	S.D.	0.011		0.044	
	S.E.	0.005		0.020	
	N	5		5	
EOS ABSOLUTE (thous/uL)					
DAY 14	MEAN	0.11		0.08	
	% DIFFERENCE			-27.3	
	S.D.	0.037		0.051	
	S.E.	0.016		0.023	
	N	5		5	

thous/uL = THOUSANDS/MICROLITER, mil/uL = MILLIONS/MICROLITER, fL = FEMTOLITERS, pg = PICOGRAMS, g/dL = GRAMS/DECILITER

None significantly different from control group

PROJECT NO.:WIL-639011
 SPONSOR:SYNGENTA

TABLE 9
 A SINGLE ORAL DOSE OF PMI-0105 WITH A 14-DAY RECOVERY IN MICE
 SUMMARY OF HEMATOLOGY VALUES

ANALYSIS		GROUP:		MALES	
		0 MG/KG		2000 MG/KG	

BASO ABSOLUTE (thous/uL)					
DAY 14	MEAN	0.01		0.01	
	% DIFFERENCE			0.0	
	S.D.	0.008		0.008	
	S.E.	0.004		0.004	
	N	5		5	
LUC ABSOLUTE (thous/uL)					
DAY 14	MEAN	0.01		0.01	
	% DIFFERENCE			0.0	
	S.D.	0.008		0.008	
	S.E.	0.004		0.004	
	N	5		5	

thous/uL = THOUSANDS/MICROLITER, mil/uL = MILLIONS/MICROLITER, fL = FEMTOLITERS, pg = PICOGRAMS, g/dL = GRAMS/DECILITER

None significantly different from control group

PROJECT NO.:WIL-639011
 SPONSOR:SYNGENTA

TABLE 9
 A SINGLE ORAL DOSE OF PMI-0105 WITH A 14-DAY RECOVERY IN MICE
 SUMMARY OF HEMATOLOGY VALUES

ANALYSIS		FEMALES	
GROUP:		0 MG/KG	2000 MG/KG
WHITE CELLS (thous/uL)			
DAY 14	MEAN	3.19	3.75
	% DIFFERENCE		17.6
	S.D.	0.714	1.125
	S.E.	0.412	0.503
	N	3	5
RED CELLS (mil/uL)			
DAY 14	MEAN	8.51	8.75
	% DIFFERENCE		2.8
	S.D.	0.579	0.524
	S.E.	0.334	0.234
	N	3	5
HEMOGLOBIN (g/dL)			
DAY 14	MEAN	14.4	14.2
	% DIFFERENCE		-1.4
	S.D.	1.02	0.63
	S.E.	0.59	0.28
	N	3	5
HEMATOCRIT (%)			
DAY 14	MEAN	40.2	40.1
	% DIFFERENCE		-0.2
	S.D.	1.74	1.61
	S.E.	1.01	0.72
	N	3	5

thous/uL = THOUSANDS/MICROLITER, mil/uL = MILLIONS/MICROLITER, fL = FEMTOLITERS, pg = PICOGRAMS, g/dL = GRAMS/DECILITER

None significantly different from control group

PROJECT NO.:WIL-639011
 SPONSOR:SYNGENTA

TABLE 9
 A SINGLE ORAL DOSE OF PMI-0105 WITH A 14-DAY RECOVERY IN MICE
 SUMMARY OF HEMATOLOGY VALUES

ANALYSIS		GROUP:	FEMALES	
			0 MG/KG	2000 MG/KG

MCV (fL)				
DAY 14	MEAN		47.3	45.9
	% DIFFERENCE			-3.0
	S.D.		2.11	1.39
	S.E.		1.22	0.62
	N		3	5
MCH (pg)				
DAY 14	MEAN		16.9	16.3
	% DIFFERENCE			-3.6
	S.D.		0.87	0.50
	S.E.		0.50	0.22
	N		3	5
MCHC (g/dL)				
DAY 14	MEAN		35.7	35.6
	% DIFFERENCE			-0.3
	S.D.		1.06	0.30
	S.E.		0.61	0.13
	N		3	5
PLATELET (thous/uL)				
DAY 14	MEAN		864.	887.
	% DIFFERENCE			2.7
	S.D.		85.3	110.0
	S.E.		49.2	49.2
	N		3	5

thous/uL = THOUSANDS/MICROLITER, mil/uL = MILLIONS/MICROLITER, fL = FEMTOLITERS, pg = PICOGRAMS, g/dL = GRAMS/DECILITER

None significantly different from control group

PROJECT NO.:WIL-639011
 SPONSOR:SYNGENTA

TABLE 9
 A SINGLE ORAL DOSE OF PMI-0105 WITH A 14-DAY RECOVERY IN MICE
 SUMMARY OF HEMATOLOGY VALUES

ANALYSIS		FEMALES	
GROUP:		0 MG/KG	2000 MG/KG
RETICULOCYTE (%)			
DAY 14	MEAN	2.9	3.1
	% DIFFERENCE		6.9
	S.D.	0.45	0.45
	S.E.	0.26	0.20
	N	3	5
RETIC ABSOLUTE (thous/uL)			
DAY 14	MEAN	248.8	270.3
	% DIFFERENCE		8.6
	S.D.	33.72	27.12
	S.E.	19.47	12.13
	N	3	5
NEUTROPHIL (%)			
DAY 14	MEAN	12.2	12.9
	% DIFFERENCE		5.7
	S.D.	2.36	2.85
	S.E.	1.36	1.27
	N	3	5
LYMPHOCYTE (%)			
DAY 14	MEAN	80.4	81.1
	% DIFFERENCE		0.9
	S.D.	0.98	3.88
	S.E.	0.57	1.74
	N	3	5

thous/uL = THOUSANDS/MICROLITER, mil/uL = MILLIONS/MICROLITER, fL = FEMTOLITERS, pg = PICOGRAMS, g/dL = GRAMS/DECILITER

None significantly different from control group

PROJECT NO.:WIL-639011
 SPONSOR:SYNGENTA

TABLE 9
 A SINGLE ORAL DOSE OF PMI-0105 WITH A 14-DAY RECOVERY IN MICE
 SUMMARY OF HEMATOLOGY VALUES

ANALYSIS		GROUP:	FEMALES	
			0 MG/KG	2000 MG/KG

MONOCYTE (%)				
DAY 14	MEAN		1.2	1.9
	% DIFFERENCE			58.3
	S.D.		0.29	0.69
	S.E.		0.17	0.31
	N		3	5
EOSINOPHIL (%)				
DAY 14	MEAN		5.5	3.7
	% DIFFERENCE			-32.7
	S.D.		1.80	1.27
	S.E.		1.04	0.57
	N		3	5
BASOPHIL (%)				
DAY 14	MEAN		0.5	0.2
	% DIFFERENCE			-60.0
	S.D.		0.50	0.23
	S.E.		0.29	0.10
	N		3	5
LG UNSTAIN CELL (%)				
DAY 14	MEAN		0.2	0.2
	% DIFFERENCE			0.0
	S.D.		0.29	0.20
	S.E.		0.17	0.09
	N		3	5

thous/uL = THOUSANDS/MICROLITER, mil/uL = MILLIONS/MICROLITER, fL = FEMTOLITERS, pg = PICOGRAMS, g/dL = GRAMS/DECILITER

None significantly different from control group

PROJECT NO.: WIL-639011
SPONSOR: SYNGENTATABLE 9
A SINGLE ORAL DOSE OF PMI-0105 WITH A 14-DAY RECOVERY IN MICE
SUMMARY OF HEMATOLOGY VALUES

PAGE 11

ANALYSIS		FEMALES	
GROUP:		0 MG/KG	2000 MG/KG
NEU ABSOLUTE (thous/uL)			
DAY 14	MEAN	0.38	0.47
	% DIFFERENCE		23.7
	S.D.	0.057	0.100
	S.E.	0.033	0.045
	N	3	5
LYMPH ABSOLUTE (thous/uL)			
DAY 14	MEAN	2.57	3.04
	% DIFFERENCE		18.3
	S.D.	0.586	0.966
	S.E.	0.339	0.432
	N	3	5
MONO ABSOLUTE (thous/uL)			
DAY 14	MEAN	0.04	0.07
	% DIFFERENCE		75.0
	S.D.	0.006	0.030
	S.E.	0.003	0.014
	N	3	5
EOS ABSOLUTE (thous/uL)			
DAY 14	MEAN	0.18	0.15
	% DIFFERENCE		-16.7
	S.D.	0.092	0.084
	S.E.	0.053	0.038
	N	3	5

thous/uL = THOUSANDS/MICROLITER, mil/uL = MILLIONS/MICROLITER, fL = FEMTOLITERS, pg = PICOGRAMS, g/dL = GRAMS/DECILITER

None significantly different from control group

PROJECT NO.:WIL-639011
 SPONSOR:SYNGENTA

TABLE 9
 A SINGLE ORAL DOSE OF PMI-0105 WITH A 14-DAY RECOVERY IN MICE
 SUMMARY OF HEMATOLOGY VALUES

ANALYSIS		FEMALES	
GROUP:		0 MG/KG	2000 MG/KG
BASO ABSOLUTE (thous/uL)			
DAY 14	MEAN	0.02	0.01
	% DIFFERENCE		-50.0
	S.D.	0.021	0.005
	S.E.	0.012	0.002
	N	3	5
LUC ABSOLUTE (thous/uL)			
DAY 14	MEAN	0.00	0.01
	% DIFFERENCE		NA
	S.D.	0.006	0.008
	S.E.	0.003	0.004
	N	3	5

thous/uL = THOUSANDS/MICROLITER, mil/uL = MILLIONS/MICROLITER, fL = FEMTOLITERS, pg = PICOGRAMS, g/dL = GRAMS/DECILITER

None significantly different from control group
 NA = NOT APPLICABLE

PCPSv5.24
 02/26/2008
 R:03/20/2009

PROJECT NO.:WIL-639011
 SPONSOR:SYNGENTA

TABLE 10
 A SINGLE ORAL DOSE OF PMI-0105 WITH A 14-DAY RECOVERY IN MICE
 SUMMARY OF SERUM CHEMISTRY VALUES

ANALYSIS		MALES	
GROUP:		0 MG/KG	2000 MG/KG
UREA NITROGEN (mg/dL)			
DAY 14	MEAN	19.5	27.5*
	% DIFFERENCE		41.0
	S.D.	1.10	6.20
	S.E.	0.55	3.10
	N	4	4
CREATININE (mg/dL)			
DAY 14	MEAN	0.1	0.0
	% DIFFERENCE		-100.0
	S.D.	0.07	0.00
	S.E.	0.05	0.00
	N	2	3
ALKALINEPHOS'TSE (U/L)			
DAY 14	MEAN	65.	92.*
	% DIFFERENCE		41.5
	S.D.	12.8	21.7
	S.E.	5.7	9.7
	N	5	5

mg/dL = MILLIGRAMS/DECILITER, U/L = INTERNATIONAL UNIT/LITER, g/dL = GRAMS/DECILITER, mEq/L = MILLIEQUIVALENTS/LITER

* = Significantly different from the control group at 0.05 using Dunnett's test
 NA = NOT APPLICABLE

PROJECT NO.:WIL-639011
 SPONSOR:SYNGENTA

TABLE 10
 A SINGLE ORAL DOSE OF PMI-0105 WITH A 14-DAY RECOVERY IN MICE
 SUMMARY OF SERUM CHEMISTRY VALUES

ANALYSIS		GROUP:		MALES	
		0 MG/KG		2000 MG/KG	
ALANINE TRANSFER (U/L)					
DAY 14	MEAN	47.		59.	
	% DIFFERENCE			25.5	
	S.D.	14.5		30.7	
	S.E.	6.5		13.7	
	N	5		5	
ASPARTATTRANSFER (U/L)					
DAY 14	MEAN	87.		92.	
	% DIFFERENCE			5.7	
	S.D.	16.1		23.3	
	S.E.	7.2		10.4	
	N	5		5	
GLUTAMYLTRANSFER (U/L)					
DAY 14	MEAN	NA		0.1	
	% DIFFERENCE			NA	
	S.D.			0.00	
	S.E.			0.00	
	N			1	
GLUCOSE (mg/dL)					
DAY 14	MEAN	186.		191.	
	% DIFFERENCE			2.7	
	S.D.	3.5		13.4	
	S.E.	2.5		9.5	
	N	2		2	

mg/dL = MILLIGRAMS/DECILITER, U/L = INTERNATIONAL UNIT/LITER, g/dL = GRAMS/DECILITER, mEq/L = MILLIEQUIVALENTS/LITER

None significantly different from control group
 NA = NOT APPLICABLE

PROJECT NO.: WIL-639011
SPONSOR: SYNGENTA

TABLE 10
A SINGLE ORAL DOSE OF PMI-0105 WITH A 14-DAY RECOVERY IN MICE
SUMMARY OF SERUM CHEMISTRY VALUES

PAGE 3

ANALYSIS		FEMALES	
GROUP:		0 MG/KG	2000 MG/KG
UREA NITROGEN (mg/dL)			
DAY 14	MEAN	20.5	16.8
	% DIFFERENCE		-18.0
	S.D.	2.67	0.71
	S.E.	1.33	0.50
	N	4	2
CREATININE (mg/dL)			
DAY 14	MEAN	0.0	0.0
	% DIFFERENCE		NA
	S.D.	0.00	0.00
	S.E.	0.00	0.00
	N	3	2
ALKALINEPHOS'TSE (U/L)			
DAY 14	MEAN	119.	128.
	% DIFFERENCE		7.6
	S.D.	30.3	31.8
	S.E.	13.5	14.2
	N	5	5

mg/dL = MILLIGRAMS/DECILITER, U/L = INTERNATIONAL UNIT/LITER, g/dL = GRAMS/DECILITER, mEq/L = MILLIEQUIVALENTS/LITER

None significantly different from control group
NA = NOT APPLICABLE

PROJECT NO.:WIL-639011
 SPONSOR:SYNGENTA

TABLE 10
 A SINGLE ORAL DOSE OF PMI-0105 WITH A 14-DAY RECOVERY IN MICE
 SUMMARY OF SERUM CHEMISTRY VALUES

ANALYSIS		FEMALES	
GROUP:		0 MG/KG	2000 MG/KG
ALANINE TRANSFER (U/L)			
DAY 14	MEAN	30.	41.*
	% DIFFERENCE		36.7
	S.D.	3.4	8.1
	S.E.	1.5	3.6
	N	5	5
ASPARTATTRANSFER (U/L)			
DAY 14	MEAN	98.	104.
	% DIFFERENCE		6.1
	S.D.	42.1	14.5
	S.E.	18.8	6.5
	N	5	5
GLUCOSE (mg/dL)			
DAY 14	MEAN	156.	158.
	% DIFFERENCE		1.3
	S.D.	28.0	33.9
	S.E.	14.0	24.0
	N	4	2

mg/dL = MILLIGRAMS/DECILITER, U/L = INTERNATIONAL UNIT/LITER, g/dL = GRAMS/DECILITER, mEq/L = MILLIEQUIVALENTS/LITER

* = Significantly different from the control group at 0.05 using Dunnett's test
 NA = NOT APPLICABLE

PROJECT NO.:WIL-639011
 SPONSOR:SYNGENTA

TABLE 10
 A SINGLE ORAL DOSE OF PMI-0105 WITH A 14-DAY RECOVERY IN MICE
 SUMMARY OF SERUM CHEMISTRY VALUES

PAGE 5

ANALYSIS		FEMALES	
GROUP:		0 MG/KG	2000 MG/KG
CHOLESTEROL (mg/dL)			
DAY 14	MEAN	86.	NA
	% DIFFERENCE		
	S.D.	0.0	
	S.E.	0.0	
	N	1	

mg/dL = MILLIGRAMS/DECILITER, U/L = INTERNATIONAL UNIT/LITER, g/dL = GRAMS/DECILITER, mEq/L = MILLIEQUIVALENTS/LITER

None significantly different from control group
 NA = NOT APPLICABLE

PCPSv5.24
 02/26/2008
 R:03/20/2009

PROJECT NO.:WIL-639011
 SPONSOR:SYNGENTA

TABLE 11
 A SINGLE ORAL DOSE OF PMI-0105 WITH A 14-DAY RECOVERY IN MICE
 SUMMARY OF MACROSCOPIC FINDINGS

SCHEDULED NECROPSY

	-----	M A L E	-----
GROUP:	1		2
NUMBER OF ANIMALS IN DOSE GROUP	5		5
NUMBER OF ANIMALS TERMINALLY EUTHANIZED	5		5
KIDNEYS			
-AREA(S), DEPRESSED	1		0
LUNGS			
-NOT FULLY COLLAPSED	0		1
NO SIGNIFICANT CHANGES OBSERVED - ALL EXAMINED TISSUES	4		4

1- 0 MG/KG 2- 2000 MG/KG

PROJECT NO.:WIL-639011
 SPONSOR:SYNGENTA

TABLE 11
 A SINGLE ORAL DOSE OF PMI-0105 WITH A 14-DAY RECOVERY IN MICE
 SUMMARY OF MACROSCOPIC FINDINGS

SCHEDULED NECROPSY

GROUP:	F E M A L E	
	1	2
NUMBER OF ANIMALS IN DOSE GROUP	5	5
NUMBER OF ANIMALS TERMINALLY EUTHANIZED	5	5
ADRENAL GLANDS -ENLARGED	0	1
ESOPHAGUS -NODULE(S)	1	0
OVARIES -CYST(S)	1	2
NO SIGNIFICANT CHANGES OBSERVED - ALL EXAMINED TISSUES	3	3
1- 0 MG/KG 2- 2000 MG/KG		

PGRSI2v4.07
 02/26/2008
 R:03/20/2009

PROJECT NO.:WIL-639011
SPONSOR:SYNGENTATABLE 12
A SINGLE ORAL DOSE OF PMI-0105 WITH A 14-DAY RECOVERY IN MICE
SUMMARY OF ORGAN WEIGHTS AND RELATIVE ORGAN WEIGHTS

PAGE 1

GROUP:	MALES	
	0 MG/KG	2000 MG/KG
FINAL BODY WT (G)		
MEAN	34.9	33.8
% DIFFERENCE		-3.2
S.D.	1.25	1.87
S.E.	0.56	0.84
N	5	5
ADRENAL GLANDS (G)		
MEAN	0.0069	0.0053
% DIFFERENCE		-23.2
S.D.	0.00237	0.00089
S.E.	0.00106	0.00040
N	5	5
ADRENAL GLANDS (G/100 G FINAL BODY WEIGHT)		
MEAN	0.019	0.016
S.D.	0.0063	0.0036
S.E.	0.0028	0.0016
N	5	5
ADRENAL GLANDS (G/100 G BRAIN)		
MEAN	1.410	1.100
S.D.	0.4792	0.1697
S.E.	0.2143	0.0759
N	5	5

None significantly different from control group

PROJECT NO.:WIL-639011
SPONSOR:SYNGENTA

TABLE 12
A SINGLE ORAL DOSE OF PMI-0105 WITH A 14-DAY RECOVERY IN MICE
SUMMARY OF ORGAN WEIGHTS AND RELATIVE ORGAN WEIGHTS

PAGE 2

GROUP:	MALES	
	0 MG/KG	2000 MG/KG

BRAIN (G)		
MEAN	0.4856	0.4854
% DIFFERENCE		0.0
S.D.	0.02919	0.01730
S.E.	0.01305	0.00773
N	5	5
BRAIN (G/100 G FINAL BODY WEIGHT)		
MEAN	1.391	1.442
S.D.	0.0775	0.1265
S.E.	0.0346	0.0566
N	5	5
EPIDIDYIMIDES (G)		
MEAN	0.1108	0.0839**
% DIFFERENCE		-24.3
S.D.	0.01171	0.00616
S.E.	0.00523	0.00275
N	5	5
EPIDIDYIMIDES (G/100 G FINAL BODY WEIGHT)		
MEAN	0.317	0.249**
S.D.	0.0310	0.0188
S.E.	0.0138	0.0084
N	5	5

** = Significantly different from the control group at 0.01 using Dunnett's test

PROJECT NO.:WIL-639011
SPONSOR:SYNGENTA

TABLE 12
A SINGLE ORAL DOSE OF PMI-0105 WITH A 14-DAY RECOVERY IN MICE
SUMMARY OF ORGAN WEIGHTS AND RELATIVE ORGAN WEIGHTS

PAGE 3

GROUP:	MALES	
	0 MG/KG	2000 MG/KG

EPIDIDYIMIDES (G/100 G BRAIN)		
MEAN	22.894	17.330**
S.D.	2.7946	1.7579
S.E.	1.2498	0.7862
N	5	5
HEART (G)		
MEAN	0.1868	0.1953
% DIFFERENCE		4.6
S.D.	0.01477	0.02916
S.E.	0.00660	0.01304
N	5	5
HEART (G/100 G FINAL BODY WEIGHT)		
MEAN	0.536	0.578
S.D.	0.0499	0.0810
S.E.	0.0223	0.0362
N	5	5
HEART (G/100 G BRAIN)		
MEAN	38.489	40.389
S.D.	2.5154	6.8851
S.E.	1.1249	3.0791
N	5	5

** = Significantly different from the control group at 0.01 using Dunnett's test

PROJECT NO.:WIL-639011
SPONSOR:SYNGENTATABLE 12
A SINGLE ORAL DOSE OF PMI-0105 WITH A 14-DAY RECOVERY IN MICE
SUMMARY OF ORGAN WEIGHTS AND RELATIVE ORGAN WEIGHTS

PAGE 4

GROUP:	MALES	
	0 MG/KG	2000 MG/KG

KIDNEYS (G)		
MEAN	0.6214	0.5770
% DIFFERENCE		-7.1
S.D.	0.05116	0.04246
S.E.	0.02288	0.01899
N	5	5
KIDNEYS (G/100 G FINAL BODY WEIGHT)		
MEAN	1.784	1.708
S.D.	0.2024	0.0998
S.E.	0.0905	0.0446
N	5	5
KIDNEYS (G/100 G BRAIN)		
MEAN	128.675	119.043
S.D.	17.0239	10.2329
S.E.	7.6133	4.5763
N	5	5
LIVER/GB (G)		
MEAN	1.6749	1.6505
% DIFFERENCE		-1.5
S.D.	0.07795	0.08644
S.E.	0.03486	0.03866
N	5	5

None significantly different from control group

PROJECT NO.:WIL-639011
SPONSOR:SYNGENTATABLE 12
A SINGLE ORAL DOSE OF PMI-0105 WITH A 14-DAY RECOVERY IN MICE
SUMMARY OF ORGAN WEIGHTS AND RELATIVE ORGAN WEIGHTS

PAGE 5

GROUP:	MALES	
	0 MG/KG	2000 MG/KG

LIVER/GB (G/100 G FINAL BODY WEIGHT)		
MEAN	4.801	4.884
S.D.	0.2648	0.0542
S.E.	0.1184	0.0243
N	5	5
LIVER/GB (G/100 G BRAIN)		
MEAN	345.262	340.700
S.D.	10.6666	26.5549
S.E.	4.7702	11.8757
N	5	5
SPLEEN (G)		
MEAN	0.0938	0.0778
% DIFFERENCE		-17.1
S.D.	0.01118	0.01157
S.E.	0.00500	0.00518
N	5	5
SPLEEN (G/100 G FINAL BODY WEIGHT)		
MEAN	0.269	0.230
S.D.	0.0386	0.0286
S.E.	0.0173	0.0128
N	5	5

None significantly different from control group

PROJECT NO.:WIL-639011
SPONSOR:SYNGENTATABLE 12
A SINGLE ORAL DOSE OF PMI-0105 WITH A 14-DAY RECOVERY IN MICE
SUMMARY OF ORGAN WEIGHTS AND RELATIVE ORGAN WEIGHTS

PAGE 6

GROUP:	MALES	
	0 MG/KG	2000 MG/KG

SPLEEN (G/100 G BRAIN)		
MEAN	19.334	16.089
S.D.	2.3371	2.8359
S.E.	1.0452	1.2683
N	5	5
TESTES (G)		
MEAN	0.2693	0.1915**
% DIFFERENCE		-28.9
S.D.	0.02111	0.02359
S.E.	0.00944	0.01055
N	5	5
TESTES (G/100 G FINAL BODY WEIGHT)		
MEAN	0.773	0.570**
S.D.	0.0832	0.0914
S.E.	0.0372	0.0409
N	5	5
TESTES (G/100 G BRAIN)		
MEAN	55.756	39.493**
S.D.	7.1401	5.1542
S.E.	3.1932	2.3050
N	5	5

** = Significantly different from the control group at 0.01 using Dunnett's test

PROJECT NO.:WIL-639011
SPONSOR:SYNGENTATABLE 12
A SINGLE ORAL DOSE OF PMI-0105 WITH A 14-DAY RECOVERY IN MICE
SUMMARY OF ORGAN WEIGHTS AND RELATIVE ORGAN WEIGHTS

PAGE 7

GROUP:	FEMALES	
	0 MG/KG	2000 MG/KG
FINAL BODY WT (G)		
MEAN	25.1	25.7
% DIFFERENCE		2.4
S.D.	1.88	1.25
S.E.	0.84	0.56
N	5	5
ADRENAL GLANDS (G)		
MEAN	0.0096	0.0125*
% DIFFERENCE		30.2
S.D.	0.00122	0.00162
S.E.	0.00055	0.00072
N	5	5
ADRENAL GLANDS (G/100 G FINAL BODY WEIGHT)		
MEAN	0.038	0.049*
S.D.	0.0048	0.0082
S.E.	0.0021	0.0037
N	5	5
ADRENAL GLANDS (G/100 G BRAIN)		
MEAN	1.990	2.539*
S.D.	0.2421	0.3028
S.E.	0.1083	0.1354
N	5	5

* = Significantly different from the control group at 0.05 using Dunnett's test

PROJECT NO.:WIL-639011
SPONSOR:SYNGENTA

TABLE 12
A SINGLE ORAL DOSE OF PMI-0105 WITH A 14-DAY RECOVERY IN MICE
SUMMARY OF ORGAN WEIGHTS AND RELATIVE ORGAN WEIGHTS

PAGE 8

GROUP:	FEMALES	
	0 MG/KG	2000 MG/KG
BRAIN (G)		
MEAN	0.4817	0.4916
% DIFFERENCE		2.1
S.D.	0.02211	0.02886
S.E.	0.00989	0.01291
N	5	5
BRAIN (G/100 G FINAL BODY WEIGHT)		
MEAN	1.922	1.911
S.D.	0.0970	0.1037
S.E.	0.0434	0.0464
N	5	5
HEART (G)		
MEAN	0.1474	0.1529
% DIFFERENCE		3.7
S.D.	0.00740	0.02624
S.E.	0.00331	0.01173
N	5	5
HEART (G/100 G FINAL BODY WEIGHT)		
MEAN	0.588	0.593
S.D.	0.0334	0.0849
S.E.	0.0149	0.0380
N	5	5

None significantly different from control group

PROJECT NO.:WIL-639011
SPONSOR:SYNGENTA

TABLE 12
A SINGLE ORAL DOSE OF PMI-0105 WITH A 14-DAY RECOVERY IN MICE
SUMMARY OF ORGAN WEIGHTS AND RELATIVE ORGAN WEIGHTS

PAGE 9

GROUP:	FEMALES	
	0 MG/KG	2000 MG/KG
HEART (G/100 G BRAIN)		
MEAN	30.644	31.005
S.D.	1.8311	3.9423
S.E.	0.8189	1.7631
N	5	5
KIDNEYS (G)		
MEAN	0.3522	0.3591
% DIFFERENCE		2.0
S.D.	0.01906	0.03130
S.E.	0.00852	0.01400
N	5	5
KIDNEYS (G/100 G FINAL BODY WEIGHT)		
MEAN	1.406	1.395
S.D.	0.0833	0.1000
S.E.	0.0372	0.0447
N	5	5
KIDNEYS (G/100 G BRAIN)		
MEAN	73.152	73.126
S.D.	3.4137	5.7154
S.E.	1.5266	2.5560
N	5	5

None significantly different from control group

PROJECT NO.:WIL-639011
SPONSOR:SYNGENTA

TABLE 12
A SINGLE ORAL DOSE OF PMI-0105 WITH A 14-DAY RECOVERY IN MICE
SUMMARY OF ORGAN WEIGHTS AND RELATIVE ORGAN WEIGHTS

PAGE 10

GROUP:	FEMALES	
	0 MG/KG	2000 MG/KG
LIVER/GB (G)		
MEAN	1.2459	1.2155
% DIFFERENCE		-2.4
S.D.	0.06700	0.15713
S.E.	0.02996	0.07027
N	5	5
LIVER/GB (G/100 G FINAL BODY WEIGHT)		
MEAN	4.968	4.715
S.D.	0.1761	0.4645
S.E.	0.0787	0.2077
N	5	5
LIVER/GB (G/100 G BRAIN)		
MEAN	258.842	247.090
S.D.	13.0337	25.6815
S.E.	5.8288	11.4851
N	5	5
OVARIES/OVIDUCTS (G)		
MEAN	0.0227	0.0314
% DIFFERENCE		38.3
S.D.	0.00236	0.01283
S.E.	0.00106	0.00574
N	5	5

None significantly different from control group

PROJECT NO.:WIL-639011
SPONSOR:SYNGENTA

TABLE 12
A SINGLE ORAL DOSE OF PMI-0105 WITH A 14-DAY RECOVERY IN MICE
SUMMARY OF ORGAN WEIGHTS AND RELATIVE ORGAN WEIGHTS

PAGE 11

GROUP:	FEMALES	
	0 MG/KG	2000 MG/KG

OVARIES/OVIDUCTS (G/100 G FINAL BODY WEIGHT)		
MEAN	0.090	0.124
S.D.	0.0093	0.0584
S.E.	0.0042	0.0261
N	5	5
OVARIES/OVIDUCTS (G/100 G BRAIN)		
MEAN	4.708	6.426
S.D.	0.4928	2.7268
S.E.	0.2204	1.2195
N	5	5
SPLEEN (G)		
MEAN	0.1090	0.0976
% DIFFERENCE		-10.5
S.D.	0.03586	0.01547
S.E.	0.01604	0.00692
N	5	5
SPLEEN (G/100 G FINAL BODY WEIGHT)		
MEAN	0.445	0.378
S.D.	0.1929	0.0504
S.E.	0.0863	0.0225
N	5	5

None significantly different from control group

PROJECT NO.:WIL-639011
 SPONSOR:SYNGENTA

TABLE 12
 A SINGLE ORAL DOSE OF PMI-0105 WITH A 14-DAY RECOVERY IN MICE
 SUMMARY OF ORGAN WEIGHTS AND RELATIVE ORGAN WEIGHTS

GROUP:	FEMALES	
	0 MG/KG	2000 MG/KG
SPLEEN (G/100 G BRAIN)		
MEAN	22.846	19.907
S.D.	8.5128	3.4103
S.E.	3.8071	1.5251
N	5	5

None significantly different from control group

POFBSTv5.11
 02/26/2008
 R:03/20/2009

PROJECT NO.:WIL-639011
 SPONSOR:SYNGENTA

TABLE 13
 A SINGLE ORAL DOSE OF PMI-0105 WITH A 14-DAY RECOVERY IN MICE
 SUMMARY OF MICROSCOPIC FINDINGS

PAGE 1

----- MALE -----		
GROUP:	1	2
NUMBER OF ANIMALS IN DOSE GROUP	5	5
NUMBER OF ANIMALS EXAMINED DAY 14	5	5
ADRENAL CORTEX		
TOTAL NUMBER EXAMINED	5	5
EXAMINED, UNREMARKABLE	5	5
ADRENAL MEDULLA		
TOTAL NUMBER EXAMINED	5	5
EXAMINED, UNREMARKABLE	5	5
AORTA		
TOTAL NUMBER EXAMINED	5	5
EXAMINED, UNREMARKABLE	5	5
BRAIN		
TOTAL NUMBER EXAMINED	5	5
EXAMINED, UNREMARKABLE	5	5
CECUM		
TOTAL NUMBER EXAMINED	5	5
EXAMINED, UNREMARKABLE	5	5
COLON		
TOTAL NUMBER EXAMINED	5	5
EXAMINED, UNREMARKABLE	5	5

1- 0 MG/KG	2-	2000 MG/KG

PROJECT NO.:WIL-639011
 SPONSOR:SYNGENTA

TABLE 13
 A SINGLE ORAL DOSE OF PMI-0105 WITH A 14-DAY RECOVERY IN MICE
 SUMMARY OF MICROSCOPIC FINDINGS

----- MALE -----		
GROUP:	1	2
NUMBER OF ANIMALS IN DOSE GROUP	5	5
NUMBER OF ANIMALS EXAMINED DAY 14	5	5
DUODENUM		
TOTAL NUMBER EXAMINED	5	5
EXAMINED, UNREMARKABLE	5	5
EPIDIDYMIDES		
TOTAL NUMBER EXAMINED	5	5
EXAMINED, UNREMARKABLE	5	5
ESOPHAGUS		
TOTAL NUMBER EXAMINED	5	5
EXAMINED, UNREMARKABLE	5	5
EYES/OPTIC N.		
TOTAL NUMBER EXAMINED	5	5
EXAMINED, UNREMARKABLE	5	5
FEMUR		
TOTAL NUMBER EXAMINED	5	5
EXAMINED, UNREMARKABLE	5	5
GALLBLADDER		
TOTAL NUMBER EXAMINED	5	4
EXAMINED, UNREMARKABLE	5	4
NOT PRESENT FOR EXAMINATION	0	1

1- 0 MG/KG 2- 2000 MG/KG

PROJECT NO.:WIL-639011
 SPONSOR:SYNGENTA

TABLE 13
 A SINGLE ORAL DOSE OF PMI-0105 WITH A 14-DAY RECOVERY IN MICE
 SUMMARY OF MICROSCOPIC FINDINGS

----- MALE -----		
GROUP:	1	2
NUMBER OF ANIMALS IN DOSE GROUP	5	5
NUMBER OF ANIMALS EXAMINED DAY 14	5	5
HEART		
TOTAL NUMBER EXAMINED	5	5
EXAMINED, UNREMARKABLE	5	5
ILEUM		
TOTAL NUMBER EXAMINED	5	5
EXAMINED, UNREMARKABLE	5	5
JEJUNUM		
TOTAL NUMBER EXAMINED	5	5
EXAMINED, UNREMARKABLE	5	5
JOINT		
TOTAL NUMBER EXAMINED	5	5
EXAMINED, UNREMARKABLE	5	5
KIDNEYS		
TOTAL NUMBER EXAMINED	5	5
EXAMINED, UNREMARKABLE	5	5
LIVER		
TOTAL NUMBER EXAMINED	5	5
EXAMINED, UNREMARKABLE	5	5

1- 0 MG/KG 2- 2000 MG/KG

PROJECT NO.:WIL-639011
 SPONSOR:SYNGENTA

TABLE 13
 A SINGLE ORAL DOSE OF PMI-0105 WITH A 14-DAY RECOVERY IN MICE
 SUMMARY OF MICROSCOPIC FINDINGS

----- MALE -----		
GROUP:	1	2
NUMBER OF ANIMALS IN DOSE GROUP	5	5
NUMBER OF ANIMALS EXAMINED DAY 14	5	5
LUNGS		
TOTAL NUMBER EXAMINED	5	5
EXAMINED, UNREMARKABLE	5	5
LYMPH NODE, MAND		
TOTAL NUMBER EXAMINED	5	5
EXAMINED, UNREMARKABLE	5	5
LYMPH NODE, MES		
TOTAL NUMBER EXAMINED	5	5
EXAMINED, UNREMARKABLE	5	5
MARROW, FEMUR		
TOTAL NUMBER EXAMINED	5	5
EXAMINED, UNREMARKABLE	5	5
MARROW, STERN		
TOTAL NUMBER EXAMINED	5	5
EXAMINED, UNREMARKABLE	5	5
NERVE, SCIATIC		
TOTAL NUMBER EXAMINED	5	5
EXAMINED, UNREMARKABLE	5	5

1- 0 MG/KG 2- 2000 MG/KG

PROJECT NO.:WIL-639011
 SPONSOR:SYNGENTA

TABLE 13
 A SINGLE ORAL DOSE OF PMI-0105 WITH A 14-DAY RECOVERY IN MICE
 SUMMARY OF MICROSCOPIC FINDINGS

----- MALE -----		
GROUP:	1	2
NUMBER OF ANIMALS IN DOSE GROUP	5	5
NUMBER OF ANIMALS EXAMINED DAY 14	5	5
PANCREAS		
TOTAL NUMBER EXAMINED	5	5
EXAMINED, UNREMARKABLE	5	5
PARATHYROIDS		
TOTAL NUMBER EXAMINED	3	3
EXAMINED, UNREMARKABLE	3	3
NOT PRESENT FOR EXAMINATION	2	2
PEYER'S PATCHES		
TOTAL NUMBER EXAMINED	5	5
EXAMINED, UNREMARKABLE	5	5
PITUITARY		
TOTAL NUMBER EXAMINED	3	5
EXAMINED, UNREMARKABLE	3	5
NOT PRESENT FOR EXAMINATION	2	0
PROSTATE		
TOTAL NUMBER EXAMINED	5	5
EXAMINED, UNREMARKABLE	5	5

1- 0 MG/KG 2- 2000 MG/KG

PROJECT NO.:WIL-639011
 SPONSOR:SYNGENTA

TABLE 13
 A SINGLE ORAL DOSE OF PMI-0105 WITH A 14-DAY RECOVERY IN MICE
 SUMMARY OF MICROSCOPIC FINDINGS

----- MALE -----		
GROUP:	1	2
NUMBER OF ANIMALS IN DOSE GROUP	5	5
NUMBER OF ANIMALS EXAMINED DAY 14	5	5
RECTUM		
TOTAL NUMBER EXAMINED	5	5
EXAMINED, UNREMARKABLE	5	5
SAL. GLAND MAND		
TOTAL NUMBER EXAMINED	5	5
EXAMINED, UNREMARKABLE	5	5
SEMINAL VESICLES		
TOTAL NUMBER EXAMINED	5	5
EXAMINED, UNREMARKABLE	5	5
SKELETAL MUSCLE		
TOTAL NUMBER EXAMINED	5	5
EXAMINED, UNREMARKABLE	5	5
SKIN		
TOTAL NUMBER EXAMINED	5	5
EXAMINED, UNREMARKABLE	5	5
SPINAL CORD		
TOTAL NUMBER EXAMINED	5	5
EXAMINED, UNREMARKABLE	5	5

1- 0 MG/KG	2- 2000 MG/KG	

PROJECT NO.:WIL-639011
 SPONSOR:SYNGENTA

TABLE 13
 A SINGLE ORAL DOSE OF PMI-0105 WITH A 14-DAY RECOVERY IN MICE
 SUMMARY OF MICROSCOPIC FINDINGS

----- MALE -----		
GROUP:	1	2
NUMBER OF ANIMALS IN DOSE GROUP	5	5
NUMBER OF ANIMALS EXAMINED DAY 14	5	5
SPLEEN		
TOTAL NUMBER EXAMINED	5	5
EXAMINED, UNREMARKABLE	5	5
STERNUM		
TOTAL NUMBER EXAMINED	5	5
EXAMINED, UNREMARKABLE	5	5
STOMACH, GLAN		
TOTAL NUMBER EXAMINED	5	5
EXAMINED, UNREMARKABLE	5	5
STOMACH, NON		
TOTAL NUMBER EXAMINED	5	5
EXAMINED, UNREMARKABLE	5	5
TESTES		
TOTAL NUMBER EXAMINED	5	5
EXAMINED, UNREMARKABLE	5	5
THYMUS		
TOTAL NUMBER EXAMINED	5	5
EXAMINED, UNREMARKABLE	5	5

1- 0 MG/KG 2- 2000 MG/KG

PROJECT NO.:WIL-639011
 SPONSOR:SYNGENTA

TABLE 13
 A SINGLE ORAL DOSE OF PMI-0105 WITH A 14-DAY RECOVERY IN MICE
 SUMMARY OF MICROSCOPIC FINDINGS

----- MALE -----		
GROUP:	1	2
NUMBER OF ANIMALS IN DOSE GROUP	5	5
NUMBER OF ANIMALS EXAMINED DAY 14	5	5
THYROID GLANDS		
TOTAL NUMBER EXAMINED	5	5
EXAMINED, UNREMARKABLE	5	5
TRACHEA		
TOTAL NUMBER EXAMINED	4	5
EXAMINED, UNREMARKABLE	4	5
NOT PRESENT FOR EXAMINATION	1	0
URINARY BLADDER		
TOTAL NUMBER EXAMINED	5	5
EXAMINED, UNREMARKABLE	5	5

1- 0 MG/KG	2- 2000 MG/KG	

PROJECT NO.:WIL-639011
 SPONSOR:SYNGENTA

TABLE 13
 A SINGLE ORAL DOSE OF PMI-0105 WITH A 14-DAY RECOVERY IN MICE
 SUMMARY OF MICROSCOPIC FINDINGS

----- FEMALE -----

GROUP:	1	2
NUMBER OF ANIMALS IN DOSE GROUP	5	5
NUMBER OF ANIMALS EXAMINED DAY 14	5	5
ADRENAL CORTEX		
TOTAL NUMBER EXAMINED	5	5
EXAMINED, UNREMARKABLE	5	5
ADRENAL MEDULLA		
TOTAL NUMBER EXAMINED	5	5
EXAMINED, UNREMARKABLE	5	5
AORTA		
TOTAL NUMBER EXAMINED	5	5
EXAMINED, UNREMARKABLE	5	5
BRAIN		
TOTAL NUMBER EXAMINED	5	5
EXAMINED, UNREMARKABLE	5	5
CECUM		
TOTAL NUMBER EXAMINED	5	5
EXAMINED, UNREMARKABLE	5	5
CERVIX		
TOTAL NUMBER EXAMINED	5	5
EXAMINED, UNREMARKABLE	5	5

1- 0 MG/KG 2- 2000 MG/KG

PROJECT NO.:WIL-639011
 SPONSOR:SYNGENTA

TABLE 13
 A SINGLE ORAL DOSE OF PMI-0105 WITH A 14-DAY RECOVERY IN MICE
 SUMMARY OF MICROSCOPIC FINDINGS

----- FEMALE -----

GROUP:	1	2
NUMBER OF ANIMALS IN DOSE GROUP	5	5
NUMBER OF ANIMALS EXAMINED DAY 14	5	5
COLON		
TOTAL NUMBER EXAMINED	5	5
EXAMINED, UNREMARKABLE	5	5
DUODENUM		
TOTAL NUMBER EXAMINED	5	5
EXAMINED, UNREMARKABLE	5	5
ESOPHAGUS		
TOTAL NUMBER EXAMINED	5	5
EXAMINED, UNREMARKABLE	4	5
-INFLAMMATION, GRANULOMATOUS	1	0
SEVERE	1	NONE
EYES/OPTIC N.		
TOTAL NUMBER EXAMINED	5	5
EXAMINED, UNREMARKABLE	5	5
FEMUR		
TOTAL NUMBER EXAMINED	5	5
EXAMINED, UNREMARKABLE	5	5

1- 0 MG/KG 2- 2000 MG/KG

PROJECT NO.:WIL-639011
 SPONSOR:SYNGENTA

TABLE 13
 A SINGLE ORAL DOSE OF PMI-0105 WITH A 14-DAY RECOVERY IN MICE
 SUMMARY OF MICROSCOPIC FINDINGS

----- FEMALE -----

GROUP:	1	2
NUMBER OF ANIMALS IN DOSE GROUP	5	5
NUMBER OF ANIMALS EXAMINED DAY 14	5	5
GALLBLADDER		
TOTAL NUMBER EXAMINED	5	5
EXAMINED, UNREMARKABLE	5	5
HEART		
TOTAL NUMBER EXAMINED	5	5
EXAMINED, UNREMARKABLE	5	4
-INFLAMMATION, CHRONIC	0	1
MINIMAL	NONE	1
ILEUM		
TOTAL NUMBER EXAMINED	5	5
EXAMINED, UNREMARKABLE	5	5
JEJUNUM		
TOTAL NUMBER EXAMINED	5	5
EXAMINED, UNREMARKABLE	5	5
JOINT		
TOTAL NUMBER EXAMINED	5	5
EXAMINED, UNREMARKABLE	5	5

1- 0 MG/KG 2- 2000 MG/KG

PROJECT NO.:WIL-639011
 SPONSOR:SYNGENTA

TABLE 13
 A SINGLE ORAL DOSE OF PMI-0105 WITH A 14-DAY RECOVERY IN MICE
 SUMMARY OF MICROSCOPIC FINDINGS

----- FEMALE -----		
GROUP:	1	2
NUMBER OF ANIMALS IN DOSE GROUP	5	5
NUMBER OF ANIMALS EXAMINED DAY 14	5	5
KIDNEYS		
TOTAL NUMBER EXAMINED	5	5
EXAMINED, UNREMARKABLE	5	4
-VACUOLATION, TUBULAR EPITHELIUM	0	1
MINIMAL	NONE	1
LIVER		
TOTAL NUMBER EXAMINED	5	5
EXAMINED, UNREMARKABLE	5	4
-INFLAMMATION, CHRONIC	0	1
MINIMAL	NONE	1
LUNGS		
TOTAL NUMBER EXAMINED	5	5
EXAMINED, UNREMARKABLE	5	5
LYMPH NODE, MAND		
TOTAL NUMBER EXAMINED	5	5
EXAMINED, UNREMARKABLE	5	5
LYMPH NODE, MES		
TOTAL NUMBER EXAMINED	5	5
EXAMINED, UNREMARKABLE	5	5

1- 0 MG/KG 2- 2000 MG/KG

PROJECT NO.:WIL-639011
 SPONSOR:SYNGENTA

TABLE 13
 A SINGLE ORAL DOSE OF PMI-0105 WITH A 14-DAY RECOVERY IN MICE
 SUMMARY OF MICROSCOPIC FINDINGS

----- FEMALE -----

GROUP:	1	2
NUMBER OF ANIMALS IN DOSE GROUP	5	5
NUMBER OF ANIMALS EXAMINED DAY 14	5	5
MAMMARY GLAND		
TOTAL NUMBER EXAMINED	5	5
EXAMINED, UNREMARKABLE	5	5
MARROW, FEMUR		
TOTAL NUMBER EXAMINED	5	5
EXAMINED, UNREMARKABLE	4	5
-HYPERPLASIA, MYELOID	1	0
MILD	1	NONE
MARROW, STERN		
TOTAL NUMBER EXAMINED	5	5
EXAMINED, UNREMARKABLE	4	5
-HYPERPLASIA, MYELOID	1	0
MILD	1	NONE
NERVE, SCIATIC		
TOTAL NUMBER EXAMINED	5	5
EXAMINED, UNREMARKABLE	5	5
OVARIES		
TOTAL NUMBER EXAMINED	5	5
EXAMINED, UNREMARKABLE	5	4
-CYST, BURSAL	0	1
PRESENT	NONE	1

1- 0 MG/KG 2- 2000 MG/KG

PROJECT NO.:WIL-639011
 SPONSOR:SYNGENTA

TABLE 13
 A SINGLE ORAL DOSE OF PMI-0105 WITH A 14-DAY RECOVERY IN MICE
 SUMMARY OF MICROSCOPIC FINDINGS

----- FEMALE -----

GROUP:	1	2
NUMBER OF ANIMALS IN DOSE GROUP	5	5
NUMBER OF ANIMALS EXAMINED DAY 14	5	5
OVIDUCTS		
TOTAL NUMBER EXAMINED	5	5
EXAMINED, UNREMARKABLE	5	5
PANCREAS		
TOTAL NUMBER EXAMINED	5	5
EXAMINED, UNREMARKABLE	5	5
PARATHYROIDS		
TOTAL NUMBER EXAMINED	1	2
EXAMINED, UNREMARKABLE	1	2
NOT PRESENT FOR EXAMINATION	4	3
PEYER'S PATCHES		
TOTAL NUMBER EXAMINED	3	5
EXAMINED, UNREMARKABLE	3	5
NOT PRESENT FOR EXAMINATION	2	0
PITUITARY		
TOTAL NUMBER EXAMINED	5	4
EXAMINED, UNREMARKABLE	5	4
NOT PRESENT FOR EXAMINATION	0	1
1- 0 MG/KG	2- 2000 MG/KG	

PROJECT NO.:WIL-639011
 SPONSOR:SYNGENTA

TABLE 13
 A SINGLE ORAL DOSE OF PMI-0105 WITH A 14-DAY RECOVERY IN MICE
 SUMMARY OF MICROSCOPIC FINDINGS

----- FEMALE -----

GROUP:	1	2
NUMBER OF ANIMALS IN DOSE GROUP	5	5
NUMBER OF ANIMALS EXAMINED DAY 14	5	5
RECTUM		
TOTAL NUMBER EXAMINED	5	5
EXAMINED, UNREMARKABLE	5	5
SAL. GLAND MAND		
TOTAL NUMBER EXAMINED	5	5
EXAMINED, UNREMARKABLE	5	5
SKELETAL MUSCLE		
TOTAL NUMBER EXAMINED	5	5
EXAMINED, UNREMARKABLE	5	5
SKIN		
TOTAL NUMBER EXAMINED	5	5
EXAMINED, UNREMARKABLE	5	5
SPINAL CORD		
TOTAL NUMBER EXAMINED	5	5
EXAMINED, UNREMARKABLE	5	5
SPLEEN		
TOTAL NUMBER EXAMINED	5	5
EXAMINED, UNREMARKABLE	5	5

 1- 0 MG/KG 2- 2000 MG/KG

PROJECT NO.:WIL-639011
 SPONSOR:SYNGENTA

TABLE 13
 A SINGLE ORAL DOSE OF PMI-0105 WITH A 14-DAY RECOVERY IN MICE
 SUMMARY OF MICROSCOPIC FINDINGS

----- FEMALE -----

GROUP:	1	2
NUMBER OF ANIMALS IN DOSE GROUP	5	5
NUMBER OF ANIMALS EXAMINED DAY 14	5	5
STERNUM		
TOTAL NUMBER EXAMINED	5	5
EXAMINED, UNREMARKABLE	5	5
STOMACH, GLAN		
TOTAL NUMBER EXAMINED	5	5
EXAMINED, UNREMARKABLE	5	5
STOMACH, NON		
TOTAL NUMBER EXAMINED	5	5
EXAMINED, UNREMARKABLE	5	5
THYMUS		
TOTAL NUMBER EXAMINED	5	5
EXAMINED, UNREMARKABLE	5	5
THYROID GLANDS		
TOTAL NUMBER EXAMINED	5	5
EXAMINED, UNREMARKABLE	5	5
TRACHEA		
TOTAL NUMBER EXAMINED	5	5
EXAMINED, UNREMARKABLE	5	5

1- 0 MG/KG 2- 2000 MG/KG

PROJECT NO.:WIL-639011
 SPONSOR:SYNGENTA

TABLE 13
 A SINGLE ORAL DOSE OF PMI-0105 WITH A 14-DAY RECOVERY IN MICE
 SUMMARY OF MICROSCOPIC FINDINGS

----- FEMALE -----

GROUP:	1	2
NUMBER OF ANIMALS IN DOSE GROUP	5	5
NUMBER OF ANIMALS EXAMINED DAY 14	5	5
URINARY BLADDER		
TOTAL NUMBER EXAMINED	5	5
EXAMINED, UNREMARKABLE	5	5
UTERUS		
TOTAL NUMBER EXAMINED	5	5
EXAMINED, UNREMARKABLE	5	5
VAGINA		
TOTAL NUMBER EXAMINED	5	5
EXAMINED, UNREMARKABLE	5	5


1- 0 MG/KG 2- 2000 MG/KG

PHSI2v4.29
 02/26/2008
 R:03/20/2009

FIGURES SECTION


PROJECT NO.: WIL-639011
SPONSOR: SYNGENTA

FIGURE 1
SUMMARY OF BODY WEIGHTS (G) - MALES



PROJECT NO.: WIL-639011
SPONSOR: SYNGENTA

FIGURE 2
SUMMARY OF BODY WEIGHTS (G) - FEMALES



APPENDICES SECTION

APPENDIX 1 Certificate of Analysis


Certificate of Analysis



Syngenta Biotechnology, Inc.
Regulatory Science
Research Triangle Park, North Carolina USA

Test Substance	PMI-0105
Date Received/Prepared	11/2005
Study Number	PMI-07-01
Active Ingredient	Phosphomannose Isomerase
Event/Production Strain	recombinant <i>Escherichia coli</i> over-expression system
Lab Notebook Reference	SY1906
Solubility	20 mg/ml in water; 5 mg/ml in 10% ethanol; 50 mg/ml in 50 mM CAPS, 2 mM EDTA, 100 mM NaCl, pH 10.0; 50 mg/ml in 50 mM Tris, 2 mM EDTA, 100 mM NaCl, pH 9.5; 50 mg/ml in 50 mM Tris, 2 mM EDTA pH 7.5; 25 mg/ml in 50 mM Tris pH 7.0
Working Buffer	50 mM Tris, 2 mM EDTA pH 7.5
Total Protein	89.9% by A280
Densitometry	99.6% full length protein
Purity	89.5% by weight
Glycosylation Analysis	NA
Activity	503.77 Units/mg PMI
Molecular Weight	42850.04 Da predicted and 42848.36 Da measured
N-terminal Sequence	MQKLINSVQNYAWGS
Storage Conditions	-20 degrees C +/- 8 degrees C
Expiration Date	11/2015

Summary Gel and Western Blot:



General Comments:

This Certificate of Analysis is summarizing data from a study that was performed in compliance with Good Laboratory Practices per 40 CFR Part 160. Raw data, documentation, protocols any amendments to study protocols or reports pertaining to this study are maintained in the Syngenta Biotechnology, Inc. Archives, 3054 East Cornwallis Rd., Research Triangle Park, NC USA 27709 in accordance with SOPs 1.06.

Study Director:

Print **Andrea Nelson**

Signature *Andrea Nelson*

Date **Sept 25, 2008**

APPENDIX 2 Pretest Clinical Observations

PROJECT NO.:WIL-639011P
SPONSOR:SYNGENTA

PRETEST CLINICAL OBSERVATIONS
A SINGLE ORAL DOSE OF PMI-0105 WITH A 14-DAY RECOVERY IN MICE
SUMMARY OF CLINICAL FINDINGS: TOTAL OCCURRENCE/NO. OF ANIMALS

PAGE 1

----- M A L E -----

TABLE RANGE: 11-30-07 TO 12-11-07
GROUP: -----

1

NORMAL
-NO SIGNIFICANT CLINICAL OBSERVATIONS

45/15

1- PRETEST

PROJECT NO.:WIL-639011P
SPONSOR:SYNGENTA

PRETEST CLINICAL OBSERVATIONS
A SINGLE ORAL DOSE OF PMI-0105 WITH A 14-DAY RECOVERY IN MICE
SUMMARY OF CLINICAL FINDINGS: TOTAL OCCURRENCE/NO. OF ANIMALS

PAGE 2

----- F E M A L E -----

TABLE RANGE: 11-30-07 TO 12-11-07
GROUP: -----

1

NORMAL
-NO SIGNIFICANT CLINICAL OBSERVATIONS

45/15

1- PRETEST

PCSUv4.07
02/26/2008
R:03/20/2009

APPENDIX 3 Animal Room Environmental Conditions

PROJECT NO.: WIL- 639011
 SPONSOR: SYNGENTA, CTL

A SINGLE DOSE ORAL STUDY IN MICE WITH PMI-0105
 TEMPERATURE/HUMIDITY - END OF STUDY SUMMARY REPORT

9:32 25-Feb-08

PAGE 1

ROOM SPECIFICATIONS:	B ROOM 71				
SPECIES:	MOUSE				
LOW TEMPERATURE:	66.0	DATE IN:	11/27/07		
HIGH TEMPERATURE:	76.0	TIME IN:	7:00		
LOW HUMIDITY:	30.0	DATE OUT:	12/26/07		
HIGH HUMIDITY:	70.0	TIME OUT:	14:00	TEMPERATURE	HUMIDITY

ROOM B ROOM 71 SUMMARY

MEAN	69.6	42.9
MIN	65.0	24.7
MAX	71.0	68.2
SD	1.04	5.02
N SAMPLES	701	701
FIRST DAY	11/27/07	
LAST DAY	12/26/07	
N DAYS	30	

NOTE: TEMPERATURE UNITS = DEGREES FAHRENHEIT
 HUMIDITY UNITS = % RELATIVE HUMIDITY
 NOTE: MEANS REPRESENT THE MEAN OF ALL VALUES

REPORT 5
 VERSION 1.10
 2/25/2008 09:32

PROJECT NO.:WIL- 639011
SPONSOR: SYNGENTA, CTL

A SINGLE DOSE ORAL STUDY IN MICE WITH PMI-0105
TEMPERATURE/HUMIDITY - END OF STUDY SUMMARY REPORT

9:32 25-Feb-08

PAGE 2

STUDY 639011 SUMMARY

MEAN	69.6	42.9
MIN	65.0	24.7
MAX	71.0	68.2
SD	1.04	5.02
N SAMPLES	701	701
FIRST DAY	11/27/07	
LAST DAY	12/26/07	
N DAYS	30	

NOTE: TEMPERATURE UNITS = DEGREES FAHRENHEIT
HUMIDITY UNITS = % RELATIVE HUMIDITY
NOTE: MEANS REPRESENT THE MEAN OF ALL VALUES

REPORT 5
VERSION 1.10
2/25/2008 09:32

APPENDIX 4 Unscheduled Clinical Observations

PROJECT NO.:WIL-639011U
SPONSOR:SYNGENTA

UNSCHEDULED CLINICAL OBSERVATIONS
A SINGLE ORAL DOSE OF PMI-0105 WITH A 14-DAY RECOVERY IN MICE
INDIVIDUAL CLINICAL OBSERVATIONS

PAGE 1

STUDY DAYS: 0 THROUGH 14

ANIMAL SEX	GROUP	CATEGORY	STUDY DAY	TIME	GRADE	OBSERVATIONS
1665 F	0 MG/KG	SPECIAL II	1	8:30 P		WATER BOTTLE ADDED- BODY WEIGHT LOSS

GRADE CODE: 1 - SLIGHT 2 - MODERATE 3 - SEVERE P - PRESENT

PCRDv4.11
02/26/2008
R:03/20/2009

APPENDIX 5 Clinical Pathology Methods, Procedures and References

CLINICAL PATHOLOGY METHODS, PROCEDURES AND REFERENCES

Serum Chemistry - Hitachi 912

Albumin - Bromcresol Green (BCG) Method, Modification of the Doumas reaction. Default unit: g/dL. Hitachi 912 Application Code 413. Roche Reagent, catalog number 11970569.

A/G Ratio - Calculated from Albumin and Globulin Results. Default unit: %.

Alkaline Phosphatase - based on the International Federation of Clinical Chemistry (IFCC) Method (Tietz *et al.* J Clin Chem Clin Biochem 1983; 21:731-748). Default unit: U/L. Hitachi 912 Application Code 158. Roche Reagent, catalog number 2172933.

Alanine Aminotransferase - Modification of the International Federation of Clinical Chemistry (IFCC) recommended method. Default unit: U/L. Hitachi 912 Application Code 706. Roche Reagent, catalog number 450065.

Aspartate Aminotransferase - Kinetic method based on the International Federation of Clinical Chemistry (IFCC) recommendations. Default unit: U/L. Hitachi 912 Application Code 713. Roche Reagent, catalog number 450064.

Bilirubin (Total) - Diazo method developed by Wahlefeld *et al.* Scand J Clin Lab Invest 1972; 29: Supplement 126. Default unit: mg/dL. Hitachi 912 Application Code 018. Roche Reagent, catalog number 1822730.

Blood Urea Nitrogen (BUN) - A urease-triggered methodology based upon the method of Talke and Schubert Klin Wschr, 1965; 43:174. Default unit: mg/dL. Hitachi 912 Application Code 427. Roche Reagent, catalog number 1489321.

Calcium - Modified method using a gamma-amino-butyric acid (GABA) buffer. Default unit: mg/dL. Hitachi 912 Application Code 180. Roche Reagent, catalog number 1125621.

Chloride - An ion-selective electrode that measures the electrical potential of the ions present in solution. Default unit: mEq/L. Hitachi 912 Application. Roche Reagent, catalog numbers 450043,450042, and 450041.

Cholesterol - Enzymatic reaction as described by Trinder. Ann Clin Biochem 1974; 12:266. Default unit: mg/dL. Hitachi 912 Application Code 722. Roche Reagent, catalog number 450061.

Creatine Kinase (CK) – Method using creatine phosphate and ADP modified by Szasz acc. to IFCC. Eur J Clin Chem Clin Biochem 1991; 29:435-456. Default unit: U/L. Hitachi 912 Application Code 057. Roche Reagent, catalog number 12132605.

Creatinine - Modified Jaffe reaction based on the work of Poper *et al.* Biochem Z 1937; 291:354, and Seelig and Wuest. Aerztl Labor 1969; 15:34. Default unit: mg/dL. Hitachi 912 Application Code 727. Roche Reagent, catalog number 450019.

Gamma-Glutamyltransferase (GGT) - Method based on the studies of Persijn and Van der Slik, J Clin Chem Clin Biochem, 1976; 14:421-427. Default unit: U/L. Hitachi 912 Application Code 479. Roche Reagent, catalog number 2016885.

Globulin - Calculation obtained by subtracting Albumin from Total Protein. Default unit: g/dL.

Glucose - Glucose hexokinase method based on the work of Schmidt, Peterson and Young. Klin Wschr 1961; 39:1244. Methods of Enzymatic Analysis, 2nd Eng ed. New York, Academic Press, 1974; 1196. Anal Biochemistry 1958; 23:301. Default unit: mg/dL. Hitachi 912 Application Code 767. Roche Reagent, catalog number 450058.

Phosphorus - Method involves the formation of ammonium phosphomolybdate. Default unit: mg/dL. Hitachi 912 Application Code 714. Roche Reagent, catalog number 1040898.

Potassium - An ion-selective electrode that measures the electrical potential of the ions present in solution. Default unit: mEq/L. Hitachi 912 Application. Roche Reagent, catalog numbers 450043,450042, and 450041.

Sodium - An ion-selective electrode that measures the electrical potential of the ions present in solution. Default unit: mEq/L. Hitachi 912 Application. Roche Reagent, catalog number 450043,450042, and 450041.

Total Protein - Endpoint biuret method that utilizes a sample blank. Default unit: g/dL. Hitachi 912 Application Code 756. Roche Reagent, catalog number 1040901.

Triglycerides - Method that utilizes lipase from a microorganism to promote rapid and complete hydrolysis of triglycerides to glycerol. Default unit: mg/dL. Hitachi 912 Application Code 781. Roche Reagent, catalog number 1488899.

Hematology - Manual Methods

White Cell Differential - Manual method of counting 100 white cells stained with Wright Giemsa and entered on-line into the data files.

Reticulocyte Count - Manual method of counting the reticulocytes present in 1000 red blood cells stained with New Methylene Blue and entered on-line into the data files.

Red Blood Cell Morphology - Manual method of evaluating red blood cells on a Wright Giemsa-stained slide and entered on-line into the data files.

Platelet Estimate- Manual method of evaluating platelets on a Wright Giemsa-stained slide. Platelet estimation is evaluated and entered on-line into the data files as decreased, adequate or increased. Platelet clumps present on the slide will be reported as part of the RBC morphology.

Hematology-Bayer Advia® 120-Siemens Healthcare Diagnostics/(Formerly: Bayer Advia®120)

WBC Count - The whole blood sample is mixed with ADVIA® 120 BASO reagent that contains acid and surfactant. The red cells are hemolyzed, and the white blood cells are then analyzed using two angle laser light scatter signals. Default unit: $\times 10^3$ cells/ μ L

RBC / Platelet Count - Both red blood cells and platelets are analyzed by a single optical cytometer after appropriate dilution of the blood sample with ADVIA® 120 RBC/PLT reagent. The red blood cells are isovolumetrically sphered and lightly fixed with glutaraldehyde to preserve the spherical shape. Red cells and platelets are counted from the signals from a common detector with 2 different gain settings. Default unit RBC: $\times 10^6$ cells/ μ L. Default unit PLT: $\times 10^3$ cells/ μ L

Hgb - Hemoglobin: The hemoglobin method is a modification of the manual cyanmethemoglobin method developed by the International Committee for standardization in Hematology (ICSH). Default unit: g/dL.

Hematocrit - The percentage of blood volume that is occupied by red blood cells. Also referred to as the packed red cell volume. On the ADVIA® 120 Hematology System this parameter is derived from the measured red cell volume (MCV) and the red cell count (RBC). Default unit: %.

MCH - Mean Corpuscular Hemoglobin: the average weight of hemoglobin in the red blood cells, calculated from the RBC and Hgb measurements. Default unit: pg.

MCHC - Mean Corpuscular Hemoglobin Concentration: the average concentration of hemoglobin in the red blood cells. This parameter is computed from the measured hemoglobin and the computed hematocrit. Default unit: g/dL.

MCV - Mean Corpuscular Volume: the average volume of the red blood cells. Default unit: fL

White blood cell differential - The ADVIA[®] 120 Hematology System White Blood Cell Differential (WBC DIFF) methods, consists of both the Peroxidase method and the Basophil/Lobularity method. The ADVIA[®] 120 Hematology System performs a six-part differential that consists of basophils, eosinophils, large unstained cells, lymphocytes, monocytes, and neutrophils. The white blood cell differential count is reported in percent and the actual number of each type of cell per microliter of blood.

Reticulocyte - This method uses a nucleic acid dye (oxazine 750) to stain cellular RNA. The ADVIA[®] 120 autoRETIC reagent isovolumetrically spheres the erythroid cells and stains cellular RNA. Low-angle laser light scatter, high-angle laser light scatter, and absorption characteristics of all cells are counted and measured. The absorption data are used to classify each cell as a reticulocyte or mature red blood cell based on its RNA content. The reticulocyte is reported in percent and actual number $\times 10^9$ cells/Liter = thous/ μ l.

References:

ADVIA[®] 120 Hematology System Operator's Guide: Copyright[©] 1997, 1998. Siemens Healthcare Diagnostics/ (Formerly: Bayer Corporation Diagnostics Division).

APPENDIX 6 Pathology Report (WIL Research Laboratories, LLC)

PMI-0105: SINGLE-DOSE ORAL (GAVAGE) TOXICITY
STUDY IN MICE WITH A 14-DAY OBSERVATION PERIOD

PATHOLOGY REPORT

Pathology Department
WIL Research Laboratories, LLC

TABLE OF CONTENTS

	<u>Page</u>
Table Of Contents	2
1. Introduction	4
2. Study Design	4
3. Methods	4
3.1. Clinical Pathology	4
3.1.1. Hematology	5
3.1.2. Serum Chemistry	5
3.2. Anatomic Pathology	6
3.2.1. Macroscopic Examination	6
3.2.2. Organ Weights	8
3.2.3. Microscopic Examination	8
3.3. Abbreviations	9
3.4. Data Interpretation	9
4. Results	10
4.1. Survival	10
4.2. Clinical Pathology	10
4.2.1. Hematology	10
4.2.2. Serum Chemistry	10
4.2.2.1. Changes Associated With Test Article Administration	10
4.3. Gross Observations	12
4.4. Organ Weights	12
4.5. Histologic Changes	13
4.5.1. Changes Associated With Test Article Administration	13
4.5.2. Changes Of Uncertain Relationship To Test Article Administration	13
5. Discussion	14
6. Conclusions	15
7. References	16

Page

8. Report Submission 17

1. INTRODUCTION

The objective of this study was to evaluate the potential toxicity of PMI-0105 when administered as a single-dose orally by gavage to mice, followed by a 14-day observation period to assess the reversibility, persistence, or delayed occurrence of any toxic effects.

2. STUDY DESIGN

Male and female Crl:CD-1 (ICR) mice were administered PMI-0105 once by oral gavage, as indicated in the following table. The dosage volume was 10 mL/kg for both groups. All animals were necropsied following a 14-day observation period.

<u>Group Number</u>	<u>Test Article</u>	<u>Dosage Level (mg/kg)</u>	<u>Number of Animals</u>	
			<u>Males</u>	<u>Females</u>
1	Vehicle ^a	0	5	5
2	PMI-0105	2000	5	5

^a = The vehicle was deionized water

3. METHODS

3.1. CLINICAL PATHOLOGY

Hematology and serum chemistry parameters were evaluated on all animals just prior to scheduled necropsy. Blood was collected for hematology and serum chemistry evaluation via the retro-orbital sinus of animals anesthetized by inhalation of isoflurane. Potassium EDTA was used as an anticoagulant for the hematology parameters. Anticoagulants were not used for serum chemistry samples.

The following parameters were evaluated depending upon sample size volumes.

3.1.1. HEMATOLOGY

Total leukocyte count (White Cells)	Differential leukocyte count -
Erythrocyte count (Red Cells)	Percent and absolute
Hemoglobin	-Neutrophil
Hematocrit	-Lymphocyte
Mean corpuscular volume (MCV)	-Monocyte
Mean corpuscular hemoglobin (MCH)	-Eosinophil
Mean corpuscular hemoglobin concentration (MCHC)	-Basophil
Platelet count (Platelet)	-Large unstained cell
Reticulocyte count	Platelet estimate ^a
Percent (Reticulocyte)	Red cell morphology
Absolute (Retic Absolute)	(RBC Morphology)

() - Designates tabular abbreviation

^a - Presented on individual tables if a manual differential was performed, and the manual data were accepted and reported instead of the automated differential data

3.1.2. SERUM CHEMISTRY

Albumin	Gamma glutamyltransferase (GlutamylTransfer)
Total protein	Glucose
Globulin [by calculation]	Total cholesterol (Cholesterol)
Albumin/globulin ratio (A/G Ratio) [by calculation]	Calcium
Total bilirubin (Total Bili)	Chloride
Urea nitrogen	Phosphorus
Creatinine	Potassium
Alkaline phosphatase (AlkalinePhos'tse)	Sodium
Alanine aminotransferase (Alanine Transfer)	Creatine kinase
Aspartate aminotransferase (AspartatTransfer)	Triglycerides (Triglyceride)

() - Designates tabular abbreviation

In the case of insufficient blood volume, the analysis of serum chemistry parameters was prioritized as follows:

- Alkaline phosphatase, alanine aminotransferase , aspartate aminotransferase
- Creatinine, urea
- Glucose, cholesterol, triglycerides
- Albumin, total protein
- Phosphorus, calcium
- Creatine kinase, gamma-glutamyl transferase, total bilirubin
- Sodium, potassium, chloride

3.2. ANATOMIC PATHOLOGY

3.2.1. MACROSCOPIC EXAMINATION

Complete postmortem examinations were performed on all animals at the scheduled necropsy. At the scheduled necropsy, animals were euthanized by carbon dioxide inhalation and exsanguinated. At the time of necropsy, the following tissues and organs were collected and placed in 10% neutral-buffered formalin fixative unless otherwise noted:

Adrenals (2)	Lymph nodes
Aorta	Mandibular
Bone with marrow	Mesenteric
Femur with joint	Ovaries (2) with oviducts ^d
Sternum	Pancreas
Bone marrow smear ^a	Peripheral nerve (sciatic)
Brain	Peyer's patches
Cerebrum (2 levels)	Pituitary
Cerebellum with pons/medulla	Prostate
Cervix	Salivary glands [mandibular (2)]
Epididymides (2) ^b	Seminal vesicles (2)
Eyes with optic nerves (2) ^c	Skeletal muscle (rectus femoris)
Gallbladder	Skin with mammary gland ^e
Gastrointestinal tract	Spinal cord (cervical, thoracic, lumbar)
Esophagus	Spleen
Stomach	Testes (2) ^b
Duodenum	Thymus
Jejunum	Thyroids [with parathyroids if present (2)] ^d
Ileum	Trachea
Cecum	Urinary bladder
Colon	Uterus
Rectum	Vagina
Heart	Gross lesions (when possible)
Kidneys (2)	
Liver	
Lungs (fixed by inflation with fixative)	

- ^a - Bone marrow smears were obtained at the scheduled necropsy, but not placed in formalin; slides were examined only if scientifically warranted.
- ^b - Fixed in Bouin's solution
- ^c - Fixed in Davidson's solution
- ^d - Examined microscopically when in the plane of section and in all cases where a gross lesion was present.
- ^e - For females; a corresponding section of skin was collected from the same anatomic area for males.

3.2.2. ORGAN WEIGHTS

The following organs were weighed from all animals at the scheduled necropsy:

Adrenals	Liver (with gall bladder)
Brain	Ovaries with oviducts (females)
Epididymides (males)	Spleen
Heart	Testes (males)
Kidneys	

Paired organs were weighed together. Organ-to-final-body-weight and organ-to-brain-weight ratios were calculated.

3.2.3. MICROSCOPIC EXAMINATION

Microscopic examination of routinely prepared hematoxylin-eosin stained paraffin sections was performed on all tissues collected at necropsy from all animals, with exceptions as indicated on the tissue list above. Stained histologic sections were examined by light microscopy and observations were entered in the WIL Toxicology Data Management System (WTDMS™) by the pathologist. All gross necropsy observations were addressed. Histologic sections were of adequate size and quality for detailed evaluation. The number of tissues examined from each dosage group may not necessarily equal the number of animals included in the group due to sectioning difficulties. The number of missing tissues was negligible and did not interfere with detection of test article-related histologic alterations in the study. Histopathologic lesions were classified using standard published terminology to the extent possible. The WTDMS™ histopathology tables contain all of the recorded data and serve as the basis for this narrative report.

3.3. ABBREVIATIONS

The following abbreviations may apply to this report:

- Interval - point in the study at which event occurred (specimen collection, necropsy, etc.)
- SN - scheduled necropsy

3.4. DATA INTERPRETATION

In the discussion of clinical pathology parameters, values derived from the control group animals at all time points evaluated were considered as concurrent control values for purposes of constructing a 'normal' range for the present study. In addition, historical control values for this laboratory were consulted to refine data interpretation. Unless otherwise stated in this report, the 'normal' historical control range was represented by values within the WIL Historical control reference range (essentially a 95% confidence interval).

In the discussion of organ weight changes, the indication of higher or lower mean organ weights refers to a statistically significant ($p < 0.05$ or $p < 0.01$ using Dunnett's test) difference between test article-treated versus control group animals in the present study. In addition, historical control values for this laboratory were consulted to refine data interpretation.

Statistical analysis of clinical pathology and/or organ weight data was not conducted if the number of animals in the group was 2 or less.

4. RESULTS

4.1. SURVIVAL

All mice survived until the scheduled necropsy without signs of physical impairment or physiologic dysfunction.

4.2. CLINICAL PATHOLOGY

4.2.1. HEMATOLOGY

There were no test article-related alterations or statistically significant findings in hematology parameters.

4.2.2. SERUM CHEMISTRY

Due to insufficient serum sample, albumin, total protein, globulin, A/G ratio, total bilirubin, glutamyl transferase, cholesterol, calcium, chloride, phosphorus, potassium, sodium, creatine kinase and triglyceride estimations were not carried out.

4.2.2.1. CHANGES ASSOCIATED WITH TEST ARTICLE ADMINISTRATION

The following alterations in serum chemistry parameters were considered to be related to test article administration: urea nitrogen levels were 41% higher ($p < 0.05$) than in the 2000 mg/kg group males on study day 14. Group mean values were within WIL Historical control ranges version 2.5 (17.4-30.3 mg/dL for males and 14.9-28.7 mg/dL for females). Only 1 of 4 male mice had urea nitrogen levels exceeding historical control ranges. Higher urea nitrogen levels may be seen with pre-renal azotemia, secondary to dehydration, as well as renal injury. Histologic changes are not expected with pre-renal azotemia, and may not be evident with transient renal injury.

Liver enzyme levels (alkaline phosphatase and alanine aminotransferase) were slightly higher in the 2000 mg/kg group males and females, with alkaline phosphatase significantly higher ($p < 0.05$) in the 2000 mg/kg group males and alanine aminotransferase significantly higher ($p < 0.05$) in the 2000 mg/kg group females. However, group mean and individual animal values for alkaline phosphatase and alanine aminotransferase for the 2000 mg/kg group

males and females were all within WIL Historical control ranges (alkaline phosphatase: 49-141 U/L in males and 64-238 U/L in females; alanine aminotransferase: 29-101 U/L in males and 24-122 U/L in females).

Alanine aminotransferase (ALT) is a leakage enzyme found in highest concentrations in the liver of mice and higher levels are consistent with hepatocellular injury (Tennant, 1999; Solter, 2005). Although there is often a positive correlation between ALT and histopathologic lesions, biochemical and histopathologic results are not always linked, possibly because of transient biochemical effects that resolved over time (Travlos, 1996). With an enzyme half-life measured in hours, optimal time for ALT analysis would be within 2-4 days after injury, and enzyme elevations may be expected to resolve by study day 14. Similarly, higher alkaline phosphatase activities would be expected to diminish by study day 14 due to biologic half life of these enzymes (Posen, 1970).

The possibility of renal and hepatic injury could not be eliminated as a consideration due to higher urea nitrogen levels in 2000 mg/kg males and higher liver enzyme levels (alkaline phosphatase and alanine aminotransferase) in 2000 mg/kg/day males and females. However, slight elevations in these serum chemistry parameters were not adverse and were not sufficient to identify kidney or liver as a target organ. Statistically significantly different serum chemistry values in the 2000 mg/kg group were within WIL Research Laboratories' historical control values (Version 2.5) as listed in Text Table 1.

Text Table 1. Comparison of Serum Chemistry Parameters That Varied Significantly from the Control Group with WIL Historical control ranges (Version 2.5, Age 9-12 weeks)

	2000 mg/kg	Historical Control Data	
	Mean	Mean	Reference Range
Males			
Urea nitrogen (mg/dL)	27.5*	23.3	17.4-30.3
Alkaline phosphatase (U/L)	92*	86	49-141
Females			
Alanine Aminotransferase (U/L)	41*	48	24-122

* = Significantly different from the control group at 0.05 using Dunnett's test

4.3. GROSS OBSERVATIONS

Test article-related gross changes were not observed.

4.4. ORGAN WEIGHTS

Organ weight changes considered to be related to the test article were restricted to the testes and epididymides of males and the adrenal glands of females. When compared with the control group, mean absolute, relative-to-body, and relative-to-brain weights for testes in the 2000 mg/kg group males were lower by 28.9%, 26.3% and 29.2%, respectively. Correspondingly, absolute, relative-to-body and relative-to-brain epididymidal weights for the 2000 mg/kg group males were lower by 24.3%, 21.5% and 24.3%, respectively. All mean testicular and epididymal weights were significantly different from the control group at $p < 0.01$ using Dunnett's test; however, there were no distinct histologic correlates for weight changes in either organ, and all organ weight differences were within the WIL Research Laboratories' historical control range for Crl:CD-1 mice (Version 2.6, June 2008), as listed in Text Table 2. Individual testicular and epididymidal weights indicated that mean weight results were not influenced by 1 or more "outlier" values.

In the 2000 mg/kg group females, mean absolute, relative-to-body, and relative-to-brain adrenal weights were higher by 30.2%, 28.9% and 27.6%, respectively, when compared with the control group. Although these higher values were statistically significantly (< 0.05 using Dunnett's test), there were no distinct histologic correlates, and a reverse trend was noted in the 2000 mg/kg group males, where adrenal weights were slightly lower than the control group. Individual adrenal weights indicated that mean weight results were not influenced by 1 or more "outlier" values. Mean adrenal weights in the 2000 mg/kg female mice were within WIL Research Laboratories' historical control values (Version 2.6) as listed in Text Table 2.

Text Table 2. Comparison of Mean Organ Weights That Varied Significantly from the Control Group with Historical Control Values for CD-1 Mice (Age 9-12 weeks)

	2000 mg/kg	Historical Control Data	
	Mean	Mean	Mean +/- 2 S.D.
Testes			
Absolute	0.1915**	0.22	0.16/0.29
Relative-to-Body	0.570**	0.682	0.509/0.854
Relative-to-Brain	39.493**	45.545	32.145/58.945
Epididymides			
Absolute	.0839**	0.09	0.05/0.13
Relative-to-Body	0.249**	0.275	0.177/0.374
Relative-to-Brain	17.330**	18.337	10.577/26.097
Adrenal Gland (Female)			
Absolute	0.0125*	0.0111	0.0065/0.0156
Relative-to-Body	0.049*	0.042	0.024/0.059
Relative-to-Brain	2.539*	2.296	1.319/3.273

* = Significantly different from the control group at 0.05 using Dunnett's test

** = Significantly different from the control group at 0.01 using Dunnett's test

4.5. HISTOLOGIC CHANGES

4.5.1. CHANGES ASSOCIATED WITH TEST ARTICLE ADMINISTRATION

Test article-related microscopic changes were not observed in the 2000 mg/kg group mice.

4.5.2. CHANGES OF UNCERTAIN RELATIONSHIP TO TEST ARTICLE ADMINISTRATION

One 2000 mg/kg group female (no. 1667) displayed minimal cytoplasmic vacuolation of renal tubular cells within the outer stripe of the outer medulla. This singular finding was most consistent with tissue processing artifact or a response to slight alterations in urine osmolality. Although a test article relationship could not be entirely ruled out, this finding was considered to represent a non-adverse physiologic adaptation that likely would have resolved uneventfully during an extended recovery period.

All additional microscopic findings were consistent with common, spontaneous alterations in laboratory mice, or changes associated with some aspect of experimental manipulation other than administration of the test article.

5. DISCUSSION

Although all mice survived 14 day post-dosing observation period without clinical signs of physical impairment or physiologic dysfunction, slight, but statistically significant alterations in select serum enzyme levels (urea nitrogen, alkaline phosphatase, alanine aminotransferase) and organ weight values (testes/epididymides in males and adrenal gland on females) suggested that the oral administration of PMI-0105 resulted in minor tissue perturbations that could not be further characterized. Clinical pathology results suggested that slight hepatocellular damage may have been present during the post-dosing observation period that resulted in significantly elevated alkaline phosphatase (males) and alanine aminotransferase (females), and, possibly, in pre-renal azotemia (males). It is likely that microscopic changes that may have identified correlating tissue alterations in the liver or kidney resolved during the 14 day post-dosing observation period. Similarly, there were no distinct histologic correlates for lower mean testicular and epididymal weights in the 2000 mg/kg males and for higher mean adrenal weights in the 2000 mg/kg females. For the females, however, adrenal weight differences may have been influenced by physiologic variations in the involution of the “X-zone.” The X-zone is a naturally occurring zone of cells that is present along the interface of the cortex and medulla in juvenile mice. In females, the X-zone increases in size to about 9 weeks of age, and then spontaneously regresses (Nyska and Maronpot, 1999). Individual variations in the spontaneous regression of this zone may have influenced mean adrenal weight values. All additional test results were within normal parameters for CD-1 mice.

Clinical and anatomical pathology findings did not identify a specific target organ toxicity. Mean testicular and epididymal weights in the 2000 mg/kg group males were slightly, but significantly, lower than control group values, and mean adrenal weights in the 2000 mg/kg group females were slightly higher than control group values. Microscopic findings in these organs did not identify histologic changes indicative of PMI-0105 toxicity; however, it should be noted that differences in adrenal weights may have been influenced by physiologic variations in the involution of the “X-zone.” The X-zone is a naturally occurring zone of

cells that is present along the interface of the cortex and medulla in juvenile mice. In females, the X-zone increases in size to about 9 weeks of age, and then spontaneously regresses (Nyska and Maronpot, 1999). Individual variations in the spontaneous regression of this zone may have influenced mean adrenal weight values. All additional test results were within normal parameters for CD-1 mice.

6. CONCLUSIONS

All CD-1 mice administered PMI-0105 as a single oral dose (2000 mg/kg) followed by a 14 day non-dosing observation period survived without clinical signs of distress or impairment. However, slight, but statistically significant, alterations in serum urea nitrogen and alkaline phosphatase in males and alanine aminotransferase in females, along with lower testicular/epididymidal weight in males and higher adrenal weight in females, suggested that PMI-0105 resulted in slight tissue perturbations that could not be further characterized. Specific target organ toxicity was not identified histologically; however, microscopic changes that may have correlated with serum chemistry and organ weight alterations likely resolved during the 14 day non-dosing observation period. Collectively, clinical and anatomical pathology findings indicated that, under the conditions of this study, the test article was well tolerated, and that the slight serum chemistry and organ weight changes observed represented minor, non-adverse, perturbations without meaningful toxicologic consequences. Clinical and anatomical pathology results did not identify a specific target organ toxicity. Slightly lower testicular and epididymidal weights in males and slightly higher adrenal weights in females may have been test article-related; however, the absence of distinct microscopic changes in these organs suggested that organ weight alterations probably represented physiologic responses of a non-adverse nature.

7. REFERENCES

Nyska, A.; Maronpot, R.R. Adrenal Gland. In *Pathology of the Laboratory Mouse*, 1st ed.; Maronpot, R.R., Boorman, G.A., Gaul, B.W., Eds.; Cache River Press, Vienna, IL, **1999**; pp 511.

Posen S. Turnover of Circulating Enzymes. *Clinical Chemistry* **1970**; *16* (2): 71-84.

Solter PF. Clinical Pathology Approaches to Hepatic Injury. *Toxicologic Pathology*; **2005**; *33*: 9-16.

Tennant BC. Assessment of Hepatic Function, In: *The Clinical Chemistry of Laboratory Animals*, Second Edition, Loeb WF and Quimby FW, eds: Taylor & Francis, Philadelphia, PA; **1999**, pp 501-517.

Travlos GS, Morris RW, Elwell MR et al. Frequency and relationships of clinical chemistry and liver and kidney histopathology findings in 13-week toxicity studies in rats. *Toxicology*; **1996**; *107*: 17-29.

8. REPORT SUBMISSION

Report Submitted By:



Ellen L. Ziemer, DVM, MS, PhD, DACVIM, DACVP*
Study Clinical Pathologist

2 APR 2009
Date


Richard H. Bruner, DVM., DACVP
Study Pathologist

31 MAR 2009
Date

Report Reviewed By:


George A. Parker, DVM, PhD, DACVP, DABT
Reviewing Pathologist

2 APR 2009
Date

* = No longer employed by WIL Research Laboratories, I.I.C. The Director of Pathology has compared the pathology report to the final report to ensure that there were no changes in interpretation. A statement signed by the Director of Pathology has been placed in the data to acknowledge that the original interpretation by the Pathologist is reflected in the final report.

APPENDIX 7 Individual Animal Data

PROJECT NO.:WIL-639011
 SPONSOR:SYNGENTA

TABLE A1
 A SINGLE ORAL DOSE OF PMI-0105 WITH A 14-DAY RECOVERY IN MICE
 INDIVIDUAL SURVIVAL AND DISPOSITION

PAGE 1

ANIMAL	SEX	GROUP	TYPE OF DEATH	AGE IN WEEKS A	DATE OF DEATH	DAYS ON STUDY
1639	M	0 MG/KG	SCHEDULED EUTHANASIA	11	26-DEC-07	14
1642	M	0 MG/KG	SCHEDULED EUTHANASIA	11	26-DEC-07	14
1645	M	0 MG/KG	SCHEDULED EUTHANASIA	11	26-DEC-07	14
1651	M	0 MG/KG	SCHEDULED EUTHANASIA	11	26-DEC-07	14
1652	M	0 MG/KG	SCHEDULED EUTHANASIA	11	26-DEC-07	14
1638	M	2000 MG/KG	SCHEDULED EUTHANASIA	11	26-DEC-07	14
1641	M	2000 MG/KG	SCHEDULED EUTHANASIA	11	26-DEC-07	14
1648	M	2000 MG/KG	SCHEDULED EUTHANASIA	11	26-DEC-07	14
1649	M	2000 MG/KG	SCHEDULED EUTHANASIA	11	26-DEC-07	14
1650	M	2000 MG/KG	SCHEDULED EUTHANASIA	11	26-DEC-07	14

A = CALCULATED TO THE NEAREST WHOLE WEEK USING THE MEAN AGE IN WEEKS AT INITIATION OF DOSING (9)

PROJECT NO.:WIL-639011
 SPONSOR:SYNGENTA

TABLE A1
 A SINGLE ORAL DOSE OF PMI-0105 WITH A 14-DAY RECOVERY IN MICE
 INDIVIDUAL SURVIVAL AND DISPOSITION

PAGE 2

ANIMAL	SEX	GROUP	TYPE OF DEATH	AGE IN WEEKS A	DATE OF DEATH	DAYS ON STUDY
1656	F	0 MG/KG	SCHEDULED EUTHANASIA	11	26-DEC-07	14
1658	F	0 MG/KG	SCHEDULED EUTHANASIA	11	26-DEC-07	14
1659	F	0 MG/KG	SCHEDULED EUTHANASIA	11	26-DEC-07	14
1665	F	0 MG/KG	SCHEDULED EUTHANASIA	11	26-DEC-07	14
1666	F	0 MG/KG	SCHEDULED EUTHANASIA	11	26-DEC-07	14
1655	F	2000 MG/KG	SCHEDULED EUTHANASIA	11	26-DEC-07	14
1662	F	2000 MG/KG	SCHEDULED EUTHANASIA	11	26-DEC-07	14
1663	F	2000 MG/KG	SCHEDULED EUTHANASIA	11	26-DEC-07	14
1664	F	2000 MG/KG	SCHEDULED EUTHANASIA	11	26-DEC-07	14
1667	F	2000 MG/KG	SCHEDULED EUTHANASIA	11	26-DEC-07	14

A = CALCULATED TO THE NEAREST WHOLE WEEK USING THE MEAN AGE IN WEEKS AT INITIATION OF DOSING (9)

PDEADv4.05
 02/27/2008
 R:03/20/2009

PROJECT NO.:WIL-639011
SPONSOR:SYNGENTATABLE A2 (DETAILED PHYSICAL EXAMINATIONS/DISPOSITIONS)
A SINGLE ORAL DOSE OF PMI-0105 WITH A 14-DAY RECOVERY IN MICE
INDIVIDUAL CLINICAL OBSERVATIONS

PAGE 1

STUDY DAYS: 0 THROUGH 14

ANIMAL	SEX	GROUP	CATEGORY	STUDY DAY	TIME	GRADE	OBSERVATIONS
1639	M	0 MG/KG	NORMAL	0	8:13	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				7	8:49	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
1639	M	0 MG/KG	DISPOSITION	14	12:10	P	PRIMARY NECROPSY (DAY 14)
1639	M	0 MG/KG	BODY/INTEG III	14	8:42	P	DRIED YELLOW MATERIAL UROGENITAL AREA
1642	M	0 MG/KG	NORMAL	0	8:14	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				7	8:50	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				14	8:42	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
1642	M	0 MG/KG	DISPOSITION	14	12:10	P	PRIMARY NECROPSY (DAY 14)
1645	M	0 MG/KG	NORMAL	0	8:14	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				7	8:51	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				14	8:43	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
1645	M	0 MG/KG	DISPOSITION	14	12:10	P	PRIMARY NECROPSY (DAY 14)
1651	M	0 MG/KG	NORMAL	0	8:14	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				7	8:52	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				14	8:43	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
1651	M	0 MG/KG	DISPOSITION	14	12:10	P	PRIMARY NECROPSY (DAY 14)
1652	M	0 MG/KG	NORMAL	7	8:52	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
1652	M	0 MG/KG	DISPOSITION	14	12:10	P	PRIMARY NECROPSY (DAY 14)
1652	M	0 MG/KG	EYES/EARS/NOSE	0	8:15	P	ABNORMAL PUPIL POSITION RIGHT EYE
				14	8:44	P	ABNORMAL PUPIL POSITION RIGHT EYE
1638	M	2000 MG/KG	NORMAL	0	8:16	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				7	8:59	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				14	8:47	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
1638	M	2000 MG/KG	DISPOSITION	14	12:10	P	PRIMARY NECROPSY (DAY 14)
1641	M	2000 MG/KG	NORMAL	0	8:16	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				7	9:00	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				14	8:47	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
1641	M	2000 MG/KG	DISPOSITION	14	12:10	P	PRIMARY NECROPSY (DAY 14)
1648	M	2000 MG/KG	NORMAL	0	8:17	P	NO SIGNIFICANT CLINICAL OBSERVATIONS

GRADE CODE: 1 - SLIGHT 2 - MODERATE 3 - SEVERE P - PRESENT

PROJECT NO.:WIL-639011
SPONSOR:SYNGENTATABLE A2 (DETAILED PHYSICAL EXAMINATIONS/DISPOSITIONS)
A SINGLE ORAL DOSE OF PMI-0105 WITH A 14-DAY RECOVERY IN MICE
INDIVIDUAL CLINICAL OBSERVATIONS

PAGE 2

STUDY DAYS: 0 THROUGH 14

ANIMAL	SEX	GROUP	CATEGORY	STUDY DAY	TIME	GRADE	OBSERVATIONS
1648	M	2000 MG/KG	NORMAL	7	9:01	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				14	8:47	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
1648	M	2000 MG/KG	DISPOSITION	14	12:10	P	PRIMARY NECROPSY (DAY 14)
1649	M	2000 MG/KG	NORMAL	0	8:17	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				7	9:01	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				14	8:48	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
1649	M	2000 MG/KG	DISPOSITION	14	12:10	P	PRIMARY NECROPSY (DAY 14)
1650	M	2000 MG/KG	NORMAL	0	8:17	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				7	9:02	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				14	8:49	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
1650	M	2000 MG/KG	DISPOSITION	14	12:10	P	PRIMARY NECROPSY (DAY 14)
1656	F	0 MG/KG	NORMAL	0	8:15	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				7	8:53	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				14	8:44	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
1656	F	0 MG/KG	DISPOSITION	14	12:10	P	PRIMARY NECROPSY (DAY 14)
1658	F	0 MG/KG	NORMAL	0	8:15	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				7	8:54	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				14	8:45	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
1658	F	0 MG/KG	DISPOSITION	14	12:10	P	PRIMARY NECROPSY (DAY 14)
1659	F	0 MG/KG	NORMAL	0	8:15	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				14	8:45	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
1659	F	0 MG/KG	DISPOSITION	14	12:10	P	PRIMARY NECROPSY (DAY 14)
1659	F	0 MG/KG	EXCRETA	7	8:55	P	FECES SMALLER THAN NORMAL
1665	F	0 MG/KG	NORMAL	0	8:15	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				14	8:46	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
1665	F	0 MG/KG	DISPOSITION	14	12:10	P	PRIMARY NECROPSY (DAY 14)
1665	F	0 MG/KG	CARDIO-PULMONARY	7	8:56	P	EXTREMITIES PALE
				7	8:57	P	BODY PALE
				7	8:57	P	RALES

GRADE CODE: 1 - SLIGHT 2 - MODERATE 3 - SEVERE P - PRESENT

PROJECT NO.:WIL-639011
 SPONSOR:SYNGENTA

TABLE A2 (DETAILED PHYSICAL EXAMINATIONS/DISPOSITIONS)
 A SINGLE ORAL DOSE OF PMI-0105 WITH A 14-DAY RECOVERY IN MICE
 INDIVIDUAL CLINICAL OBSERVATIONS

STUDY DAYS: 0 THROUGH 14

ANIMAL	SEX	GROUP	CATEGORY	STUDY DAY	TIME	GRADE	OBSERVATIONS
1665	F	0 MG/KG	EXCRETA	7	8:56	P	DEFECATION DECREASED
1666	F	0 MG/KG	NORMAL	0	8:16	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				7	8:58	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				14	8:46	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
1666	F	0 MG/KG	DISPOSITION	14	12:10	P	PRIMARY NECROPSY (DAY 14)
1655	F	2000 MG/KG	NORMAL	0	8:18	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				7	9:03	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				14	8:49	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
1655	F	2000 MG/KG	DISPOSITION	14	12:10	P	PRIMARY NECROPSY (DAY 14)
1662	F	2000 MG/KG	NORMAL	0	8:18	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				7	9:04	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				14	8:49	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
1662	F	2000 MG/KG	DISPOSITION	14	12:11	P	PRIMARY NECROPSY (DAY 14)
1663	F	2000 MG/KG	NORMAL	0	8:18	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				7	9:05	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				14	8:50	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
1663	F	2000 MG/KG	DISPOSITION	14	12:11	P	PRIMARY NECROPSY (DAY 14)
1664	F	2000 MG/KG	NORMAL	0	8:19	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				7	9:05	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				14	8:50	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
1664	F	2000 MG/KG	DISPOSITION	14	12:11	P	PRIMARY NECROPSY (DAY 14)
1667	F	2000 MG/KG	NORMAL	0	8:19	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				7	9:06	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				14	8:50	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
1667	F	2000 MG/KG	DISPOSITION	14	12:11	P	PRIMARY NECROPSY (DAY 14)

GRADE CODE: 1 - SLIGHT 2 - MODERATE 3 - SEVERE P - PRESENT

PCRDv4.11
 02/27/2008
 R:03/20/2009

PROJECT NO.:WIL-639011
 SPONSOR:SYNGENTA

TABLE A3 (AT TIME OF DOSING OBSERVATIONS)
 A SINGLE ORAL DOSE OF PMI-0105 WITH A 14-DAY RECOVERY IN MICE
 INDIVIDUAL CLINICAL OBSERVATIONS

PAGE 1

STUDY DAYS: 0 THROUGH 0

ANIMAL	SEX	GROUP	CATEGORY	STUDY DAY	TIME	GRADE	OBSERVATIONS
1639	M	0 MG/KG	NORMAL	0	11:57	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
1642	M	0 MG/KG	NORMAL	0	11:58	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
1645	M	0 MG/KG	NORMAL	0	11:59	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
1651	M	0 MG/KG	NORMAL	0	11:59	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
1652	M	0 MG/KG	NORMAL	0	12:00	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
1638	M	2000 MG/KG	NORMAL	0	12:06	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
1641	M	2000 MG/KG	NORMAL	0	12:07	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
1648	M	2000 MG/KG	NORMAL	0	12:07	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
1649	M	2000 MG/KG	NORMAL	0	12:08	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
1650	M	2000 MG/KG	NORMAL	0	12:09	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
1656	F	0 MG/KG	NORMAL	0	12:01	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
1658	F	0 MG/KG	NORMAL	0	12:01	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
1659	F	0 MG/KG	NORMAL	0	12:02	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
1665	F	0 MG/KG	NORMAL	0	12:02	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
1666	F	0 MG/KG	NORMAL	0	12:03	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
1655	F	2000 MG/KG	NORMAL	0	12:11	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
1662	F	2000 MG/KG	NORMAL	0	12:12	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
1663	F	2000 MG/KG	NORMAL	0	12:12	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
1664	F	2000 MG/KG	NORMAL	0	12:13	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
1667	F	2000 MG/KG	NORMAL	0	12:14	P	NO SIGNIFICANT CLINICAL OBSERVATIONS

GRADE CODE: 1 - SLIGHT 2 - MODERATE 3 - SEVERE P - PRESENT

PCRDv4.11
 02/27/2008
 R:03/20/2009

PROJECT NO.:WIL-639011
 SPONSOR:SYNGENTA

TABLE A4 (POST-DOSING OBSERVATIONS)
 A SINGLE ORAL DOSE OF PMI-0105 WITH A 14-DAY RECOVERY IN MICE
 INDIVIDUAL CLINICAL OBSERVATIONS

STUDY DAYS: 0 THROUGH 0

ANIMAL	SEX	GROUP	CATEGORY	STUDY DAY	TIME	GRADE	OBSERVATIONS
POST-DOSING OBSERVATIONS							
1639	M	0 MG/KG	NORMAL	0	13:21	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				0	16:03	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
1642	M	0 MG/KG	NORMAL	0	13:21	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				0	16:03	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
1645	M	0 MG/KG	NORMAL	0	13:21	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				0	16:04	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
1651	M	0 MG/KG	NORMAL	0	13:21	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				0	16:04	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
1652	M	0 MG/KG	NORMAL	0	13:22	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				0	16:04	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
1638	M	2000 MG/KG	NORMAL	0	13:25	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				0	16:08	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
1641	M	2000 MG/KG	NORMAL	0	13:25	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				0	16:09	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
1648	M	2000 MG/KG	NORMAL	0	13:25	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				0	16:09	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
1649	M	2000 MG/KG	NORMAL	0	13:26	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				0	16:09	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
1650	M	2000 MG/KG	NORMAL	0	13:26	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				0	16:09	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
1656	F	0 MG/KG	NORMAL	0	13:22	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				0	16:05	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
1658	F	0 MG/KG	NORMAL	0	13:23	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				0	16:05	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
1659	F	0 MG/KG	NORMAL	0	13:23	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				0	16:05	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
1665	F	0 MG/KG	NORMAL	0	13:23	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				0	16:05	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
1666	F	0 MG/KG	NORMAL	0	13:23	P	NO SIGNIFICANT CLINICAL OBSERVATIONS

GRADE CODE: 1 - SLIGHT 2 - MODERATE 3 - SEVERE P - PRESENT

PROJECT NO.:WIL-639011
 SPONSOR:SYNGENTA

TABLE A4 (POST-DOSING OBSERVATIONS)
 A SINGLE ORAL DOSE OF PMI-0105 WITH A 14-DAY RECOVERY IN MICE
 INDIVIDUAL CLINICAL OBSERVATIONS

PAGE 2

STUDY DAYS: 0 THROUGH 0

ANIMAL	SEX	GROUP	CATEGORY	STUDY DAY	TIME	GRADE	OBSERVATIONS
POST-DOSING OBSERVATIONS							
1666	F	0 MG/KG	NORMAL	0	16:06	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
1655	F	2000 MG/KG	NORMAL	0	13:26	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				0	16:10	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
1662	F	2000 MG/KG	NORMAL	0	13:26	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				0	16:11	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
1663	F	2000 MG/KG	NORMAL	0	13:27	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				0	16:12	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
1664	F	2000 MG/KG	NORMAL	0	13:27	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				0	16:13	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
1667	F	2000 MG/KG	NORMAL	0	13:27	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				0	16:14	P	NO SIGNIFICANT CLINICAL OBSERVATIONS

GRADE CODE: 1 - SLIGHT 2 - MODERATE 3 - SEVERE P - PRESENT

PCRDv4.11
 02/27/2008
 R:03/20/2009

PROJECT NO.:WIL-639011R
 SPONSOR:SYNGENTA

TABLE A5 (DAILY OBSERVATIONS - NONDOSING DAYS)
 A SINGLE ORAL DOSE OF PMI-0105 WITH A 14-DAY RECOVERY IN MICE
 INDIVIDUAL CLINICAL OBSERVATIONS

STUDY DAYS: 1 THROUGH 13

ANIMAL	SEX	GROUP	CATEGORY	STUDY DAY	TIME	GRADE	OBSERVATIONS				
1639	M	0 MG/KG	NORMAL	1	7:56	P	NO SIGNIFICANT CLINICAL OBSERVATIONS				
				2	9:09	P	NO SIGNIFICANT CLINICAL OBSERVATIONS				
				3	9:43	P	NO SIGNIFICANT CLINICAL OBSERVATIONS				
				4	7:46	P	NO SIGNIFICANT CLINICAL OBSERVATIONS				
				11	6:08	P	NO SIGNIFICANT CLINICAL OBSERVATIONS				
				12	7:11	P	NO SIGNIFICANT CLINICAL OBSERVATIONS				
				13	7:06	P	NO SIGNIFICANT CLINICAL OBSERVATIONS				
				1639	M	0 MG/KG	BODY/INTEG III	5	7:47	P	WET YELLOW MATERIAL UROGENITAL AREA
								6	7:28	P	DRIED YELLOW MATERIAL UROGENITAL AREA
								8	7:34	P	DRIED YELLOW MATERIAL UROGENITAL AREA
								9	8:16	P	WET YELLOW MATERIAL UROGENITAL AREA
								9	8:16	P	WET YELLOW MATERIAL VENTRAL TRUNK
				1642	M	0 MG/KG	NORMAL	10	6:16	P	DRIED YELLOW MATERIAL UROGENITAL AREA
1	7:56	P	NO SIGNIFICANT CLINICAL OBSERVATIONS								
2	9:09	P	NO SIGNIFICANT CLINICAL OBSERVATIONS								
3	9:44	P	NO SIGNIFICANT CLINICAL OBSERVATIONS								
4	7:47	P	NO SIGNIFICANT CLINICAL OBSERVATIONS								
5	7:47	P	NO SIGNIFICANT CLINICAL OBSERVATIONS								
6	7:28	P	NO SIGNIFICANT CLINICAL OBSERVATIONS								
8	7:34	P	NO SIGNIFICANT CLINICAL OBSERVATIONS								
9	8:16	P	NO SIGNIFICANT CLINICAL OBSERVATIONS								
10	6:17	P	NO SIGNIFICANT CLINICAL OBSERVATIONS								
11	6:08	P	NO SIGNIFICANT CLINICAL OBSERVATIONS								
12	7:11	P	NO SIGNIFICANT CLINICAL OBSERVATIONS								
13	7:06	P	NO SIGNIFICANT CLINICAL OBSERVATIONS								
1645	M	0 MG/KG	NORMAL	1	7:56	P	NO SIGNIFICANT CLINICAL OBSERVATIONS				
				2	9:09	P	NO SIGNIFICANT CLINICAL OBSERVATIONS				
				3	9:44	P	NO SIGNIFICANT CLINICAL OBSERVATIONS				
				4	7:47	P	NO SIGNIFICANT CLINICAL OBSERVATIONS				

GRADE CODE: 1 - SLIGHT 2 - MODERATE 3 - SEVERE P - PRESENT

PROJECT NO.:WIL-639011R
 SPONSOR:SYNGENTA

TABLE A5 (DAILY OBSERVATIONS - NONDOSING DAYS)
 A SINGLE ORAL DOSE OF PMI-0105 WITH A 14-DAY RECOVERY IN MICE
 INDIVIDUAL CLINICAL OBSERVATIONS

STUDY DAYS: 1 THROUGH 13

ANIMAL	SEX	GROUP	CATEGORY	STUDY DAY	TIME	GRADE	OBSERVATIONS				
1645	M	0 MG/KG	NORMAL	5	7:47	P	NO SIGNIFICANT CLINICAL OBSERVATIONS				
				6	7:28	P	NO SIGNIFICANT CLINICAL OBSERVATIONS				
				8	7:34	P	NO SIGNIFICANT CLINICAL OBSERVATIONS				
				9	8:17	P	NO SIGNIFICANT CLINICAL OBSERVATIONS				
				10	6:17	P	NO SIGNIFICANT CLINICAL OBSERVATIONS				
				11	6:08	P	NO SIGNIFICANT CLINICAL OBSERVATIONS				
				12	7:11	P	NO SIGNIFICANT CLINICAL OBSERVATIONS				
				13	7:06	P	NO SIGNIFICANT CLINICAL OBSERVATIONS				
				1651	M	0 MG/KG	NORMAL	1	7:57	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
								2	9:09	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
								3	9:44	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
								4	7:47	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
								5	7:47	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
6	7:28	P	NO SIGNIFICANT CLINICAL OBSERVATIONS								
8	7:34	P	NO SIGNIFICANT CLINICAL OBSERVATIONS								
9	8:17	P	NO SIGNIFICANT CLINICAL OBSERVATIONS								
10	6:17	P	NO SIGNIFICANT CLINICAL OBSERVATIONS								
11	6:08	P	NO SIGNIFICANT CLINICAL OBSERVATIONS								
12	7:11	P	NO SIGNIFICANT CLINICAL OBSERVATIONS								
13	7:06	P	NO SIGNIFICANT CLINICAL OBSERVATIONS								
1652	M	0 MG/KG	NORMAL					1	7:57	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				2	9:09	P	NO SIGNIFICANT CLINICAL OBSERVATIONS				
				3	9:44	P	NO SIGNIFICANT CLINICAL OBSERVATIONS				
				6	7:29	P	NO SIGNIFICANT CLINICAL OBSERVATIONS				
				8	7:34	P	NO SIGNIFICANT CLINICAL OBSERVATIONS				
				10	6:18	P	NO SIGNIFICANT CLINICAL OBSERVATIONS				
				12	7:12	P	NO SIGNIFICANT CLINICAL OBSERVATIONS				
				13	7:07	P	NO SIGNIFICANT CLINICAL OBSERVATIONS				
				1652	M	0 MG/KG	BODY/INTEG III	4	7:47	P	WET YELLOW MATERIAL UROGENITAL AREA

GRADE CODE: 1 - SLIGHT 2 - MODERATE 3 - SEVERE P - PRESENT

PROJECT NO.:WIL-639011R
SPONSOR:SYNGENTATABLE A5 (DAILY OBSERVATIONS - NONDOSING DAYS)
A SINGLE ORAL DOSE OF PMI-0105 WITH A 14-DAY RECOVERY IN MICE
INDIVIDUAL CLINICAL OBSERVATIONS

PAGE 3

STUDY DAYS: 1 THROUGH 13

ANIMAL	SEX	GROUP	CATEGORY	STUDY DAY	TIME	GRADE	OBSERVATIONS
1652	M	0 MG/KG	BODY/INTEG III	5	7:47	P	DRIED YELLOW MATERIAL UROGENITAL AREA
				9	8:17	P	WET YELLOW MATERIAL UROGENITAL AREA
				11	6:09	P	DRIED YELLOW MATERIAL UROGENITAL AREA
1638	M	2000 MG/KG	NORMAL	1	7:58	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				2	9:10	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				3	9:45	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				4	7:48	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				5	7:48	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				6	7:30	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				8	7:36	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				9	8:18	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				10	6:19	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				12	7:14	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				13	7:07	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
1638	M	2000 MG/KG	BODY/INTEG III	11	6:10	P	DRIED YELLOW MATERIAL UROGENITAL AREA
1641	M	2000 MG/KG	NORMAL	1	7:58	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				2	9:10	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				3	9:45	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				4	7:48	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				6	7:30	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				8	7:36	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				10	6:19	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				11	6:11	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				12	7:14	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				13	7:07	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
1641	M	2000 MG/KG	BODY/INTEG III	5	7:49	P	DRIED YELLOW MATERIAL UROGENITAL AREA
				9	8:18	P	DRIED YELLOW MATERIAL UROGENITAL AREA
1648	M	2000 MG/KG	NORMAL	1	7:59	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				2	9:10	P	NO SIGNIFICANT CLINICAL OBSERVATIONS

GRADE CODE: 1 - SLIGHT 2 - MODERATE 3 - SEVERE P - PRESENT

PROJECT NO.:WIL-639011R
 SPONSOR:SYNGENTA

TABLE A5 (DAILY OBSERVATIONS - NONDOSING DAYS)
 A SINGLE ORAL DOSE OF PMI-0105 WITH A 14-DAY RECOVERY IN MICE
 INDIVIDUAL CLINICAL OBSERVATIONS

STUDY DAYS: 1 THROUGH 13

ANIMAL	SEX	GROUP	CATEGORY	STUDY DAY	TIME	GRADE	OBSERVATIONS				
1648	M	2000 MG/KG	NORMAL	3	9:45	P	NO SIGNIFICANT CLINICAL OBSERVATIONS				
				4	7:48	P	NO SIGNIFICANT CLINICAL OBSERVATIONS				
				5	7:49	P	NO SIGNIFICANT CLINICAL OBSERVATIONS				
				6	7:30	P	NO SIGNIFICANT CLINICAL OBSERVATIONS				
				6	7:30	P	NO SIGNIFICANT CLINICAL OBSERVATIONS				
1648	M	2000 MG/KG	BODY/INTEG III	8	7:36	P	DRIED YELLOW MATERIAL UROGENITAL AREA				
				9	8:18	P	WET YELLOW MATERIAL UROGENITAL AREA				
				10	6:19	P	DRIED YELLOW MATERIAL UROGENITAL AREA				
				11	6:11	P	WET YELLOW MATERIAL UROGENITAL AREA				
				12	7:14	P	DRIED YELLOW MATERIAL UROGENITAL AREA				
				12	7:14	P	DRIED YELLOW MATERIAL ANOGENITAL AREA				
				13	7:07	P	DRIED YELLOW MATERIAL UROGENITAL AREA				
				13	7:08	P	DRIED YELLOW MATERIAL ANOGENITAL AREA				
				1649	M	2000 MG/KG	NORMAL	1	7:59	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
								2	9:10	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
3	9:45	P	NO SIGNIFICANT CLINICAL OBSERVATIONS								
4	7:48	P	NO SIGNIFICANT CLINICAL OBSERVATIONS								
5	7:49	P	NO SIGNIFICANT CLINICAL OBSERVATIONS								
6	7:30	P	NO SIGNIFICANT CLINICAL OBSERVATIONS								
10	6:20	P	NO SIGNIFICANT CLINICAL OBSERVATIONS								
11	6:11	P	NO SIGNIFICANT CLINICAL OBSERVATIONS								
1649	M	2000 MG/KG	BODY/INTEG III					8	7:36	P	DRIED YELLOW MATERIAL UROGENITAL AREA
								9	8:18	P	WET YELLOW MATERIAL UROGENITAL AREA
				12	7:14	P	DRIED YELLOW MATERIAL UROGENITAL AREA				
				13	7:08	P	DRIED YELLOW MATERIAL VENTRAL TRUNK				
				13	7:08	P	DRIED YELLOW MATERIAL UROGENITAL AREA				
1650	M	2000 MG/KG	NORMAL	1	7:59	P	NO SIGNIFICANT CLINICAL OBSERVATIONS				
				2	9:10	P	NO SIGNIFICANT CLINICAL OBSERVATIONS				
				3	9:45	P	NO SIGNIFICANT CLINICAL OBSERVATIONS				
				4	7:48	P	NO SIGNIFICANT CLINICAL OBSERVATIONS				

GRADE CODE: 1 - SLIGHT 2 - MODERATE 3 - SEVERE P - PRESENT

PROJECT NO.:WIL-639011R
 SPONSOR:SYNGENTA

TABLE A5 (DAILY OBSERVATIONS - NONDOSING DAYS)
 A SINGLE ORAL DOSE OF PMI-0105 WITH A 14-DAY RECOVERY IN MICE
 INDIVIDUAL CLINICAL OBSERVATIONS

STUDY DAYS: 1 THROUGH 13

ANIMAL SEX	GROUP	CATEGORY	STUDY DAY	TIME	GRADE	OBSERVATIONS			
1650 M	2000 MG/KG	NORMAL	5	7:49 P		NO SIGNIFICANT CLINICAL OBSERVATIONS			
			6	7:30 P		NO SIGNIFICANT CLINICAL OBSERVATIONS			
			8	7:36 P		NO SIGNIFICANT CLINICAL OBSERVATIONS			
			9	8:18 P		NO SIGNIFICANT CLINICAL OBSERVATIONS			
			10	6:20 P		NO SIGNIFICANT CLINICAL OBSERVATIONS			
			11	6:11 P		NO SIGNIFICANT CLINICAL OBSERVATIONS			
			12	7:15 P		NO SIGNIFICANT CLINICAL OBSERVATIONS			
			13	7:08 P		NO SIGNIFICANT CLINICAL OBSERVATIONS			
			1656 F	0 MG/KG	NORMAL	1	7:57 P		NO SIGNIFICANT CLINICAL OBSERVATIONS
						2	9:10 P		NO SIGNIFICANT CLINICAL OBSERVATIONS
						3	9:44 P		NO SIGNIFICANT CLINICAL OBSERVATIONS
						4	7:47 P		NO SIGNIFICANT CLINICAL OBSERVATIONS
						5	7:48 P		NO SIGNIFICANT CLINICAL OBSERVATIONS
6	7:29 P					NO SIGNIFICANT CLINICAL OBSERVATIONS			
8	7:35 P					NO SIGNIFICANT CLINICAL OBSERVATIONS			
9	8:17 P					NO SIGNIFICANT CLINICAL OBSERVATIONS			
10	6:18 P					NO SIGNIFICANT CLINICAL OBSERVATIONS			
11	6:09 P					NO SIGNIFICANT CLINICAL OBSERVATIONS			
12	7:12 P					NO SIGNIFICANT CLINICAL OBSERVATIONS			
13	7:07 P					NO SIGNIFICANT CLINICAL OBSERVATIONS			
1658 F	0 MG/KG	NORMAL				1	7:57 P		NO SIGNIFICANT CLINICAL OBSERVATIONS
			2	9:10 P		NO SIGNIFICANT CLINICAL OBSERVATIONS			
			3	9:44 P		NO SIGNIFICANT CLINICAL OBSERVATIONS			
			4	7:47 P		NO SIGNIFICANT CLINICAL OBSERVATIONS			
			5	7:48 P		NO SIGNIFICANT CLINICAL OBSERVATIONS			
			6	7:29 P		NO SIGNIFICANT CLINICAL OBSERVATIONS			
			8	7:35 P		NO SIGNIFICANT CLINICAL OBSERVATIONS			
			9	8:17 P		NO SIGNIFICANT CLINICAL OBSERVATIONS			
			10	6:18 P		NO SIGNIFICANT CLINICAL OBSERVATIONS			

GRADE CODE: 1 - SLIGHT 2 - MODERATE 3 - SEVERE P - PRESENT

PROJECT NO.:WIL-639011R
 SPONSOR:SYNGENTA

TABLE A5 (DAILY OBSERVATIONS - NONDOSING DAYS)
 A SINGLE ORAL DOSE OF PMI-0105 WITH A 14-DAY RECOVERY IN MICE
 INDIVIDUAL CLINICAL OBSERVATIONS

STUDY DAYS: 1 THROUGH 13

ANIMAL	SEX	GROUP	CATEGORY	STUDY DAY	TIME	GRADE	OBSERVATIONS				
1658	F	0 MG/KG	NORMAL	11	6:09	P	NO SIGNIFICANT CLINICAL OBSERVATIONS				
				12	7:12	P	NO SIGNIFICANT CLINICAL OBSERVATIONS				
				13	7:07	P	NO SIGNIFICANT CLINICAL OBSERVATIONS				
1659	F	0 MG/KG	NORMAL	1	7:57	P	NO SIGNIFICANT CLINICAL OBSERVATIONS				
				2	9:10	P	NO SIGNIFICANT CLINICAL OBSERVATIONS				
				3	9:44	P	NO SIGNIFICANT CLINICAL OBSERVATIONS				
				4	7:47	P	NO SIGNIFICANT CLINICAL OBSERVATIONS				
				5	7:48	P	NO SIGNIFICANT CLINICAL OBSERVATIONS				
				6	7:29	P	NO SIGNIFICANT CLINICAL OBSERVATIONS				
				8	7:35	P	NO SIGNIFICANT CLINICAL OBSERVATIONS				
				9	8:17	P	NO SIGNIFICANT CLINICAL OBSERVATIONS				
				10	6:18	P	NO SIGNIFICANT CLINICAL OBSERVATIONS				
				11	6:10	P	NO SIGNIFICANT CLINICAL OBSERVATIONS				
				12	7:12	P	NO SIGNIFICANT CLINICAL OBSERVATIONS				
				13	7:07	P	NO SIGNIFICANT CLINICAL OBSERVATIONS				
				1665	F	0 MG/KG	NORMAL	1	7:58	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
2	9:10	P	NO SIGNIFICANT CLINICAL OBSERVATIONS								
3	9:44	P	NO SIGNIFICANT CLINICAL OBSERVATIONS								
5	7:48	P	NO SIGNIFICANT CLINICAL OBSERVATIONS								
6	7:29	P	NO SIGNIFICANT CLINICAL OBSERVATIONS								
8	7:35	P	NO SIGNIFICANT CLINICAL OBSERVATIONS								
10	6:18	P	NO SIGNIFICANT CLINICAL OBSERVATIONS								
11	6:10	P	NO SIGNIFICANT CLINICAL OBSERVATIONS								
12	7:13	P	NO SIGNIFICANT CLINICAL OBSERVATIONS								
1665	F	0 MG/KG	BODY/INTEG III					4	7:48	P	DRIED YELLOW MATERIAL ANOGENITAL AREA
								9	8:17	P	DRIED YELLOW MATERIAL UROGENITAL AREA
				13	7:07	P	DRIED YELLOW MATERIAL ANOGENITAL AREA				
1666	F	0 MG/KG	NORMAL	1	7:58	P	NO SIGNIFICANT CLINICAL OBSERVATIONS				
				2	9:10	P	NO SIGNIFICANT CLINICAL OBSERVATIONS				

GRADE CODE: 1 - SLIGHT 2 - MODERATE 3 - SEVERE P - PRESENT

PROJECT NO.:WIL-639011R
 SPONSOR:SYNGENTA

TABLE A5 (DAILY OBSERVATIONS - NONDOSING DAYS)
 A SINGLE ORAL DOSE OF PMI-0105 WITH A 14-DAY RECOVERY IN MICE
 INDIVIDUAL CLINICAL OBSERVATIONS

STUDY DAYS: 1 THROUGH 13

ANIMAL	SEX	GROUP	CATEGORY	STUDY DAY	TIME	GRADE	OBSERVATIONS				
1666	F	0 MG/KG	NORMAL	3	9:44	P	NO SIGNIFICANT CLINICAL OBSERVATIONS				
				4	7:48	P	NO SIGNIFICANT CLINICAL OBSERVATIONS				
				5	7:48	P	NO SIGNIFICANT CLINICAL OBSERVATIONS				
				6	7:30	P	NO SIGNIFICANT CLINICAL OBSERVATIONS				
				8	7:36	P	NO SIGNIFICANT CLINICAL OBSERVATIONS				
				9	8:17	P	NO SIGNIFICANT CLINICAL OBSERVATIONS				
				10	6:18	P	NO SIGNIFICANT CLINICAL OBSERVATIONS				
				11	6:10	P	NO SIGNIFICANT CLINICAL OBSERVATIONS				
				12	7:13	P	NO SIGNIFICANT CLINICAL OBSERVATIONS				
				13	7:07	P	NO SIGNIFICANT CLINICAL OBSERVATIONS				
				1655	F	2000 MG/KG	NORMAL	1	7:59	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
								2	9:10	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
								3	9:45	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
4	7:49	P	NO SIGNIFICANT CLINICAL OBSERVATIONS								
5	7:49	P	NO SIGNIFICANT CLINICAL OBSERVATIONS								
6	7:31	P	NO SIGNIFICANT CLINICAL OBSERVATIONS								
8	7:37	P	NO SIGNIFICANT CLINICAL OBSERVATIONS								
9	8:18	P	NO SIGNIFICANT CLINICAL OBSERVATIONS								
10	6:20	P	NO SIGNIFICANT CLINICAL OBSERVATIONS								
11	6:12	P	NO SIGNIFICANT CLINICAL OBSERVATIONS								
12	7:15	P	NO SIGNIFICANT CLINICAL OBSERVATIONS								
13	7:08	P	NO SIGNIFICANT CLINICAL OBSERVATIONS								
1662	F	2000 MG/KG	NORMAL					1	7:59	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				2	9:10	P	NO SIGNIFICANT CLINICAL OBSERVATIONS				
				3	9:46	P	NO SIGNIFICANT CLINICAL OBSERVATIONS				
				4	7:49	P	NO SIGNIFICANT CLINICAL OBSERVATIONS				
				5	7:49	P	NO SIGNIFICANT CLINICAL OBSERVATIONS				
				6	7:31	P	NO SIGNIFICANT CLINICAL OBSERVATIONS				
				9	8:19	P	NO SIGNIFICANT CLINICAL OBSERVATIONS				

GRADE CODE: 1 - SLIGHT 2 - MODERATE 3 - SEVERE P - PRESENT

PROJECT NO.:WIL-639011R
 SPONSOR:SYNGENTA

TABLE A5 (DAILY OBSERVATIONS - NONDOSING DAYS)
 A SINGLE ORAL DOSE OF PMI-0105 WITH A 14-DAY RECOVERY IN MICE
 INDIVIDUAL CLINICAL OBSERVATIONS

STUDY DAYS: 1 THROUGH 13

ANIMAL	SEX	GROUP	CATEGORY	STUDY DAY	TIME	GRADE	OBSERVATIONS
1662	F	2000 MG/KG	NORMAL	10	6:20	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				11	6:12	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				12	7:15	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				13	7:08	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
1662	F	2000 MG/KG	BODY/INTEG III	8	7:37	P	WET YELLOW MATERIAL UROGENITAL AREA
1663	F	2000 MG/KG	NORMAL	1	7:59	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				2	9:11	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				3	9:46	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				4	7:49	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				5	7:49	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				6	7:31	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				8	7:37	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				9	8:19	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				10	6:21	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				11	6:12	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				12	7:15	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				13	7:08	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
1664	F	2000 MG/KG	NORMAL	1	7:59	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				2	9:11	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				3	9:46	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				4	7:49	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				5	7:49	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				6	7:31	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				8	7:37	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				9	8:19	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				10	6:21	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				11	6:12	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				12	7:15	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				13	7:08	P	NO SIGNIFICANT CLINICAL OBSERVATIONS

GRADE CODE: 1 - SLIGHT 2 - MODERATE 3 - SEVERE P - PRESENT

PROJECT NO.:WIL-639011R
 SPONSOR:SYNGENTA

TABLE A5 (DAILY OBSERVATIONS - NONDOSING DAYS)
 A SINGLE ORAL DOSE OF PMI-0105 WITH A 14-DAY RECOVERY IN MICE
 INDIVIDUAL CLINICAL OBSERVATIONS

PAGE 9

STUDY DAYS: 1 THROUGH 13

ANIMAL	SEX	GROUP	CATEGORY	STUDY DAY	TIME	GRADE	OBSERVATIONS
1667	F	2000 MG/KG	NORMAL	1	8:00	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				2	9:11	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				3	9:46	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				4	7:49	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				5	7:49	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				6	7:31	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				8	7:37	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				9	8:19	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				10	6:21	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				11	6:12	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				12	7:15	P	NO SIGNIFICANT CLINICAL OBSERVATIONS
				13	7:09	P	NO SIGNIFICANT CLINICAL OBSERVATIONS

GRADE CODE: 1 - SLIGHT 2 - MODERATE 3 - SEVERE P - PRESENT

PCRDv4.11
 02/27/2008
 R:03/20/2009

PROJECT NO.:WIL-639011
 SPONSOR:SYNGENTA

TABLE A6
 A SINGLE ORAL DOSE OF PMI-0105 WITH A 14-DAY RECOVERY IN MICE
 INDIVIDUAL BODY WEIGHTS [G]

DAY	-12	-8	-2	0	MALE GROUP: 1	0 MG/KG 2	3	4
ANIMAL								
1639	28.5	30.1	31.0	30.9	32.6	32.7	31.9	32.4
1642	29.7	31.6	33.3	34.1	34.7	35.1	34.6	35.7
1645	30.5	31.8	33.6	32.8	33.2	33.6	33.6	34.8
1651	31.5	32.0	32.6	32.4	34.0	33.8	33.5	34.2
1652	27.9	30.0	30.9	31.3	33.4	32.6	32.6	33.3
MEAN	29.6	31.1	32.3	32.3	33.6	33.6	33.2	34.1
S.D.	1.46	0.97	1.27	1.27	0.80	1.01	1.03	1.28
S.E.	0.65	0.43	0.57	0.57	0.36	0.45	0.46	0.57
N	5	5	5	5	5	5	5	5

PROJECT NO.:WIL-639011
 SPONSOR:SYNGENTA

TABLE A6
 A SINGLE ORAL DOSE OF PMI-0105 WITH A 14-DAY RECOVERY IN MICE
 INDIVIDUAL BODY WEIGHTS [G]

DAY	-12	-8	-2	0	MALE GROUP: 1	2000 MG/KG 2	3	4
ANIMAL								
1638	30.6	29.8	33.0	33.1	34.1	34.8	34.7	34.3
1641	27.7	29.0	30.5	28.7	30.6	31.0	29.6	30.2
1648	29.5	30.0	32.4	32.1	33.2	34.2	33.5	34.2
1649	28.9	30.7	31.6	31.1	31.5	32.5	32.6	32.6
1650	30.3	30.4	33.3	31.5	32.0	32.3	32.1	32.8
MEAN	29.4	30.0	32.2	31.3	32.3	33.0	32.5	32.8
S.D.	1.16	0.65	1.13	1.64	1.38	1.53	1.90	1.66
S.E.	0.52	0.29	0.51	0.73	0.62	0.69	0.85	0.74
N	5	5	5	5	5	5	5	5

PROJECT NO.:WIL-639011
 SPONSOR:SYNGENTA

TABLE A6
 A SINGLE ORAL DOSE OF PMI-0105 WITH A 14-DAY RECOVERY IN MICE
 INDIVIDUAL BODY WEIGHTS [G]

DAY	5	6	7	8	MALE GROUP: 9	0 MG/KG 10	11	12
ANIMAL								
1639	32.5	32.4	32.4	33.0	32.9	33.1	33.2	32.9
1642	35.8	35.9	35.7	36.5	36.0	36.8	36.9	36.8
1645	35.5	35.8	35.8	36.1	36.1	36.7	36.9	36.6
1651	34.1	33.8	34.4	35.1	34.8	34.5	34.7	34.6
1652	33.5	34.1	33.2	34.8	34.6	34.9	35.2	34.5
MEAN	34.3	34.4	34.3	35.1	34.9	35.2	35.4	35.1
S.D.	1.38	1.47	1.50	1.37	1.30	1.57	1.57	1.63
S.E.	0.62	0.66	0.67	0.61	0.58	0.70	0.70	0.73
N	5	5	5	5	5	5	5	5

PROJECT NO.:WIL-639011
 SPONSOR:SYNGENTA

TABLE A6
 A SINGLE ORAL DOSE OF PMI-0105 WITH A 14-DAY RECOVERY IN MICE
 INDIVIDUAL BODY WEIGHTS [G]

DAY	5	6	7	8	MALE GROUP: 9	2000 MG/KG 10	11	12
ANIMAL								
1638	34.5	34.5	34.2	35.0	35.0	35.4	35.2	33.9
1641	30.0	30.6	30.8	31.2	31.0	30.9	30.7	30.7
1648	34.1	34.6	34.6	36.2	35.5	35.5	35.7	35.3
1649	32.7	32.9	32.7	33.5	33.2	33.3	33.5	33.7
1650	32.7	32.9	32.9	33.2	32.9	32.8	33.2	33.3
MEAN	32.8	33.1	33.0	33.8	33.5	33.6	33.7	33.4
S.D.	1.76	1.62	1.49	1.90	1.80	1.93	1.97	1.68
S.E.	0.79	0.73	0.67	0.85	0.80	0.86	0.88	0.75
N	5	5	5	5	5	5	5	5

PROJECT NO.:WIL-639011
 SPONSOR:SYNGENTA

TABLE A6
 A SINGLE ORAL DOSE OF PMI-0105 WITH A 14-DAY RECOVERY IN MICE
 INDIVIDUAL BODY WEIGHTS [G]

DAY	13	14
ANIMAL		
1639	33.8	32.9
1642	36.4	36.0
1645	36.8	35.9
1651	34.5	34.7
1652	35.6	35.1
MEAN	35.4	34.9
S.D.	1.26	1.25
S.E.	0.56	0.56
N	5	5

PROJECT NO.:WIL-639011
 SPONSOR:SYNGENTA

TABLE A6
 A SINGLE ORAL DOSE OF PMI-0105 WITH A 14-DAY RECOVERY IN MICE
 INDIVIDUAL BODY WEIGHTS [G]

DAY	13	14
ANIMAL		
1638	35.3	35.3
1641	31.0	30.9
1648	36.2	35.6
1649	34.2	33.6
1650	33.9	33.6
MEAN	34.1	33.8
S.D.	1.97	1.87
S.E.	0.88	0.84
N	5	5

PROJECT NO.:WIL-639011
 SPONSOR:SYNGENTA

TABLE A6
 A SINGLE ORAL DOSE OF PMI-0105 WITH A 14-DAY RECOVERY IN MICE
 INDIVIDUAL BODY WEIGHTS [G]

DAY	FEMALE GROUP:							
	-12	-8	-2	0	1	2	3	4
ANIMAL								
1656	22.4	23.5	25.1	24.2	25.2	25.9	26.0	26.5
1658	21.1	22.8	23.3	23.0	23.5	23.4	23.4	24.2
1659	21.3	23.1	24.1	23.0	23.8	23.3	23.2	23.6
1665	22.1	23.3	23.6	23.3	21.0	19.7	19.6	19.2
1666	22.4	23.1	24.8	24.0	24.1	24.1	24.4	25.3
MEAN	21.9	23.2	24.2	23.5	23.5	23.3	23.3	23.8
S.D.	0.62	0.26	0.77	0.57	1.55	2.26	2.36	2.78
S.E.	0.28	0.12	0.34	0.25	0.69	1.01	1.05	1.24
N	5	5	5	5	5	5	5	5

PROJECT NO.:WIL-639011
 SPONSOR:SYNGENTA

TABLE A6
 A SINGLE ORAL DOSE OF PMI-0105 WITH A 14-DAY RECOVERY IN MICE
 INDIVIDUAL BODY WEIGHTS [G]

DAY	FEMALE GROUP: 2000 MG/KG							
	-12	-8	-2	0	1	2	3	4
ANIMAL								
1655	23.0	23.4	24.5	23.4	24.5	25.1	25.3	25.1
1662	23.2	23.5	25.6	23.2	24.6	25.7	25.4	24.6
1663	22.3	22.8	24.1	23.0	24.8	24.8	24.3	25.0
1664	22.4	22.5	22.9	22.9	23.1	23.1	23.4	24.4
1667	22.5	23.2	23.4	22.8	23.4	23.5	23.5	23.7
MEAN	22.7	23.1	24.1	23.1	24.1	24.4	24.4	24.6
S.D.	0.40	0.42	1.04	0.24	0.77	1.10	0.95	0.56
S.E.	0.18	0.19	0.47	0.11	0.35	0.49	0.43	0.25
N	5	5	5	5	5	5	5	5

PROJECT NO.:WIL-639011
 SPONSOR:SYNGENTA

TABLE A6
 A SINGLE ORAL DOSE OF PMI-0105 WITH A 14-DAY RECOVERY IN MICE
 INDIVIDUAL BODY WEIGHTS [G]

DAY	5	6	7	8	FEMALE GROUP: 9	0 MG/KG 10	11	12
ANIMAL								
1656	26.2	26.5	26.4	27.1	26.8	26.8	26.4	26.8
1658	24.0	23.9	24.5	25.6	24.6	25.0	25.6	25.4
1659	24.3	24.5	23.7	24.1	24.3	25.4	24.9	24.7
1665	19.8	19.6	20.0	19.7	20.0	20.1	19.8	20.1
1666	24.6	25.4	25.3	26.4	25.4	26.3	26.2	26.4
MEAN	23.8	24.0	24.0	24.6	24.2	24.7	24.6	24.7
S.D.	2.38	2.64	2.44	2.95	2.55	2.68	2.74	2.69
S.E.	1.07	1.18	1.09	1.32	1.14	1.20	1.22	1.20
N	5	5	5	5	5	5	5	5

PROJECT NO.:WIL-639011
 SPONSOR:SYNGENTA

TABLE A6
 A SINGLE ORAL DOSE OF PMI-0105 WITH A 14-DAY RECOVERY IN MICE
 INDIVIDUAL BODY WEIGHTS [G]

DAY	5	6	7	8	FEMALE GROUP: 9	2000 MG/KG 10	11	12
ANIMAL								
1655	24.9	25.6	26.0	26.1	25.9	26.0	26.8	27.0
1662	24.4	25.3	25.7	25.2	25.6	26.0	26.7	25.6
1663	25.5	25.4	24.6	25.5	25.9	26.1	26.2	26.0
1664	23.5	23.8	23.6	24.4	24.1	23.4	23.5	23.5
1667	23.5	23.8	24.1	24.3	24.2	24.5	24.8	24.9
MEAN	24.4	24.8	24.8	25.1	25.1	25.2	25.6	25.4
S.D.	0.88	0.90	1.03	0.76	0.91	1.21	1.42	1.31
S.E.	0.39	0.40	0.46	0.34	0.41	0.54	0.63	0.58
N	5	5	5	5	5	5	5	5

PROJECT NO.:WIL-639011
 SPONSOR:SYNGENTA

TABLE A6
 A SINGLE ORAL DOSE OF PMI-0105 WITH A 14-DAY RECOVERY IN MICE
 INDIVIDUAL BODY WEIGHTS [G]

DAY	13	14

ANIMAL		
1656	27.0	26.4
1658	25.7	25.1
1659	25.9	25.8
1665	21.1	21.9
1666	26.3	26.4
MEAN	25.2	25.1
S.D.	2.35	1.88
S.E.	1.05	0.84
N	5	5

FEMALE GROUP: 0 MG/KG

PROJECT NO.:WIL-639011
 SPONSOR:SYNGENTA

TABLE A6
 A SINGLE ORAL DOSE OF PMI-0105 WITH A 14-DAY RECOVERY IN MICE
 INDIVIDUAL BODY WEIGHTS [G]

FEMALE GROUP: 2000 MG/KG

DAY	13	14
ANIMAL		
1655	27.3	26.9
1662	26.5	26.7
1663	26.5	26.0
1664	24.0	23.8
1667	24.9	25.3
MEAN	25.8	25.7
S.D.	1.35	1.25
S.E.	0.60	0.56
N	5	5

PBFTSv4.44
 02/27/2008
 R:03/20/2009

PROJECT NO.:WIL-639011
 SPONSOR:SYNGENTA

TABLE A7
 A SINGLE ORAL DOSE OF PMI-0105 WITH A 14-DAY RECOVERY IN MICE
 INDIVIDUAL BODY WEIGHT CHANGES [G]

DAY	-12 TO -8	-8 TO -2	-2 TO 0	0 TO 1	MALE GROUP: 1 TO 2	0 MG/KG 2 TO 3	3 TO 4	4 TO 5
ANIMAL								
1639	1.6	0.9	-0.1	1.7	0.1	-0.8	0.5	0.1
1642	1.9	1.7	0.8	0.6	0.4	-0.5	1.1	0.1
1645	1.3	1.8	-0.8	0.4	0.4	0.0	1.2	0.7
1651	0.5	0.6	-0.2	1.6	-0.2	-0.3	0.7	-0.1
1652	2.1	0.9	0.4	2.1	-0.8	0.0	0.7	0.2
MEAN	1.5	1.2	0.0	1.3	0.0	-0.3	0.8	0.2
S.D.	0.63	0.54	0.61	0.74	0.50	0.34	0.30	0.30
S.E.	0.28	0.24	0.27	0.33	0.22	0.15	0.13	0.13
N	5	5	5	5	5	5	5	5

PROJECT NO.:WIL-639011
 SPONSOR:SYNGENTA

TABLE A7
 A SINGLE ORAL DOSE OF PMI-0105 WITH A 14-DAY RECOVERY IN MICE
 INDIVIDUAL BODY WEIGHT CHANGES [G]

DAY	-12 TO -8	-8 TO -2	-2 TO 0	0 TO 1	MALE GROUP: 1 TO 2	2000 MG/KG 2 TO 3	3 TO 4	4 TO 5
ANIMAL								
1638	-0.8	3.2	0.1	1.0	0.7	-0.1	-0.4	0.2
1641	1.3	1.5	-1.8	1.9	0.4	-1.4	0.6	-0.2
1648	0.5	2.4	-0.3	1.1	1.0	-0.7	0.7	-0.1
1649	1.8	0.9	-0.5	0.4	1.0	0.1	0.0	0.1
1650	0.1	2.9	-1.8	0.5	0.3	-0.2	0.7	-0.1
MEAN	0.6	2.2	-0.9	1.0	0.7	-0.5	0.3	0.0
S.D.	1.02	0.96	0.88	0.60	0.33	0.60	0.50	0.16
S.E.	0.46	0.43	0.40	0.27	0.15	0.27	0.22	0.07
N	5	5	5	5	5	5	5	5

PROJECT NO.:WIL-639011
 SPONSOR:SYNGENTA

TABLE A7
 A SINGLE ORAL DOSE OF PMI-0105 WITH A 14-DAY RECOVERY IN MICE
 INDIVIDUAL BODY WEIGHT CHANGES [G]

DAY	5 TO 6	6 TO 7	7 TO 8	8 TO 9	9 TO 10	10 TO 11	11 TO 12	12 TO 13
ANIMAL								
1639	-0.1	0.0	0.6	-0.1	0.2	0.1	-0.3	0.9
1642	0.1	-0.2	0.8	-0.5	0.8	0.1	-0.1	-0.4
1645	0.3	0.0	0.3	0.0	0.6	0.2	-0.3	0.2
1651	-0.3	0.6	0.7	-0.3	-0.3	0.2	-0.1	-0.1
1652	0.6	-0.9	1.6	-0.2	0.3	0.3	-0.7	1.1
MEAN	0.1	-0.1	0.8	-0.2	0.3	0.2	-0.3	0.3
S.D.	0.35	0.54	0.48	0.19	0.42	0.08	0.24	0.64
S.E.	0.16	0.24	0.22	0.09	0.19	0.04	0.11	0.29
N	5	5	5	5	5	5	5	5

PROJECT NO.:WIL-639011
 SPONSOR:SYNGENTA

TABLE A7
 A SINGLE ORAL DOSE OF PMI-0105 WITH A 14-DAY RECOVERY IN MICE
 INDIVIDUAL BODY WEIGHT CHANGES [G]

DAY	5 TO 6	6 TO 7	7 TO 8	8 TO 9	9 TO 10	10 TO 11	11 TO 12	12 TO 13
ANIMAL								
1638	0.0	-0.3	0.8	0.0	0.4	-0.2	-1.3	1.4
1641	0.6	0.2	0.4	-0.2	-0.1	-0.2	0.0	0.3
1648	0.5	0.0	1.6	-0.7	0.0	0.2	-0.4	0.9
1649	0.2	-0.2	0.8	-0.3	0.1	0.2	0.2	0.5
1650	0.2	0.0	0.3	-0.3	-0.1	0.4	0.1	0.6
MEAN	0.3	-0.1	0.8	-0.3	0.1	0.1	-0.3	0.7
S.D.	0.24	0.19	0.51	0.25	0.21	0.27	0.61	0.43
S.E.	0.11	0.09	0.23	0.11	0.09	0.12	0.27	0.19
N	5	5	5	5	5	5	5	5

PROJECT NO.:WIL-639011
 SPONSOR:SYNGENTA

TABLE A7
 A SINGLE ORAL DOSE OF PMI-0105 WITH A 14-DAY RECOVERY IN MICE
 INDIVIDUAL BODY WEIGHT CHANGES [G]

DAY	13 TO	14

ANIMAL		
1639		-0.9
1642		-0.4
1645		-0.9
1651		0.2
1652		-0.5
MEAN		-0.5
S.D.		0.45
S.E.		0.20
N		5

MALE GROUP: 0 MG/KG

PROJECT NO.:WIL-639011
 SPONSOR:SYNGENTA

TABLE A7
 A SINGLE ORAL DOSE OF PMI-0105 WITH A 14-DAY RECOVERY IN MICE
 INDIVIDUAL BODY WEIGHT CHANGES [G]

MALE GROUP: 2000 MG/KG

DAY	13 TO	14

ANIMAL		
1638		0.0
1641		-0.1
1648		-0.6
1649		-0.6
1650		-0.3
MEAN		-0.3
S.D.		0.28
S.E.		0.12
N		5

PROJECT NO.:WIL-639011
 SPONSOR:SYNGENTA

TABLE A7
 A SINGLE ORAL DOSE OF PMI-0105 WITH A 14-DAY RECOVERY IN MICE
 INDIVIDUAL BODY WEIGHT CHANGES [G]

DAY	-12 TO -8	-8 TO -2	-2 TO 0	0 TO 1	1 TO 2	2 TO 3	3 TO 4	4 TO 5
FEMALE GROUP: 0 MG/KG								
ANIMAL								
1656	1.1	1.6	-0.9	1.0	0.7	0.1	0.5	-0.3
1658	1.7	0.5	-0.3	0.5	-0.1	0.0	0.8	-0.2
1659	1.8	1.0	-1.1	0.8	-0.5	-0.1	0.4	0.7
1665	1.2	0.3	-0.3	-2.3	-1.3	-0.1	-0.4	0.6
1666	0.7	1.7	-0.8	0.1	0.0	0.3	0.9	-0.7
MEAN	1.3	1.0	-0.7	0.0	-0.2	0.0	0.4	0.0
S.D.	0.45	0.63	0.36	1.34	0.73	0.17	0.51	0.61
S.E.	0.20	0.28	0.16	0.60	0.33	0.07	0.23	0.27
N	5	5	5	5	5	5	5	5

PROJECT NO.:WIL-639011
 SPONSOR:SYNGENTA

TABLE A7
 A SINGLE ORAL DOSE OF PMI-0105 WITH A 14-DAY RECOVERY IN MICE
 INDIVIDUAL BODY WEIGHT CHANGES [G]

DAY	-12 TO -8	-8 TO -2	-2 TO 0	0 TO 1	1 TO 2	2 TO 3	3 TO 4	4 TO 5
FEMALE GROUP: 2000 MG/KG								
ANIMAL								
1655	0.4	1.1	-1.1	1.1	0.6	0.2	-0.2	-0.2
1662	0.3	2.1	-2.4	1.4	1.1	-0.3	-0.8	-0.2
1663	0.5	1.3	-1.1	1.8	0.0	-0.5	0.7	0.5
1664	0.1	0.4	0.0	0.2	0.0	0.3	1.0	-0.9
1667	0.7	0.2	-0.6	0.6	0.1	0.0	0.2	-0.2
MEAN	0.4	1.0	-1.0	1.0	0.4	-0.1	0.2	-0.2
S.D.	0.22	0.76	0.88	0.63	0.48	0.34	0.72	0.49
S.E.	0.10	0.34	0.40	0.28	0.22	0.15	0.32	0.22
N	5	5	5	5	5	5	5	5

PROJECT NO.:WIL-639011
 SPONSOR:SYNGENTA

TABLE A7
 A SINGLE ORAL DOSE OF PMI-0105 WITH A 14-DAY RECOVERY IN MICE
 INDIVIDUAL BODY WEIGHT CHANGES [G]

DAY	FEMALE GROUP: 0 MG/KG									
	5 TO 6	6 TO 7	7 TO 8	8 TO 9	9 TO 10	10 TO 11	11 TO 12	12 TO 13		
ANIMAL										
1656	0.3	-0.1	0.7	-0.3	0.0	-0.4	0.4	0.2		
1658	-0.1	0.6	1.1	-1.0	0.4	0.6	-0.2	0.3		
1659	0.2	-0.8	0.4	0.2	1.1	-0.5	-0.2	1.2		
1665	-0.2	0.4	-0.3	0.3	0.1	-0.3	0.3	1.0		
1666	0.8	-0.1	1.1	-1.0	0.9	-0.1	0.2	-0.1		
MEAN	0.2	0.0	0.6	-0.4	0.5	-0.1	0.1	0.5		
S.D.	0.39	0.54	0.58	0.63	0.48	0.44	0.28	0.55		
S.E.	0.18	0.24	0.26	0.28	0.22	0.20	0.13	0.25		
N	5	5	5	5	5	5	5	5		

PROJECT NO.:WIL-639011
 SPONSOR:SYNGENTA

TABLE A7
 A SINGLE ORAL DOSE OF PMI-0105 WITH A 14-DAY RECOVERY IN MICE
 INDIVIDUAL BODY WEIGHT CHANGES [G]

DAY	FEMALE GROUP: 2000 MG/KG									
	5 TO 6	6 TO 7	7 TO 8	8 TO 9	9 TO 10	10 TO 11	11 TO 12	12 TO 13		
ANIMAL										
1655	0.7	0.4	0.1	-0.2	0.1	0.8	0.2	0.3		
1662	0.9	0.4	-0.5	0.4	0.4	0.7	-1.1	0.9		
1663	-0.1	-0.8	0.9	0.4	0.2	0.1	-0.2	0.5		
1664	0.3	-0.2	0.8	-0.3	-0.7	0.1	0.0	0.5		
1667	0.3	0.3	0.2	-0.1	0.3	0.3	0.1	0.0		
MEAN	0.4	0.0	0.3	0.0	0.1	0.4	-0.2	0.4		
S.D.	0.39	0.52	0.57	0.34	0.44	0.33	0.52	0.33		
S.E.	0.17	0.23	0.25	0.15	0.20	0.15	0.23	0.15		
N	5	5	5	5	5	5	5	5		

PROJECT NO.:WIL-639011
 SPONSOR:SYNGENTA

TABLE A7
 A SINGLE ORAL DOSE OF PMI-0105 WITH A 14-DAY RECOVERY IN MICE
 INDIVIDUAL BODY WEIGHT CHANGES [G]

FEMALE GROUP: 0 MG/KG

DAY	13 TO	14

ANIMAL		
1656		-0.6
1658		-0.6
1659		-0.1
1665		0.8
1666		0.1
MEAN		-0.1
S.D.		0.58
S.E.		0.26
N		5

PROJECT NO.:WIL-639011
 SPONSOR:SYNGENTA

TABLE A7
 A SINGLE ORAL DOSE OF PMI-0105 WITH A 14-DAY RECOVERY IN MICE
 INDIVIDUAL BODY WEIGHT CHANGES [G]

FEMALE GROUP: 2000 MG/KG

DAY	13	TO	14

ANIMAL			
	1655		-0.4
	1662		0.2
	1663		-0.5
	1664		-0.2
	1667		0.4
MEAN			-0.1
S.D.			0.39
S.E.			0.17
N			5

PBFTSv4.44
 03/05/2008
 R:03/20/2009

PROJECT NO.:WIL-639011
 SPONSOR:SYNGENTA

TABLE A8
 A SINGLE ORAL DOSE OF PMI-0105 WITH A 14-DAY RECOVERY IN MICE
 INDIVIDUAL CUMULATIVE BODY WEIGHT CHANGES [G]

DAY	0 TO 1	0 TO 2	0 TO 3	0 TO 4	MALE GROUP: 0 TO 5	0 MG/KG 0 TO 6	0 TO 7	0 TO 8
ANIMAL								
1639	1.7	1.8	1.0	1.5	1.6	1.5	1.5	2.1
1642	0.6	1.0	0.5	1.6	1.7	1.8	1.6	2.4
1645	0.4	0.8	0.8	2.0	2.7	3.0	3.0	3.3
1651	1.6	1.4	1.1	1.8	1.7	1.4	2.0	2.7
1652	2.1	1.3	1.3	2.0	2.2	2.8	1.9	3.5
MEAN	1.3	1.3	0.9	1.8	2.0	2.1	2.0	2.8
S.D.	0.74	0.38	0.30	0.23	0.47	0.75	0.60	0.59
S.E.	0.33	0.17	0.14	0.10	0.21	0.33	0.27	0.26
N	5	5	5	5	5	5	5	5

PROJECT NO.:WIL-639011
 SPONSOR:SYNGENTA

TABLE A8
 A SINGLE ORAL DOSE OF PMI-0105 WITH A 14-DAY RECOVERY IN MICE
 INDIVIDUAL CUMULATIVE BODY WEIGHT CHANGES [G]

DAY	0 TO 1	0 TO 2	0 TO 3	0 TO 4	MALE GROUP: 0 TO 5	2000 MG/KG 0 TO 6	0 TO 7	0 TO 8
ANIMAL								
1638	1.0	1.7	1.6	1.2	1.4	1.4	1.1	1.9
1641	1.9	2.3	0.9	1.5	1.3	1.9	2.1	2.5
1648	1.1	2.1	1.4	2.1	2.0	2.5	2.5	4.1
1649	0.4	1.4	1.5	1.5	1.6	1.8	1.6	2.4
1650	0.5	0.8	0.6	1.3	1.2	1.4	1.4	1.7
MEAN	1.0	1.7	1.2	1.5	1.5	1.8	1.7	2.5
S.D.	0.60	0.59	0.43	0.35	0.32	0.45	0.56	0.94
S.E.	0.27	0.27	0.19	0.16	0.14	0.20	0.25	0.42
N	5	5	5	5	5	5	5	5

PROJECT NO.:WIL-639011
 SPONSOR:SYNGENTA

TABLE A8
 A SINGLE ORAL DOSE OF PMI-0105 WITH A 14-DAY RECOVERY IN MICE
 INDIVIDUAL CUMULATIVE BODY WEIGHT CHANGES [G]

DAY	0 TO 9	0 TO 10	0 TO 11	0 TO 12	MALE GROUP: 0 TO 13	0 MG/KG 0 TO 14

ANIMAL						
1639	2.0	2.2	2.3	2.0	2.9	2.0
1642	1.9	2.7	2.8	2.7	2.3	1.9
1645	3.3	3.9	4.1	3.8	4.0	3.1
1651	2.4	2.1	2.3	2.2	2.1	2.3
1652	3.3	3.6	3.9	3.2	4.3	3.8
MEAN	2.6	2.9	3.1	2.8	3.1	2.6
S.D.	0.68	0.82	0.87	0.74	0.99	0.81
S.E.	0.31	0.36	0.39	0.33	0.44	0.36
N	5	5	5	5	5	5

PROJECT NO.:WIL-639011
 SPONSOR:SYNGENTA

TABLE A8
 A SINGLE ORAL DOSE OF PMI-0105 WITH A 14-DAY RECOVERY IN MICE
 INDIVIDUAL CUMULATIVE BODY WEIGHT CHANGES [G]

DAY	0 TO 9	0 TO 10	0 TO 11	0 TO 12	MALE GROUP: 0 TO 13	2000 MG/KG 0 TO 14
ANIMAL						
1638	1.9	2.3	2.1	0.8	2.2	2.2
1641	2.3	2.2	2.0	2.0	2.3	2.2
1648	3.4	3.4	3.6	3.2	4.1	3.5
1649	2.1	2.2	2.4	2.6	3.1	2.5
1650	1.4	1.3	1.7	1.8	2.4	2.1
MEAN	2.2	2.3	2.4	2.1	2.8	2.5
S.D.	0.74	0.75	0.74	0.90	0.80	0.58
S.E.	0.33	0.33	0.33	0.40	0.36	0.26
N	5	5	5	5	5	5

PROJECT NO.:WIL-639011
 SPONSOR:SYNGENTA

TABLE A8
 A SINGLE ORAL DOSE OF PMI-0105 WITH A 14-DAY RECOVERY IN MICE
 INDIVIDUAL CUMULATIVE BODY WEIGHT CHANGES [G]

DAY	FEMALE GROUP: 0 MG/KG							
	0 TO 1	0 TO 2	0 TO 3	0 TO 4	0 TO 5	0 TO 6	0 TO 7	0 TO 8
ANIMAL								
1656	1.0	1.7	1.8	2.3	2.0	2.3	2.2	2.9
1658	0.5	0.4	0.4	1.2	1.0	0.9	1.5	2.6
1659	0.8	0.3	0.2	0.6	1.3	1.5	0.7	1.1
1665	-2.3	-3.6	-3.7	-4.1	-3.5	-3.7	-3.3	-3.6
1666	0.1	0.1	0.4	1.3	0.6	1.4	1.3	2.4
MEAN	0.0	-0.2	-0.2	0.3	0.3	0.5	0.5	1.1
S.D.	1.34	1.99	2.07	2.51	2.17	2.39	2.18	2.70
S.E.	0.60	0.89	0.93	1.12	0.97	1.07	0.97	1.21
N	5	5	5	5	5	5	5	5

PROJECT NO.:WIL-639011
 SPONSOR:SYNGENTA

TABLE A8
 A SINGLE ORAL DOSE OF PMI-0105 WITH A 14-DAY RECOVERY IN MICE
 INDIVIDUAL CUMULATIVE BODY WEIGHT CHANGES [G]

DAY	FEMALE GROUP: 2000 MG/KG									
	0 TO 1	0 TO 2	0 TO 3	0 TO 4	0 TO 5	0 TO 6	0 TO 7	0 TO 8		
ANIMAL										
1655	1.1	1.7	1.9	1.7	1.5	2.2	2.6	2.7		
1662	1.4	2.5	2.2	1.4	1.2	2.1	2.5	2.0		
1663	1.8	1.8	1.3	2.0	2.5	2.4	1.6	2.5		
1664	0.2	0.2	0.5	1.5	0.6	0.9	0.7	1.5		
1667	0.6	0.7	0.7	0.9	0.7	1.0	1.3	1.5		
MEAN	1.0	1.4	1.3	1.5	1.3	1.7	1.7	2.0		
S.D.	0.63	0.92	0.74	0.41	0.76	0.71	0.81	0.55		
S.E.	0.28	0.41	0.33	0.18	0.34	0.32	0.36	0.25		
N	5	5	5	5	5	5	5	5		

PROJECT NO.:WIL-639011
 SPONSOR:SYNGENTA

TABLE A8
 A SINGLE ORAL DOSE OF PMI-0105 WITH A 14-DAY RECOVERY IN MICE
 INDIVIDUAL CUMULATIVE BODY WEIGHT CHANGES [G]

DAY	FEMALE GROUP:					
	0 TO 9	0 TO 10	0 TO 11	0 TO 12	0 TO 13	0 TO 14
ANIMAL						
1656	2.6	2.6	2.2	2.6	2.8	2.2
1658	1.6	2.0	2.6	2.4	2.7	2.1
1659	1.3	2.4	1.9	1.7	2.9	2.8
1665	-3.3	-3.2	-3.5	-3.2	-2.2	-1.4
1666	1.4	2.3	2.2	2.4	2.3	2.4
MEAN	0.7	1.2	1.1	1.2	1.7	1.6
S.D.	2.31	2.48	2.57	2.47	2.19	1.71
S.E.	1.03	1.11	1.15	1.11	0.98	0.76
N	5	5	5	5	5	5

PROJECT NO.:WIL-639011
 SPONSOR:SYNGENTA

TABLE A8
 A SINGLE ORAL DOSE OF PMI-0105 WITH A 14-DAY RECOVERY IN MICE
 INDIVIDUAL CUMULATIVE BODY WEIGHT CHANGES [G]

DAY	FEMALE GROUP: 2000 MG/KG					
	0 TO 9	0 TO 10	0 TO 11	0 TO 12	0 TO 13	0 TO 14
ANIMAL						
1655	2.5	2.6	3.4	3.6	3.9	3.5
1662	2.4	2.8	3.5	2.4	3.3	3.5
1663	2.9	3.1	3.2	3.0	3.5	3.0
1664	1.2	0.5	0.6	0.6	1.1	0.9
1667	1.4	1.7	2.0	2.1	2.1	2.5
MEAN	2.1	2.1	2.5	2.3	2.8	2.7
S.D.	0.74	1.05	1.24	1.13	1.15	1.08
S.E.	0.33	0.47	0.55	0.51	0.52	0.48
N	5	5	5	5	5	5

PBFTSv4.44
 02/27/2008
 R:03/20/2009

PROJECT NO.:WIL-639011
 SPONSOR:SYNGENTA

TABLE A9
 A SINGLE ORAL DOSE OF PMI-0105 WITH A 14-DAY RECOVERY IN MICE
 INDIVIDUAL FOOD CONSUMPTION [G/ANIMAL/DAY]

DAY	-8 TO -2	0 TO 1	1 TO 2	2 TO 3	3 TO 4	4 TO 5	5 TO 6	6 TO 7
ANIMAL								
1639	5.6	6.0	6.1	6.3	6.4	6.6	6.3	6.5
1642	7.2	6.4	7.6	8.2	7.7	8.6	8.6	6.6
1645	7.2	5.0	6.1	6.6	8.5	7.8	7.0	7.7
1651	7.1	6.0	6.0	7.4	NA	NA	7.2	6.8
1652	9.6	9.9	NA	NA	NA	4.8	7.1	8.0
MEAN	7.3	6.7	6.5	7.1	7.5	7.0	7.2	7.1
S.D.	1.43	1.88	0.77	0.85	1.06	1.65	0.84	0.68
S.E.	0.64	0.84	0.38	0.43	0.61	0.83	0.37	0.31
N	5	5	4	4	3	4	5	5

NA = NOT APPLICABLE

PROJECT NO.:WIL-639011
 SPONSOR:SYNGENTA

TABLE A9
 A SINGLE ORAL DOSE OF PMI-0105 WITH A 14-DAY RECOVERY IN MICE
 INDIVIDUAL FOOD CONSUMPTION [G/ANIMAL/DAY]

DAY	-8 TO -2	0 TO 1	1 TO 2	2 TO 3	MALE GROUP: 3 TO 4	2000 MG/KG 4 TO 5	5 TO 6	6 TO 7
ANIMAL								
1638	9.9	5.7	6.1	8.0	NA	6.0	5.5	6.4
1641	6.4	5.3	4.7	5.3	NA	5.3	5.9	6.6
1648	8.1	5.3	5.4	8.2	NA	8.8	6.4	6.9
1649	9.3	5.1	6.6	6.4	7.9	8.6	5.8	5.9
1650	7.1	4.3	5.1	5.6	9.9	NA	5.4	6.0
MEAN	8.2	5.1	5.6	6.7	8.9	7.2	5.8	6.4
S.D.	1.46	0.52	0.77	1.34	1.41	1.79	0.39	0.42
S.E.	0.65	0.23	0.34	0.60	1.00	0.89	0.18	0.19
N	5	5	5	5	2	4	5	5

NA = NOT APPLICABLE

PROJECT NO.:WIL-639011
 SPONSOR:SYNGENTA

TABLE A9
 A SINGLE ORAL DOSE OF PMI-0105 WITH A 14-DAY RECOVERY IN MICE
 INDIVIDUAL FOOD CONSUMPTION [G/ANIMAL/DAY]

DAY	7 TO 8	8 TO 9	9 TO 10	10 TO 11	MALE GROUP: 11 TO 12	0 MG/KG 12 TO 13	13 TO 14
ANIMAL							
1639	5.5	6.5	5.8	5.6	6.2	5.9	6.7
1642	6.7	6.0	NA	4.2	5.4	1.9	2.1
1645	6.1	7.2	7.1	6.8	7.6	6.2	6.3
1651	5.6	7.0	5.9	6.3	6.8	5.8	6.7
1652	8.6	NA	NA	NA	8.1	NA	1.3
MEAN	6.5	6.7	6.3	5.7	6.8	5.0	4.6
S.D.	1.27	0.54	0.72	1.13	1.08	2.04	2.69
S.E.	0.57	0.27	0.42	0.56	0.48	1.02	1.20
N	5	4	3	4	5	4	5

NA = NOT APPLICABLE

PROJECT NO.:WIL-639011
 SPONSOR:SYNGENTA

TABLE A9
 A SINGLE ORAL DOSE OF PMI-0105 WITH A 14-DAY RECOVERY IN MICE
 INDIVIDUAL FOOD CONSUMPTION [G/ANIMAL/DAY]

DAY	MALE GROUP: 2000 MG/KG													
	7 TO 8	8 TO 9	9 TO 10	10 TO 11	11 TO 12	12 TO 13	13 TO 14							
ANIMAL														
1638	5.7	5.9	6.6	6.6	8.2	6.0	7.1							
1641	4.9	5.3	5.6	5.4	5.8	5.4	5.7							
1648	7.6	8.0	6.5	6.2	8.2	6.7	7.0							
1649	5.5	5.6	6.0	5.8	6.4	6.3	6.6							
1650	5.5	5.4	5.9	5.8	5.8	5.8	6.3							
MEAN	5.8	6.0	6.1	6.0	6.9	6.0	6.5							
S.D.	1.03	1.12	0.42	0.46	1.23	0.49	0.57							
S.E.	0.46	0.50	0.19	0.20	0.55	0.22	0.25							
N	5	5	5	5	5	5	5							

PROJECT NO.:WIL-639011
 SPONSOR:SYNGENTA

TABLE A9
 A SINGLE ORAL DOSE OF PMI-0105 WITH A 14-DAY RECOVERY IN MICE
 INDIVIDUAL FOOD CONSUMPTION [G/ANIMAL/DAY]

DAY	-8 TO -2	0 TO 1	1 TO 2	2 TO 3	3 TO 4	4 TO 5	5 TO 6	6 TO 7
ANIMAL								
1656	6.0	5.6	5.9	6.3	7.1	6.9	5.8	6.4
1658	8.7	5.2	5.9	NA	NA	NA	NA	NA
1659	6.7	4.2	5.5	5.2	9.8	7.2	7.8	6.0
1665	6.6	0.2	3.1	4.0	NA	6.7	5.2	6.8
1666	6.2	4.0	4.8	5.4	9.3	6.0	6.4	6.3
MEAN	6.8	3.8	5.0	5.2	8.7	6.7	6.3	6.4
S.D.	1.08	2.14	1.17	0.95	1.44	0.51	1.11	0.33
S.E.	0.48	0.96	0.52	0.47	0.83	0.25	0.56	0.17
N	5	5	5	4	3	4	4	4

NA = NOT APPLICABLE

PROJECT NO.:WIL-639011
 SPONSOR:SYNGENTA

TABLE A9
 A SINGLE ORAL DOSE OF PMI-0105 WITH A 14-DAY RECOVERY IN MICE
 INDIVIDUAL FOOD CONSUMPTION [G/ANIMAL/DAY]

DAY	-8 TO -2	0 TO 1	1 TO 2	2 TO 3	FEMALE GROUP: 3 TO 4	2000 MG/KG 4 TO 5	5 TO 6	6 TO 7
ANIMAL								
1655	5.5	5.4	5.8	5.4	9.3	9.4	5.9	6.1
1662	6.9	5.0	6.7	6.2	NA	0.0	6.4	8.2
1663	5.7	5.2	6.0	5.1	NA	NA	5.2	NA
1664	8.8	8.1	NA	8.6	NA	NA	6.9	6.8
1667	5.1	4.1	3.7	4.2	4.7	5.1	5.1	5.1
MEAN	6.4	5.6	5.6	5.9	7.0	4.8	5.9	6.6
S.D.	1.50	1.50	1.29	1.67	3.25	4.71	0.77	1.30
S.E.	0.67	0.67	0.65	0.75	2.30	2.72	0.34	0.65
N	5	5	4	5	2	3	5	4

NA = NOT APPLICABLE

PROJECT NO.:WIL-639011
 SPONSOR:SYNGENTA

TABLE A9
 A SINGLE ORAL DOSE OF PMI-0105 WITH A 14-DAY RECOVERY IN MICE
 INDIVIDUAL FOOD CONSUMPTION [G/ANIMAL/DAY]

DAY	FEMALE GROUP:									
	7 TO 8	8 TO 9	9 TO 10	10 TO 11	11 TO 12	12 TO 13	13 TO 14			
ANIMAL										
1656	5.8	6.0	5.3	5.3	5.4	5.8	5.3			
1658	6.9	7.6	7.9	8.9	7.5	7.6	7.6			
1659	4.6	6.1	5.5	5.2	5.2	6.1	6.1			
1665	4.5	6.9	5.7	4.7	4.0	4.1	4.5			
1666	5.6	6.8	6.6	6.1	6.3	5.8	6.7			
MEAN	5.5	6.7	6.2	6.0	5.7	5.9	6.0			
S.D.	0.98	0.65	1.07	1.68	1.31	1.24	1.20			
S.E.	0.44	0.29	0.48	0.75	0.58	0.56	0.54			
N	5	5	5	5	5	5	5			

PROJECT NO.:WIL-639011
 SPONSOR:SYNGENTA

TABLE A9
 A SINGLE ORAL DOSE OF PMI-0105 WITH A 14-DAY RECOVERY IN MICE
 INDIVIDUAL FOOD CONSUMPTION [G/ANIMAL/DAY]

DAY	FEMALE GROUP: 2000 MG/KG									
	7 TO 8	8 TO 9	9 TO 10	10 TO 11	11 TO 12	12 TO 13	13 TO 14			
ANIMAL										
1655	6.3	5.7	5.3	6.7	6.2	5.6	5.6			
1662	NA	9.1	NA	NA	NA	NA	2.5			
1663	5.1	5.7	6.2	6.3	5.5	5.8	5.4			
1664	6.3	NA	NA	8.0	7.3	6.0	6.4			
1667	4.8	4.6	4.8	5.3	5.1	5.1	5.0			
MEAN	5.6	6.3	5.4	6.6	6.0	5.6	5.0			
S.D.	0.79	1.95	0.71	1.12	0.96	0.39	1.48			
S.E.	0.39	0.98	0.41	0.56	0.48	0.19	0.66			
N	4	4	3	4	4	4	5			

NA = NOT APPLICABLE

PROJECT NO.:WIL-639011
 SPONSOR:SYNGENTA

TABLE A10
 A SINGLE ORAL DOSE OF PMI-0105 WITH A 14-DAY RECOVERY IN MICE
 INDIVIDUAL HEMATOLOGY VALUES

PAGE 1
 DAY 14

ANIMAL	WHITE CELLS	RED CELLS	HEMO-GLOBIN	HEMATO-CRIT	MCV	MCH	MCHC	PLATELET
	thous/uL	mil/uL	g/dL	%	fL	pg	g/dL	thous/uL
GROUP:	0 MG/KG	MALES						
1639	3.09	9.47	16.6	46.6	49.2	17.5	35.7	993.
1642	4.05	9.40	15.8	44.2	47.0	16.8	35.7	987.
1645	2.35	8.88	14.6	40.8	46.0	16.5	35.8	1152.
1651	1.83	8.21	13.9	38.2	46.5	16.9	36.4	1061.
1652	3.34	8.82	13.9	40.6	46.1	15.8	34.3	1071.
MEAN	2.93	8.96	15.0	42.1	47.0	16.7	35.6	1053.
S.D.	0.865	0.510	1.20	3.31	1.31	0.62	0.77	67.4
S.E.	0.387	0.228	0.54	1.48	0.59	0.28	0.35	30.1
N	5	5	5	5	5	5	5	5

thous/uL = THOUSANDS/MICROLITER, mil/uL = MILLIONS/MICROLITER, fL = FEMTOLITERS, pg = PICOGRAMS, g/dL = GRAMS/DECILITER

PROJECT NO.:WIL-639011
 SPONSOR:SYNGENTA

TABLE A10
 A SINGLE ORAL DOSE OF PMI-0105 WITH A 14-DAY RECOVERY IN MICE
 INDIVIDUAL HEMATOLOGY VALUES

PAGE 2
 DAY 14

ANIMAL	RETIC- ULOCYTE	RETIC ABSOLUTE	NEUTRO- PHIL	LYMPH- OCYTE	MONOCYTE	EOSIN- OPHIL	BASOPHIL	LG UNST- AIN CELL
	%	thous/uL	%	%	%	%	%	%
GROUP:	0 MG/KG	MALES						
1639	2.5	235.7	15.5	79.0	1.6	2.9	0.6	0.5
1642	2.5	236.9	16.6	77.8	0.9	3.7	0.6	0.4
1645	2.6	226.9	14.2	80.3	1.4	3.5	0.3	0.2
1651	2.3	190.9	18.0	76.3	1.2	4.1	0.2	0.1
1652	2.7	235.9	11.0	83.1	0.8	4.6	0.3	0.2
MEAN	2.5	225.3	15.1	79.3	1.2	3.8	0.4	0.3
S.D.	0.15	19.63	2.67	2.59	0.33	0.64	0.19	0.16
S.E.	0.07	8.78	1.19	1.16	0.15	0.29	0.08	0.07
N	5	5	5	5	5	5	5	5

thous/uL = THOUSANDS/MICROLITER

PROJECT NO.:WIL-639011
 SPONSOR:SYNGENTA

TABLE A10
 A SINGLE ORAL DOSE OF PMI-0105 WITH A 14-DAY RECOVERY IN MICE
 INDIVIDUAL HEMATOLOGY VALUES

PAGE 3
 DAY 14

ANIMAL	NEU ABSOLUTE	LYMPH ABSOLUTE	MONO ABSOLUTE	EOS ABSOLUTE	BASO ABSOLUTE	LUC ABSOLUTE	PLATELET ESTIMATE	RBC MORPHOLOGY
	thous/uL	thous/uL	thous/uL	thous/uL	thous/uL	thous/uL		
GROUP:	0 MG/KG	MALES						
1639	0.48	2.44	0.05	0.09	0.02	0.02	ADEQUATE	1-PLT CLUM 2-POL,1-HJB
1642	0.67	3.15	0.04	0.15	0.02	0.01	ADEQUATE	1-PLT CLUM 2-POL,1-HJB
1645	0.33	1.89	0.03	0.08	0.01	0.00	DECREASE	2-PLT CLUM 2-POL,1-HJB
1651	0.33	1.40	0.02	0.08	0.00	0.00	ADEQUATE	2-PLT CLUM 2-POL,1-HJB
1652	0.37	2.77	0.03	0.15	0.01	0.01	ADEQUATE	1-PLT CLUM 1-POL,1-HJB
MEAN	0.44	2.33	0.03	0.11	0.01	0.01		
S.D.	0.144	0.696	0.011	0.037	0.008	0.008		
S.E.	0.065	0.311	0.005	0.016	0.004	0.004		
N	5	5	5	5	5	5		

thous/uL = THOUSANDS/MICROLITER

----- MORPHOLOGY CODE -----

1 = FEW, 2 = MODERATE, PLT CLUM = PLATELET CLUMPS, POL = POLYCHROMASIA, HJB = HOWELL-JOLLEY BODY

PROJECT NO.:WIL-639011
 SPONSOR:SYNGENTA

TABLE A10
 A SINGLE ORAL DOSE OF PMI-0105 WITH A 14-DAY RECOVERY IN MICE
 INDIVIDUAL HEMATOLOGY VALUES

PAGE 4
 DAY 14

ANIMAL	WHITE CELLS	RED CELLS	HEMO-GLOBIN	HEMATO-CRIT	MCV	MCH	MCHC	PLATELET
	thous/uL	mil/uL	g/dL	%	fL	pg	g/dL	thous/uL
GROUP:	2000 MG/KG	MALES						
1638	3.36	9.42	15.3	43.2	45.9	16.3	35.5	1144.
1641	2.90	9.15	14.5	40.4	44.1	15.9	35.9	1156.
1648	5.03	8.72	14.8	41.6	47.7	16.9	35.5	1201.
1649	3.84	8.74	14.2	40.2	46.0	16.2	35.3	801.
1650	2.47	9.09	14.7	40.6	44.7	16.1	36.1	1203.
MEAN	3.52	9.02	14.7	41.2	45.7	16.3	35.7	1101.
S.D.	0.987	0.296	0.41	1.24	1.39	0.38	0.33	169.8
S.E.	0.441	0.132	0.18	0.55	0.62	0.17	0.15	75.9
N	5	5	5	5	5	5	5	5

thous/uL = THOUSANDS/MICROLITER, mil/uL = MILLIONS/MICROLITER, fL = FEMTOLITERS, pg = PICOGRAMS, g/dL = GRAMS/DECILITER

PROJECT NO.:WIL-639011
 SPONSOR:SYNGENTA

TABLE A10
 A SINGLE ORAL DOSE OF PMI-0105 WITH A 14-DAY RECOVERY IN MICE
 INDIVIDUAL HEMATOLOGY VALUES

PAGE 5
 DAY 14

ANIMAL	RETIC- ULOCYTE	RETIC ABSOLUTE	NEUTRO- PHIL	LYMPH- OCYTE	MONOCYTE	EOSIN- OPHIL	BASOPHIL	LG UNST- AIN CELL
	%	thous/uL	%	%	%	%	%	%
GROUP:	2000 MG/KG	MALES						
1638	2.5	239.8	12.8	80.6	2.8	2.6	0.7	0.5
1641	2.5	226.3	16.0	74.9	3.3	4.7	0.5	0.5
1648	3.1	268.3	13.0	82.6	1.8	1.8	0.4	0.4
1649	2.5	218.5	19.0	81.0	0.0	0.0	0.0	0.0
1650	2.5	229.1	12.6	82.8	1.1	2.8	0.3	0.3
MEAN	2.6	236.4	14.7	80.4	1.8	2.4	0.4	0.3
S.D.	0.27	19.40	2.79	3.21	1.32	1.70	0.26	0.21
S.E.	0.12	8.67	1.25	1.44	0.59	0.76	0.12	0.09
N	5	5	5	5	5	5	5	5

thous/uL = THOUSANDS/MICROLITER

PROJECT NO.:WIL-639011
 SPONSOR:SYNGENTA

TABLE A10
 A SINGLE ORAL DOSE OF PMI-0105 WITH A 14-DAY RECOVERY IN MICE
 INDIVIDUAL HEMATOLOGY VALUES

PAGE 6
 DAY 14

ANIMAL	NEU ABSOLUTE	LYMPH ABSOLUTE	MONO ABSOLUTE	EOS ABSOLUTE	BASO ABSOLUTE	LUC ABSOLUTE	PLATELET ESTIMATE	RBC MORPHOLOGY
	thous/uL	thous/uL	thous/uL	thous/uL	thous/uL	thous/uL		
GROUP:	2000 MG/KG	MALES						
1638	0.43	2.71	0.09	0.09	0.02	0.02	ADEQUATE	2-PLT CLUM 2-POL,1-HJB
1641	0.47	2.17	0.10	0.14	0.01	0.01	ADEQUATE	2-PLT CLUM 1-POL,1-HJB
1648	0.66	4.16	0.09	0.09	0.02	0.02	ADEQUATE	1-PLT CLUM 2-POL,1-HJB
1649	0.73	3.11	0.00	0.00	0.00	0.00	ADEQUATE	3-PLT CLUM 2-POL,1-HJB
1650	0.31	2.05	0.03	0.07	0.01	0.01	ADEQUATE	1-PLT CLUM 1-POL
MEAN	0.52	2.84	0.06	0.08	0.01	0.01		
S.D.	0.172	0.852	0.044	0.051	0.008	0.008		
S.E.	0.077	0.381	0.020	0.023	0.004	0.004		
N	5	5	5	5	5	5		

thous/uL = THOUSANDS/MICROLITER

----- MORPHOLOGY CODE -----

1 = FEW, 2 = MODERATE, 3 = MANY, PLT CLUM = PLATELET CLUMPS, POL = POLYCHROMASIA, HJB = HOWELL-JOLLEY BODY

PROJECT NO.:WIL-639011
 SPONSOR:SYNGENTA

TABLE A10
 A SINGLE ORAL DOSE OF PMI-0105 WITH A 14-DAY RECOVERY IN MICE
 INDIVIDUAL HEMATOLOGY VALUES

PAGE 7
 DAY 14

ANIMAL	WHITE CELLS	RED CELLS	HEMO-GLOBIN	HEMATO-CRIT	MCV	MCH	MCHC	PLATELET
	thous/uL	mil/uL	g/dL	%	fL	pg	g/dL	thous/uL
GROUP:	0 MG/KG	FEMALES						
1656	2.65	8.43	15.1	41.4	49.1	17.9	36.5	856.
1658	4.00	9.12	14.8	41.0	45.0	16.3	36.1	783.
1659	2.92	7.97	13.2	38.2	47.9	16.5	34.5	953.
1665	CLT	CLT	CLT	CLT	CLT	CLT	CLT	CLT
1666	QNS	QNS	QNS	QNS	QNS	QNS	QNS	QNS
MEAN	3.19	8.51	14.4	40.2	47.3	16.9	35.7	864.
S.D.	0.714	0.579	1.02	1.74	2.11	0.87	1.06	85.3
S.E.	0.412	0.334	0.59	1.01	1.22	0.50	0.61	49.2
N	3	3	3	3	3	3	3	3

CLT = CLOTTED, QNS = QUANTITY NOT SUFFICIENT

thous/uL = THOUSANDS/MICROLITER, mil/uL = MILLIONS/MICROLITER, fL = FEMTOLITERS, pg = PICOGRAMS, g/dL = GRAMS/DECILITER

PROJECT NO.:WIL-639011
 SPONSOR:SYNGENTA

TABLE A10
 A SINGLE ORAL DOSE OF PMI-0105 WITH A 14-DAY RECOVERY IN MICE
 INDIVIDUAL HEMATOLOGY VALUES

PAGE 8
 DAY 14

ANIMAL	RETIC- ULOCYTE	RETIC ABSOLUTE	NEUTRO- PHIL	LYMPH- OCYTE	MONOCYTE	EOSIN- OPHIL	BASOPHIL	LG UNST- AIN CELL
	%	thous/uL	%	%	%	%	%	%
GROUP:	0 MG/KG	FEMALES						
1656	2.5	210.0	12.0	81.0	1.0	6.0	0.0	0.0
1658	2.9	265.4	10.0	81.0	1.0	7.0	1.0	0.0
1659	3.4	271.0	14.7	79.3	1.5	3.5	0.5	0.5
1665	CLT	CLT	CLT	CLT	CLT	CLT	CLT	CLT
1666	QNS	QNS	QNS	QNS	QNS	QNS	QNS	QNS
MEAN	2.9	248.8	12.2	80.4	1.2	5.5	0.5	0.2
S.D.	0.45	33.72	2.36	0.98	0.29	1.80	0.50	0.29
S.E.	0.26	19.47	1.36	0.57	0.17	1.04	0.29	0.17
N	3	3	3	3	3	3	3	3

CLT = CLOTTED, QNS = QUANTITY NOT SUFFICIENT

thous/uL = THOUSANDS/MICROLITER

PROJECT NO.:WIL-639011
 SPONSOR:SYNGENTA

TABLE A10
 A SINGLE ORAL DOSE OF PMI-0105 WITH A 14-DAY RECOVERY IN MICE
 INDIVIDUAL HEMATOLOGY VALUES

PAGE 9
 DAY 14

ANIMAL	NEU ABSOLUTE	LYMPH ABSOLUTE	MONO ABSOLUTE	EOS ABSOLUTE	BASO ABSOLUTE	LUC ABSOLUTE	PLATELET ESTIMATE	RBC MORPHOLOGY
	thous/uL	thous/uL	thous/uL	thous/uL	thous/uL	thous/uL		
GROUP:	0 MG/KG	FEMALES						
1656	0.32	2.15	0.03	0.16	0.00	0.00	ADEQUATE	2-PLT CLUM 1-POL,1-HJB
1658	0.40	3.24	0.04	0.28	0.04	0.00	ADEQUATE	3-PLT CLUM 2-POL,1-HJB
1659	0.43	2.32	0.04	0.10	0.01	0.01	ADEQUATE	1-PLT CLUM 1-POL,1-HJB
1665	CLT	CLT	CLT	CLT	CLT	CLT	PLATELET ESTIMATE AND	MORPHOLOGY NOT REVIEWED
1666	QNS	QNS	QNS	QNS	QNS	QNS	PLATELET ESTIMATE AND	MORPHOLOGY NOT REVIEWED
MEAN	0.38	2.57	0.04	0.18	0.02	0.00		
S.D.	0.057	0.586	0.006	0.092	0.021	0.006		
S.E.	0.033	0.339	0.003	0.053	0.012	0.003		
N	3	3	3	3	3	3		

CLT = CLOTTED, QNS = QUANTITY NOT SUFFICIENT

thous/uL = THOUSANDS/MICROLITER

----- MORPHOLOGY CODE -----

1 = FEW, 2 = MODERATE, 3 = MANY, PLT CLUM = PLATELET CLUMPS, POL = POLYCHROMASIA, HJB = HOWELL-JOLLEY BODY

PROJECT NO.:WIL-639011
 SPONSOR:SYNGENTA

TABLE A10
 A SINGLE ORAL DOSE OF PMI-0105 WITH A 14-DAY RECOVERY IN MICE
 INDIVIDUAL HEMATOLOGY VALUES

PAGE 10
 DAY 14

ANIMAL	WHITE CELLS	RED CELLS	HEMO- GLOBIN	HEMATO- CRIT	MCV	MCH	MCHC	PLATELET
	thous/uL	mil/uL	g/dL	%	fL	pg	g/dL	thous/uL
GROUP:	2000 MG/KG	FEMALES						
1655	3.04	8.01	13.6	38.3	47.8	17.0	35.7	928.
1662	2.85	8.37	13.6	38.6	46.1	16.3	35.3	1031.
1663	3.86	9.14	14.2	40.2	43.9	15.6	35.5	915.
1664	5.64	9.12	14.8	41.9	45.9	16.2	35.3	743.
1667	3.34	9.09	14.9	41.4	45.6	16.4	36.0	820.
MEAN	3.75	8.75	14.2	40.1	45.9	16.3	35.6	887.
S.D.	1.125	0.524	0.63	1.61	1.39	0.50	0.30	110.0
S.E.	0.503	0.234	0.28	0.72	0.62	0.22	0.13	49.2
N	5	5	5	5	5	5	5	5

thous/uL = THOUSANDS/MICROLITER, mil/uL = MILLIONS/MICROLITER, fL = FEMTOLITERS, pg = PICOGRAMS, g/dL = GRAMS/DECILITER

PROJECT NO.:WIL-639011
 SPONSOR:SYNGENTA

TABLE A10
 A SINGLE ORAL DOSE OF PMI-0105 WITH A 14-DAY RECOVERY IN MICE
 INDIVIDUAL HEMATOLOGY VALUES

PAGE 11
 DAY 14

ANIMAL	RETIC- ULOCYTE	RETIC ABSOLUTE	NEUTRO- PHIL	LYMPH- OCYTE	MONOCYTE	EOSIN- OPHIL	BASOPHIL	LG UNST- AIN CELL
	%	thous/uL	%	%	%	%	%	%
GROUP:	2000 MG/KG	FEMALES						
1655	3.8	302.2	17.1	75.8	1.7	4.6	0.4	0.4
1662	2.9	245.3	14.7	78.9	2.9	2.8	0.5	0.3
1663	2.7	250.6	10.8	82.7	1.7	4.2	0.3	0.4
1664	3.3	297.0	11.0	82.0	2.0	5.0	0.0	0.0
1667	2.8	256.2	11.0	86.0	1.0	2.0	0.0	0.0
MEAN	3.1	270.3	12.9	81.1	1.9	3.7	0.2	0.2
S.D.	0.45	27.12	2.85	3.88	0.69	1.27	0.23	0.20
S.E.	0.20	12.13	1.27	1.74	0.31	0.57	0.10	0.09
N	5	5	5	5	5	5	5	5

thous/uL = THOUSANDS/MICROLITER

PROJECT NO.:WIL-639011
 SPONSOR:SYNGENTA

TABLE A10
 A SINGLE ORAL DOSE OF PMI-0105 WITH A 14-DAY RECOVERY IN MICE
 INDIVIDUAL HEMATOLOGY VALUES

PAGE 12
 DAY 14

ANIMAL	NEU ABSOLUTE	LYMPH ABSOLUTE	MONO ABSOLUTE	EOS ABSOLUTE	BASO ABSOLUTE	LUC ABSOLUTE	PLATELET ESTIMATE	RBC MORPHOLOGY
	thous/uL	thous/uL	thous/uL	thous/uL	thous/uL	thous/uL		
GROUP:	2000 MG/KG	FEMALES						
1655	0.52	2.30	0.05	0.14	0.01	0.01	ADEQUATE	1-PLT CLUM 2-POL,1-HJB
1662	0.42	2.24	0.08	0.08	0.01	0.01	ADEQUATE	1-PLT CLUM 1-POL,1-HJB
1663	0.42	3.19	0.06	0.16	0.01	0.02	ADEQUATE	2-PLT CLUM 2-POL,1-HJB
1664	0.62	4.62	0.11	0.28	0.00	0.00	ADEQUATE	3-PLT CLUM 2-POL,1-HJB
1667	0.37	2.87	0.03	0.07	0.00	0.00	ADEQUATE	3-PLT CLUM 1-POL,1-HJB
MEAN	0.47	3.04	0.07	0.15	0.01	0.01		
S.D.	0.100	0.966	0.030	0.084	0.005	0.008		
S.E.	0.045	0.432	0.014	0.038	0.002	0.004		
N	5	5	5	5	5	5		

thous/uL = THOUSANDS/MICROLITER

----- MORPHOLOGY CODE -----

1 = FEW, 2 = MODERATE, 3 = MANY, PLT CLUM = PLATELET CLUMPS, POL = POLYCHROMASIA, HJB = HOWELL-JOLLEY BODY

PHEMAv1.34
 02/27/2008
 R:03/20/2009

PROJECT NO.:WIL-639011
 SPONSOR:SYNGENTA

TABLE A11
 A SINGLE ORAL DOSE OF PMI-0105 WITH A 14-DAY RECOVERY IN MICE
 INDIVIDUAL SERUM CHEMISTRY VALUES

PAGE 1
 DAY 14

ANIMAL	ALBUMIN	TOTAL PROTEIN	GLOBULIN	A/G RATIO	TOTAL BILI	UREA NITROGEN	CREAT-ININE	ALKALINE PHOS'TSE	ALANINE TRANSFER	ASPARTAT TRANSFER	GLUTAMYL TRANSFER
	g/dL	g/dL	g/dL		mg/dL	mg/dL	mg/dL	U/L	U/L	U/L	U/L
GROUP:	0 MG/KG	MALES									
1639	QNS	QNS	QNS	QNS	QNS	21.1	UR	80.	68.	91.	QNS
1642	QNS	QNS	QNS	QNS	QNS	19.1	UR	57.	48.	112.	QNS
1645	QNS	QNS	QNS	QNS	QNS	QNS	0.0	48.	52.	84.	QNS
1651	QNS	QNS	QNS	QNS	QNS	19.0	UR	72.	31.	74.	QNS
1652	QNS	QNS	QNS	QNS	QNS	18.7	0.1	70.	36.	72.	QNS
MEAN	NA	NA	NA	NA	NA	19.5	0.1	65.	47.	87.	NA
S.D.						1.10	0.07	12.8	14.5	16.1	
S.E.						0.55	0.05	5.7	6.5	7.2	
N						4	2	5	5	5	

QNS = QUANTITY NOT SUFFICIENT, UR = BELOW INSTRUMENT RANGE

mg/dL = MILLIGRAMS/DECILITER, U/L = INTERNATIONAL UNIT/LITER, g/dL = GRAMS/DECILITER

PROJECT NO.:WIL-639011
 SPONSOR:SYNGENTA

TABLE A11
 A SINGLE ORAL DOSE OF PMI-0105 WITH A 14-DAY RECOVERY IN MICE
 INDIVIDUAL SERUM CHEMISTRY VALUES

PAGE 2
 DAY 14

ANIMAL	GLUCOSE	CHOL- ESTEROL	CALCIUM	CHLORIDE	PHOS- PHORUS	POTAS- SIUM	SODIUM	CREATINE KINASE	TRIGLY- CERIDE
	mg/dL	mg/dL	mg/dL	mEq/L	mg/dL	mEq/L	mEq/L	U/L	mg/dL
GROUP:	0 MG/KG	MALES							
1639	QNS	QNS	QNS	QNS	QNS	QNS	QNS	QNS	QNS
1642	188.	QNS	QNS	QNS	QNS	QNS	QNS	QNS	QNS
1645	QNS	QNS	QNS	QNS	QNS	QNS	QNS	QNS	QNS
1651	183.	QNS	QNS	QNS	QNS	QNS	QNS	QNS	QNS
1652	QNS	QNS	QNS	QNS	QNS	QNS	QNS	QNS	QNS
MEAN	186.	NA	NA	NA	NA	NA	NA	NA	NA
S.D.	3.5								
S.E.	2.5								
N	2								

QNS = QUANTITY NOT SUFFICIENT

mg/dL = MILLIGRAMS/DECILITER, U/L = INTERNATIONAL UNIT/LITER, mEq/L = MILLIEQUIVALENTS/LITER

PROJECT NO.:WIL-639011
 SPONSOR:SYNGENTA

TABLE A11
 A SINGLE ORAL DOSE OF PMI-0105 WITH A 14-DAY RECOVERY IN MICE
 INDIVIDUAL SERUM CHEMISTRY VALUES

PAGE 3
 DAY 14

ANIMAL	ALBUMIN	TOTAL PROTEIN	GLOBULIN	A/G RATIO	TOTAL BILI	UREA NITROGEN	CREAT-ININE	ALKALINE PHOS'TSE	ALANINE TRANSFER	ASPARTAT TRANSFER	GLUTAMYL TRANSFER
	g/dL	g/dL	g/dL		mg/dL	mg/dL	mg/dL	U/L	U/L	U/L	U/L
GROUP:	2000 MG/KG	MALES									
1638	QNS	QNS	QNS	QNS	QNS	29.3	0.0	126.	44.	98.	QNS
1641	QNS	QNS	QNS	QNS	QNS	22.5	UR	86.	104.	84.	0.1
1648	QNS	QNS	QNS	QNS	QNS	35.5	0.0	80.	42.	82.	QNS
1649	QNS	QNS	QNS	QNS	QNS	QNS	UR	100.	77.	128.	QNS
1650	QNS	QNS	QNS	QNS	QNS	22.7	0.0	70.	29.	66.	QNS
MEAN	NA	NA	NA	NA	NA	27.5	0.0	92.	59.	92.	0.1
S.D.						6.20	0.00	21.7	30.7	23.3	0.00
S.E.						3.10	0.00	9.7	13.7	10.4	0.00
N						4	3	5	5	5	1

QNS = QUANTITY NOT SUFFICIENT, UR = BELOW INSTRUMENT RANGE

mg/dL = MILLIGRAMS/DECILITER, U/L = INTERNATIONAL UNIT/LITER, g/dL = GRAMS/DECILITER

PROJECT NO.:WIL-639011
 SPONSOR:SYNGENTA

TABLE A11
 A SINGLE ORAL DOSE OF PMI-0105 WITH A 14-DAY RECOVERY IN MICE
 INDIVIDUAL SERUM CHEMISTRY VALUES

PAGE 4
 DAY 14

ANIMAL	GLUCOSE	CHOL- ESTEROL	CALCIUM	CHLORIDE	PHOS- PHORUS	POTAS- SIUM	SODIUM	CREATINE KINASE	TRIGLY- CERIDE
	mg/dL	mg/dL	mg/dL	mEq/L	mg/dL	mEq/L	mEq/L	U/L	mg/dL
GROUP:	2000 MG/KG	MALES							
1638	QNS	QNS	QNS	QNS	QNS	QNS	QNS	QNS	QNS
1641	200.	QNS	QNS	QNS	QNS	QNS	QNS	QNS	QNS
1648	QNS	QNS	QNS	QNS	QNS	QNS	QNS	QNS	QNS
1649	QNS	QNS	QNS	QNS	QNS	QNS	QNS	QNS	QNS
1650	181.	QNS	QNS	QNS	QNS	QNS	QNS	QNS	QNS
MEAN	191.	NA	NA	NA	NA	NA	NA	NA	NA
S.D.	13.4								
S.E.	9.5								
N	2								

QNS = QUANTITY NOT SUFFICIENT

mg/dL = MILLIGRAMS/DECILITER, U/L = INTERNATIONAL UNIT/LITER, mEq/L = MILLIEQUIVALENTS/LITER

PROJECT NO.:WIL-639011
 SPONSOR:SYNGENTA

TABLE A11
 A SINGLE ORAL DOSE OF PMI-0105 WITH A 14-DAY RECOVERY IN MICE
 INDIVIDUAL SERUM CHEMISTRY VALUES

PAGE 5
 DAY 14

ANIMAL	ALBUMIN	TOTAL PROTEIN	GLOBULIN	A/G RATIO	TOTAL BILI	UREA NITROGEN	CREAT-ININE	ALKALINE PHOS'TSE	ALANINE TRANSFER	ASPARTAT TRANSFER	GLUTAMYL TRANSFER
	g/dL	g/dL	g/dL		mg/dL	mg/dL	mg/dL	U/L	U/L	U/L	U/L
GROUP:	0 MG/KG	FEMALES									
1656	QNS	QNS	QNS	QNS	QNS	16.5	UR	117.	24.	65.	QNS
1658	QNS	QNS	QNS	QNS	QNS	QNS	0.0	171.	33.	73.	QNS
1659	QNS	QNS	QNS	QNS	QNS	21.4	UR	99.	30.	95.	QNS
1665	QNS	QNS	QNS	QNS	QNS	22.1	0.0	96.	31.	170.	QNS
1666	QNS	QNS	QNS	QNS	QNS	21.9	0.0	114.	31.	85.	QNS
MEAN	NA	NA	NA	NA	NA	20.5	0.0	119.	30.	98.	NA
S.D.						2.67	0.00	30.3	3.4	42.1	
S.E.						1.33	0.00	13.5	1.5	18.8	
N						4	3	5	5	5	

QNS = QUANTITY NOT SUFFICIENT, UR = BELOW INSTRUMENT RANGE

mg/dL = MILLIGRAMS/DECILITER, U/L = INTERNATIONAL UNIT/LITER, g/dL = GRAMS/DECILITER

PROJECT NO.: WIL-639011
 SPONSOR: SYNGENTA

TABLE A11
 A SINGLE ORAL DOSE OF PMI-0105 WITH A 14-DAY RECOVERY IN MICE
 INDIVIDUAL SERUM CHEMISTRY VALUES

PAGE 6
 DAY 14

ANIMAL	GLUCOSE	CHOL- ESTEROL	CALCIUM	CHLORIDE	PHOS- PHORUS	POTAS- SIUM	SODIUM	CREATINE KINASE	TRIGLY- CERIDE
	mg/dL	mg/dL	mg/dL	mEq/L	mg/dL	mEq/L	mEq/L	U/L	mg/dL
GROUP:	0 MG/KG	FEMALES							
1656	175.	86.	QNS	QNS	QNS	QNS	QNS	QNS	QNS
1658	QNS	QNS	QNS	QNS	QNS	QNS	QNS	QNS	QNS
1659	163.	QNS	QNS	QNS	QNS	QNS	QNS	QNS	QNS
1665	115.	QNS	QNS	QNS	QNS	QNS	QNS	QNS	QNS
1666	172.	QNS	QNS	QNS	QNS	QNS	QNS	QNS	QNS
MEAN	156.	86.	NA	NA	NA	NA	NA	NA	NA
S.D.	28.0	0.0							
S.E.	14.0	0.0							
N	4	1							

QNS = QUANTITY NOT SUFFICIENT

mg/dL = MILLIGRAMS/DECILITER, U/L = INTERNATIONAL UNIT/LITER, mEq/L = MILLIEQUIVALENTS/LITER

TABLE A11

PROJECT NO.:WIL-639011
SPONSOR:SYNGENTA

A SINGLE ORAL DOSE OF PMI-0105 WITH A 14-DAY RECOVERY IN MICE
INDIVIDUAL SERUM CHEMISTRY VALUES

PAGE 7
DAY 14

ANIMAL	ALBUMIN	TOTAL PROTEIN	GLOBULIN	A/G RATIO	TOTAL BILI	UREA NITROGEN	CREAT-ININE	ALKALINE PHOS'TSE	ALANINE TRANSFER	ASPARTAT TRANSFER	GLUTAMYL TRANSFER
	g/dL	g/dL	g/dL		mg/dL	mg/dL	mg/dL	U/L	U/L	U/L	U/L
GROUP:	2000 MG/KG	FEMALES									
1655	QNS	QNS	QNS	QNS	QNS	16.3	UR	128.	41.	95.	QNS
1662	QNS	QNS	QNS	QNS	QNS	17.3	UR	142.	37.	89.	QNS
1663	QNS	QNS	QNS	QNS	QNS	QNS	UR	137.	31.	115.	QNS
1664	QNS	QNS	QNS	QNS	QNS	QNS	0.0	157.	43.	97.	QNS
1667	QNS	QNS	QNS	QNS	QNS	QNS	0.0	74.	53.	123.	QNS
MEAN	NA	NA	NA	NA	NA	16.8	0.0	128.	41.	104.	NA
S.D.						0.71	0.00	31.8	8.1	14.5	
S.E.						0.50	0.00	14.2	3.6	6.5	
N						2	2	5	5	5	

QNS = QUANTITY NOT SUFFICIENT, UR = BELOW INSTRUMENT RANGE

mg/dL = MILLIGRAMS/DECILITER, U/L = INTERNATIONAL UNIT/LITER, g/dL = GRAMS/DECILITER

PROJECT NO.:WIL-639011
 SPONSOR:SYNGENTA

TABLE A11
 A SINGLE ORAL DOSE OF PMI-0105 WITH A 14-DAY RECOVERY IN MICE
 INDIVIDUAL SERUM CHEMISTRY VALUES

PAGE 8
 DAY 14

ANIMAL	GLUCOSE	CHOL- ESTEROL	CALCIUM	CHLORIDE	PHOS- PHORUS	POTAS- SIUM	SODIUM	CREATINE KINASE	TRIGLY- CERIDE
	mg/dL	mg/dL	mg/dL	mEq/L	mg/dL	mEq/L	mEq/L	U/L	mg/dL
GROUP:	2000 MG/KG	FEMALES							
1655	134.	QNS	QNS	QNS	QNS	QNS	QNS	QNS	QNS
1662	182.	QNS	QNS	QNS	QNS	QNS	QNS	QNS	QNS
1663	QNS	QNS	QNS	QNS	QNS	QNS	QNS	QNS	QNS
1664	QNS	QNS	QNS	QNS	QNS	QNS	QNS	QNS	QNS
1667	QNS	QNS	QNS	QNS	QNS	QNS	QNS	QNS	QNS
MEAN	158.	NA	NA	NA	NA	NA	NA	NA	NA
S.D.	33.9								
S.E.	24.0								
N	2								

QNS = QUANTITY NOT SUFFICIENT

mg/dL = MILLIGRAMS/DECILITER, U/L = INTERNATIONAL UNIT/LITER, mEq/L = MILLIEQUIVALENTS/LITER

PCHEv4.03
 02/27/2008
 R:03/20/2009

PROJECT NO.:WIL-639011
 SPONSOR:SYNGENTA

TABLE A12
 A SINGLE ORAL DOSE OF PMI-0105 WITH A 14-DAY RECOVERY IN MICE
 INDIVIDUAL MACROSCOPIC AND MICROSCOPIC FINDINGS

PAGE 1

ANIMAL NO. 1639 GROUP 1: 0 MG/KG MALE SCHEDULED EUTH 12/26/07 DATE OF DEATH: 12/26/07 STUDY DAY: 14
 GRADE

ORGAN WEIGHT	ABS.(G)	REL.	EYES/OPTIC N.	MICRO: NO SIGNIFICANT CHANGES OBSERVED			
BRAIN	0.4465	1.357		ONE OPTIC NERVE NOT IN PLANE; RECUT MADE AND EXAMINED.			
LIVER/GB	1.6142	4.906	KIDNEYS	GROSS: AREA(S), DEPRESSED			
KIDNEYS	0.6976	2.120		ONE, 3 MM IN DIAMETER, IN CORTEX, LEFT			
SPLEEN	0.1008	0.306	NO SIGNIFICANT				
HEART	0.1859	0.565	CHANGES OBSERVED	GROSS:ADRENAL GLANDS AORTA STERNUM FEMUR			
EPIDIDYMIDES	0.1039	0.316		JOINT	BRAIN	CECUM	COLON
TESTES	0.2966	0.902		DUODENUM	EPIDIDYMIDES	ESOPHAGUS	EYES/OPTIC N.
ADRENAL GLANDS	0.0044	0.013		GALLBLADDER	HEART	ILEUM	JEJUNUM
FINAL BODY WT(G)	32.9			LYMPH NODE, MAND	LIVER	LYMPH NODE, MES	LUNGS
				NERVE, SCIATIC	PANCREAS	PITUITARY	PROSTATE
				RECTUM	SPINAL CORD	SAL. GLAND MAND	STOMACH
				SKELETAL MUSCLE	SKIN	SPLEEN	SEMINAL VESICLES
				TESTES	THYROID GLANDS	THYMUS	TRACHEA
				URINARY BLADDER	PEYER'S PATCHES		
				MICRO:ADRENAL CORTEX	ADRENAL MEDULLA	AORTA	STERNUM
				MARROW, STERN	FEMUR	MARROW, FEMUR	JOINT
				BRAIN	CECUM	COLON	DUODENUM
				EPIDIDYMIDES	ESOPHAGUS	EYES/OPTIC N.	GALLBLADDER
				HEART	ILEUM	JEJUNUM	KIDNEYS
				LYMPH NODE, MAND	LIVER	LYMPH NODE, MES	LUNGS
				NERVE, SCIATIC	PANCREAS	PITUITARY	PROSTATE
				RECTUM	SPINAL CORD	SAL. GLAND MAND	STOMACH, GLAN
				STOMACH, NON	SKELETAL MUSCLE	SKIN	SPLEEN
				SEMINAL VESICLES	TESTES	THYROID GLANDS	PARATHYROIDS
				THYMUS	TRACHEA	URINARY BLADDER	PEYER'S PATCHES

PROJECT NO.:WIL-639011
SPONSOR:SYNGENTA

TABLE A12
A SINGLE ORAL DOSE OF PMI-0105 WITH A 14-DAY RECOVERY IN MICE
INDIVIDUAL MACROSCOPIC AND MICROSCOPIC FINDINGS

PAGE 2

ANIMAL NO. 1639 GROUP 1: 0 MG/KG MALE SCHEDULED EUTH 12/26/07 DATE OF DEATH: 12/26/07 STUDY DAY: 14
GRADE

GROSS/MICRO CORRELATIONS
GROSS FINDING

<====> CONFIRMING MICROSCOPIC FINDING

KIDNEYS: AREA(S), DEPRESSED

<====>GROSS UNCONFIRMED

GROSS GRADE CODE: 1-SLIGHT, 2-MODERATE, 3-MARKED, P-PRESENT

MICRO GRADE CODE: 1-MINIMAL, 2-MILD, 3-MODERATE, 4-SEVERE, P-PRESENT

PROJECT NO.:WIL-639011
 SPONSOR:SYNGENTA

TABLE A12
 A SINGLE ORAL DOSE OF PMI-0105 WITH A 14-DAY RECOVERY IN MICE
 INDIVIDUAL MACROSCOPIC AND MICROSCOPIC FINDINGS

PAGE 3

ANIMAL NO. 1642 GROUP 1: 0 MG/KG MALE SCHEDULED EUTH 12/26/07 DATE OF DEATH: 12/26/07 STUDY DAY: 14
 GRADE

ORGAN WEIGHT	ABS.(G)	REL.	GENERAL COMMENT	GROSS: ORGAN DAMAGED AT NECROPSY				
BRAIN	0.4787	1.330		FEMUR, RIGHT				P
LIVER/GB	1.6734	4.648	EYES/OPTIC N.	MICRO: NO SIGNIFICANT CHANGES OBSERVED				
KIDNEYS	0.6315	1.754		ONE OPTIC NERVE NOT IN PLANE; RECUT MADE AND EXAMINED.				
SPLEEN	0.0889	0.247	PITUITARY	MICRO: NOT PRESENT FOR EXAMINATION				
HEART	0.1752	0.487		NOT IN PLANE OF SECTION; RECUT MADE AND EXAMINED.				
EPIDIDYMIDES	0.1135	0.315	NO SIGNIFICANT					
TESTES	0.2798	0.777	CHANGES OBSERVED	GROSS:ADRENAL GLANDS	AORTA	STERNUM	FEMUR	
ADRENAL GLANDS	0.0102	0.028		JOINT	BRAIN	CECUM	COLON	
FINAL BODY WT(G)	36.0			DUODENUM	EPIDIDYMIDES	ESOPHAGUS	EYES/OPTIC N.	
				GALLBLADDER	HEART	ILEUM	JEJUNUM	
				KIDNEYS	LYMPH NODE, MAND	LIVER	LYMPH NODE, MES	
				LUNGS	NERVE, SCIATIC	PANCREAS	PITUITARY	
				PROSTATE	RECTUM	SPINAL CORD	SAL. GLAND MAND	
				STOMACH	SKELETAL MUSCLE	SKIN	SPLEEN	
				SEMINAL VESICLES	TESTES	THYROID GLANDS	THYMUS	
				TRACHEA	URINARY BLADDER	PEYER'S PATCHES		
				MICRO:ADRENAL CORTEX	ADRENAL MEDULLA	AORTA	STERNUM	
				MARROW, STERN	FEMUR	MARROW, FEMUR	JOINT	
				BRAIN	CECUM	COLON	DUODENUM	
				EPIDIDYMIDES	ESOPHAGUS	EYES/OPTIC N.	GALLBLADDER	
				HEART	ILEUM	JEJUNUM	KIDNEYS	
				LYMPH NODE, MAND	LIVER	LYMPH NODE, MES	LUNGS	
				NERVE, SCIATIC	PANCREAS	PROSTATE	RECTUM	
				SPINAL CORD	SAL. GLAND MAND	STOMACH, GLAN	STOMACH, NON	
				SKELETAL MUSCLE	SKIN	SPLEEN	SEMINAL VESICLES	
				TESTES	THYROID GLANDS	PARATHYROIDS	THYMUS	
				TRACHEA	URINARY BLADDER	PEYER'S PATCHES		

NOT PRESENT FOR EXAMINATION

MICRO:PITUITARY

PROJECT NO.:WIL-639011
SPONSOR:SYNGENTA

TABLE A12
A SINGLE ORAL DOSE OF PMI-0105 WITH A 14-DAY RECOVERY IN MICE
INDIVIDUAL MACROSCOPIC AND MICROSCOPIC FINDINGS

PAGE 4

ANIMAL NO. 1642 GROUP 1: 0 MG/KG MALE SCHEDULED EUTH 12/26/07 DATE OF DEATH: 12/26/07 STUDY DAY: 14
GRADE

GROSS GRADE CODE: 1-SLIGHT, 2-MODERATE, 3-MARKED, P-PRESENT

MICRO GRADE CODE: 1-MINIMAL, 2-MILD, 3-MODERATE, 4-SEVERE, P-PRESENT

PROJECT NO.:WIL-639011
 SPONSOR:SYNGENTA

TABLE A12
 A SINGLE ORAL DOSE OF PMI-0105 WITH A 14-DAY RECOVERY IN MICE
 INDIVIDUAL MACROSCOPIC AND MICROSCOPIC FINDINGS

PAGE 5

ANIMAL NO. 1645 GROUP 1: 0 MG/KG MALE SCHEDULED EUTH 12/26/07 DATE OF DEATH: 12/26/07 STUDY DAY: 14
 GRADE

ORGAN WEIGHT	ABS.(G)	REL.	PITUITARY	MICRO: NOT PRESENT FOR EXAMINATION			
BRAIN	0.4736	1.319		NOT PRESENT AT TRIMMING.			
LIVER/GB	1.5842	4.413	PARATHYROIDS	MICRO: NOT PRESENT FOR EXAMINATION			
KIDNEYS	0.5776	1.609		PARATHYROIDS NOT IN PLANE OF SECTION.			
SPLEEN	0.0766	0.213	NO SIGNIFICANT				
HEART	0.1745	0.486	CHANGES OBSERVED	GROSS:ADRENAL GLANDS	AORTA	STERNUM	FEMUR
EPIDIDYMIDES	0.1220	0.340		JOINT	BRAIN	CECUM	COLON
TESTES	0.2516	0.701		DUODENUM	EPIDIDYMIDES	ESOPHAGUS	EYES/OPTIC N.
ADRENAL GLANDS	0.0062	0.017		GALLBLADDER	HEART	ILEUM	JEJUNUM
FINAL BODY WT(G)	35.9			KIDNEYS	LYMPH NODE, MAND	LIVER	LYMPH NODE, MES
				LUNGS	NERVE, SCIATIC	PANCREAS	PITUITARY
				PROSTATE	RECTUM	SPINAL CORD	SAL. GLAND MAND
				STOMACH	SKELETAL MUSCLE	SKIN	SPLEEN
				SEMINAL VESICLES	TESTES	THYROID GLANDS	THYMUS
				TRACHEA	URINARY BLADDER	PEYER'S PATCHES	
				MICRO:ADRENAL CORTEX	ADRENAL MEDULLA	AORTA	STERNUM
				MARROW, STERN	FEMUR	MARROW, FEMUR	JOINT
				BRAIN	CECUM	COLON	DUODENUM
				EPIDIDYMIDES	ESOPHAGUS	EYES/OPTIC N.	GALLBLADDER
				HEART	ILEUM	JEJUNUM	KIDNEYS
				LYMPH NODE, MAND	LIVER	LYMPH NODE, MES	LUNGS
				NERVE, SCIATIC	PANCREAS	PROSTATE	RECTUM
				SPINAL CORD	SAL. GLAND MAND	STOMACH, GLAN	STOMACH, NON
				SKELETAL MUSCLE	SKIN	SPLEEN	SEMINAL VESICLES
				TESTES	THYROID GLANDS	THYMUS	TRACHEA
				URINARY BLADDER	PEYER'S PATCHES		

NOT PRESENT FOR EXAMINATION

MICRO:PITUITARY PARATHYROIDS

GROSS GRADE CODE: 1-SLIGHT, 2-MODERATE, 3-MARKED, P-PRESENT

MICRO GRADE CODE: 1-MINIMAL, 2-MILD, 3-MODERATE, 4-SEVERE, P-PRESENT

PROJECT NO.:WIL-639011
 SPONSOR:SYNGENTA

TABLE A12
 A SINGLE ORAL DOSE OF PMI-0105 WITH A 14-DAY RECOVERY IN MICE
 INDIVIDUAL MACROSCOPIC AND MICROSCOPIC FINDINGS

PAGE 6

ANIMAL NO. 1651 GROUP 1: 0 MG/KG MALE SCHEDULED EUTH 12/26/07 DATE OF DEATH: 12/26/07 STUDY DAY: 14
 GRADE

ORGAN WEIGHT	ABS.(G)	REL.	PARATHYROIDS	MICRO: NOT PRESENT FOR EXAMINATION			
BRAIN	0.5121	1.476		PARATHYROIDS NOT IN PLANE OF SECTION.			
LIVER/GB	1.7326	4.993	NO SIGNIFICANT				
KIDNEYS	0.5707	1.645	CHANGES OBSERVED	GROSS:ADRENAL GLANDS	AORTA	STERNUM	FEMUR
SPLEEN	0.0981	0.283		JOINT	BRAIN	CECUM	COLON
HEART	0.1872	0.539		DUODENUM	EPIDIDYMIDES	ESOPHAGUS	EYES/OPTIC N.
EPIDIDYMIDES	0.1204	0.347		GALLBLADDER	HEART	ILEUM	JEJUNUM
TESTES	0.2735	0.788		KIDNEYS	LYMPH NODE, MAND	LIVER	LYMPH NODE, MES
ADRENAL GLANDS	0.0083	0.024		LUNGS	NERVE, SCIATIC	PANCREAS	PITUITARY
FINAL BODY WT(G)	34.7			PROSTATE	RECTUM	SPINAL CORD	SAL. GLAND MAND
				STOMACH	SKELETAL MUSCLE	SKIN	SPLEEN
				SEMINAL VESICLES	TESTES	THYROID GLANDS	THYMUS
				TRACHEA	URINARY BLADDER	PEYER'S PATCHES	
				MICRO:ADRENAL CORTEX	ADRENAL MEDULLA	AORTA	STERNUM
				MARROW, STERN	FEMUR	MARROW, FEMUR	JOINT
				BRAIN	CECUM	COLON	DUODENUM
				EPIDIDYMIDES	ESOPHAGUS	EYES/OPTIC N.	GALLBLADDER
				HEART	ILEUM	JEJUNUM	KIDNEYS
				LYMPH NODE, MAND	LIVER	LYMPH NODE, MES	LUNGS
				NERVE, SCIATIC	PANCREAS	PITUITARY	PROSTATE
				RECTUM	SPINAL CORD	SAL. GLAND MAND	STOMACH, GLAN
				STOMACH, NON	SKELETAL MUSCLE	SKIN	SPLEEN
				SEMINAL VESICLES	TESTES	THYROID GLANDS	THYMUS
				TRACHEA	URINARY BLADDER	PEYER'S PATCHES	

NOT PRESENT FOR EXAMINATION

MICRO:PARATHYROIDS

GROSS GRADE CODE: 1-SLIGHT, 2-MODERATE, 3-MARKED, P-PRESENT

MICRO GRADE CODE: 1-MINIMAL, 2-MILD, 3-MODERATE, 4-SEVERE, P-PRESENT

PROJECT NO.:WIL-639011
 SPONSOR:SYNGENTA

TABLE A12
 A SINGLE ORAL DOSE OF PMI-0105 WITH A 14-DAY RECOVERY IN MICE
 INDIVIDUAL MACROSCOPIC AND MICROSCOPIC FINDINGS

PAGE 7

ANIMAL NO. 1652 GROUP 1: 0 MG/KG MALE SCHEDULED EUTH 12/26/07 DATE OF DEATH: 12/26/07 STUDY DAY: 14
 GRADE

ORGAN WEIGHT	ABS.(G)	REL.	TRACHEA	MICRO: NOT PRESENT FOR EXAMINATION			
BRAIN	0.5170	1.473		TRACHEA NOT IN PLANE OF SECTION; RECUT MADE AND EXAMINED.			
LIVER/GB	1.7701	5.043	NO SIGNIFICANT				
KIDNEYS	0.6298	1.794	CHANGES OBSERVED	GROSS:ADRENAL GLANDS	AORTA	STERNUM	FEMUR
SPLEEN	0.1044	0.297		JOINT	BRAIN	CECUM	COLON
HEART	0.2110	0.601		DUODENUM	EPIDIDYMIDES	ESOPHAGUS	EYES/OPTIC N.
EPIDIDYMIDES	0.0942	0.268		GALLBLADDER	HEART	ILEUM	JEJUNUM
TESTES	0.2449	0.698		KIDNEYS	LYMPH NODE, MAND	LIVER	LYMPH NODE, MES
ADRENAL GLANDS	0.0052	0.015		LUNGS	NERVE, SCIATIC	PANCREAS	PITUITARY
FINAL BODY WT(G)	35.1			PROSTATE	RECTUM	SPINAL CORD	SAL. GLAND MAND
				STOMACH	SKELETAL MUSCLE	SKIN	SPLEEN
				SEMINAL VESICLES	TESTES	THYROID GLANDS	THYMUS
				TRACHEA	URINARY BLADDER	PEYER'S PATCHES	
				MICRO:ADRENAL CORTEX	ADRENAL MEDULLA	AORTA	STERNUM
				MARROW, STERN	FEMUR	MARROW, FEMUR	JOINT
				BRAIN	CECUM	COLON	DUODENUM
				EPIDIDYMIDES	ESOPHAGUS	EYES/OPTIC N.	GALLBLADDER
				HEART	ILEUM	JEJUNUM	KIDNEYS
				LYMPH NODE, MAND	LIVER	LYMPH NODE, MES	LUNGS
				NERVE, SCIATIC	PANCREAS	PITUITARY	PROSTATE
				RECTUM	SPINAL CORD	SAL. GLAND MAND	STOMACH, GLAN
				STOMACH, NON	SKELETAL MUSCLE	SKIN	SPLEEN
				SEMINAL VESICLES	TESTES	THYROID GLANDS	PARATHYROIDS
				THYMUS	URINARY BLADDER	PEYER'S PATCHES	

NOT PRESENT FOR EXAMINATION

MICRO:TRACHEA

GROSS GRADE CODE: 1-SLIGHT, 2-MODERATE, 3-MARKED, P-PRESENT

MICRO GRADE CODE: 1-MINIMAL, 2-MILD, 3-MODERATE, 4-SEVERE, P-PRESENT

PROJECT NO.:WIL-639011
 SPONSOR:SYNGENTA

TABLE A12
 A SINGLE ORAL DOSE OF PMI-0105 WITH A 14-DAY RECOVERY IN MICE
 INDIVIDUAL MACROSCOPIC AND MICROSCOPIC FINDINGS

PAGE 8

ANIMAL NO. 1638 GROUP 2: 2000 MG/KG MALE SCHEDULED EUTH 12/26/07 DATE OF DEATH: 12/26/07 STUDY DAY: 14
 GRADE

ORGAN WEIGHT	ABS.(G)	REL.	NO SIGNIFICANT CHANGES OBSERVED	GROSS:ADRENAL GLANDS	AORTA	STERNUM	FEMUR
BRAIN	0.4644	1.316		JOINT	BRAIN	CECUM	COLON
LIVER/GB	1.7010	4.819		DUODENUM	EPIDIDYMIDES	ESOPHAGUS	EYES/OPTIC N.
KIDNEYS	0.5654	1.602		GALLBLADDER	HEART	ILEUM	JEJUNUM
SPLEEN	0.0852	0.241		KIDNEYS	LYMPH NODE, MAND	LIVER	LYMPH NODE, MES
HEART	0.1914	0.542		LUNGS	NERVE, SCIATIC	PANCREAS	PITUITARY
EPIDIDYMIDES	0.0854	0.242		PROSTATE	RECTUM	SPINAL CORD	SAL. GLAND MAND
TESTES	0.1824	0.517		STOMACH	SKELETAL MUSCLE	SKIN	SPLEEN
ADRENAL GLANDS	0.0052	0.015		SEMINAL VESICLES	TESTES	THYROID GLANDS	THYMUS
FINAL BODY WT(G)	35.3			TRACHEA	URINARY BLADDER	PEYER'S PATCHES	
				MICRO:ADRENAL CORTEX	ADRENAL MEDULLA	AORTA	STERNUM
				MARROW, STERN	FEMUR	MARROW, FEMUR	JOINT
				BRAIN	CECUM	COLON	DUODENUM
				EPIDIDYMIDES	ESOPHAGUS	EYES/OPTIC N.	GALLBLADDER
				HEART	ILEUM	JEJUNUM	KIDNEYS
				LYMPH NODE, MAND	LIVER	LYMPH NODE, MES	LUNGS
				NERVE, SCIATIC	PANCREAS	PITUITARY	PROSTATE
				RECTUM	SPINAL CORD	SAL. GLAND MAND	STOMACH, GLAN
				STOMACH, NON	SKELETAL MUSCLE	SKIN	SPLEEN
				SEMINAL VESICLES	TESTES	THYROID GLANDS	PARATHYROIDS
				THYMUS	TRACHEA	URINARY BLADDER	PEYER'S PATCHES

GROSS GRADE CODE: 1-SLIGHT, 2-MODERATE, 3-MARKED, P-PRESENT

MICRO GRADE CODE: 1-MINIMAL, 2-MILD, 3-MODERATE, 4-SEVERE, P-PRESENT

PROJECT NO.:WIL-639011
 SPONSOR:SYNGENTA

TABLE A12
 A SINGLE ORAL DOSE OF PMI-0105 WITH A 14-DAY RECOVERY IN MICE
 INDIVIDUAL MACROSCOPIC AND MICROSCOPIC FINDINGS

PAGE 9

ANIMAL NO. 1641 GROUP 2: 2000 MG/KG MALE SCHEDULED EUTH 12/26/07 DATE OF DEATH: 12/26/07 STUDY DAY: 14
 GRADE

ORGAN WEIGHT	ABS.(G)	REL.	NO SIGNIFICANT CHANGES OBSERVED	GROSS:ADRENAL GLANDS	AORTA	STERNUM	FEMUR
BRAIN	0.5102	1.651		JOINT	BRAIN	CECUM	COLON
LIVER/GB	1.5105	4.888		DUODENUM	EPIDIDYMIDES	ESOPHAGUS	EYES/OPTIC N.
KIDNEYS	0.5230	1.693		GALLBLADDER	HEART	ILEUM	JEJUNUM
SPLEEN	0.0641	0.207		KIDNEYS	LYMPH NODE, MAND	LIVER	LYMPH NODE, MES
HEART	0.1547	0.501		LUNGS	NERVE, SCIATIC	PANCREAS	PITUITARY
EPIDIDYMIDES	0.0762	0.247		PROSTATE	RECTUM	SPINAL CORD	SAL. GLAND MAND
TESTES	0.2012	0.651		STOMACH	SKELETAL MUSCLE	SKIN	SPLEEN
ADRENAL GLANDS	0.0064	0.021		SEMINAL VESICLES	TESTES	THYROID GLANDS	THYMUS
FINAL BODY WT(G)	30.9			TRACHEA	URINARY BLADDER	PEYER'S PATCHES	
				MICRO:ADRENAL CORTEX	ADRENAL MEDULLA	AORTA	STERNUM
				MARROW, STERN	FEMUR	MARROW, FEMUR	JOINT
				BRAIN	CECUM	COLON	DUODENUM
				EPIDIDYMIDES	ESOPHAGUS	EYES/OPTIC N.	GALLBLADDER
				HEART	ILEUM	JEJUNUM	KIDNEYS
				LYMPH NODE, MAND	LIVER	LYMPH NODE, MES	LUNGS
				NERVE, SCIATIC	PANCREAS	PITUITARY	PROSTATE
				RECTUM	SPINAL CORD	SAL. GLAND MAND	STOMACH, GLAN
				STOMACH, NON	SKELETAL MUSCLE	SKIN	SPLEEN
				SEMINAL VESICLES	TESTES	THYROID GLANDS	PARATHYROIDS
				THYMUS	TRACHEA	URINARY BLADDER	PEYER'S PATCHES

GROSS GRADE CODE: 1-SLIGHT, 2-MODERATE, 3-MARKED, P-PRESENT

MICRO GRADE CODE: 1-MINIMAL, 2-MILD, 3-MODERATE, 4-SEVERE, P-PRESENT

PROJECT NO.:WIL-639011
 SPONSOR:SYNGENTA

TABLE A12
 A SINGLE ORAL DOSE OF PMI-0105 WITH A 14-DAY RECOVERY IN MICE
 INDIVIDUAL MACROSCOPIC AND MICROSCOPIC FINDINGS

PAGE 10

ANIMAL NO. 1648 GROUP 2: 2000 MG/KG MALE SCHEDULED EUTH 12/26/07 DATE OF DEATH: 12/26/07 STUDY DAY: 14
 GRADE

ORGAN WEIGHT	ABS.(G)	REL.	GALLBLADDER	MICRO: NOT PRESENT FOR EXAMINATION			
BRAIN	0.4916	1.381		GALLBLADDER NOT IN PLANE; RECUT MADE AND EXAMINED.			
LIVER/GB	1.7352	4.874	NO SIGNIFICANT				
KIDNEYS	0.6111	1.717	CHANGES OBSERVED	GROSS:ADRENAL GLANDS	AORTA	STERNUM	FEMUR
SPLEEN	0.0796	0.224		JOINT	BRAIN	CECUM	COLON
HEART	0.1839	0.517		DUODENUM	EPIDIDYMIDES	ESOPHAGUS	EYES/OPTIC N.
EPIDIDYMIDES	0.0791	0.222		GALLBLADDER	HEART	ILEUM	JEJUNUM
TESTES	0.1587	0.446		KIDNEYS	LYMPH NODE, MAND	LIVER	LYMPH NODE, MES
ADRENAL GLANDS	0.0040	0.011		LUNGS	NERVE, SCIATIC	PANCREAS	PITUITARY
FINAL BODY WT(G)	35.6			PROSTATE	RECTUM	SPINAL CORD	SAL. GLAND MAND
				STOMACH	SKELETAL MUSCLE	SKIN	SPLEEN
				SEMINAL VESICLES	TESTES	THYROID GLANDS	THYMUS
				TRACHEA	URINARY BLADDER	PEYER'S PATCHES	
				MICRO:ADRENAL CORTEX	ADRENAL MEDULLA	AORTA	STERNUM
				MARROW, STERN	FEMUR	MARROW, FEMUR	JOINT
				BRAIN	CECUM	COLON	DUODENUM
				EPIDIDYMIDES	ESOPHAGUS	EYES/OPTIC N.	HEART
				ILEUM	JEJUNUM	KIDNEYS	LYMPH NODE, MAND
				LIVER	LYMPH NODE, MES	LUNGS	NERVE, SCIATIC
				PANCREAS	PITUITARY	PROSTATE	RECTUM
				SPINAL CORD	SAL. GLAND MAND	STOMACH, GLAN	STOMACH, NON
				SKELETAL MUSCLE	SKIN	SPLEEN	SEMINAL VESICLES
				TESTES	THYROID GLANDS	PARATHYROIDS	THYMUS
				TRACHEA	URINARY BLADDER	PEYER'S PATCHES	

NOT PRESENT FOR EXAMINATION

MICRO:GALLBLADDER

GROSS GRADE CODE: 1-SLIGHT, 2-MODERATE, 3-MARKED, P-PRESENT

MICRO GRADE CODE: 1-MINIMAL, 2-MILD, 3-MODERATE, 4-SEVERE, P-PRESENT

PROJECT NO.:WIL-639011
 SPONSOR:SYNGENTA

TABLE A12
 A SINGLE ORAL DOSE OF PMI-0105 WITH A 14-DAY RECOVERY IN MICE
 INDIVIDUAL MACROSCOPIC AND MICROSCOPIC FINDINGS

PAGE 11

ANIMAL NO. 1649 GROUP 2: 2000 MG/KG MALE SCHEDULED EUTH 12/26/07 DATE OF DEATH: 12/26/07 STUDY DAY: 14
 GRADE

ORGAN WEIGHT	ABS.(G)	REL.	ADRENAL MEDULLA	MICRO: NO SIGNIFICANT CHANGES OBSERVED			
BRAIN	0.4854	1.445		ONE MEDULLA LOST DURING MICROTOMY.			
LIVER/GB	1.6695	4.969	LUNGS	GROSS: NOT FULLY COLLAPSED			P
KIDNEYS	0.6281	1.869		ALL LOBES			
SPLEEN	0.0681	0.203	PARATHYROIDS	MICRO: NOT PRESENT FOR EXAMINATION			
HEART	0.2189	0.651		PARATHYROIDS NOT IN PLANE OF SECTION.			
EPIDIDYMIDES	0.0876	0.261	NO SIGNIFICANT				
TESTES	0.1923	0.572	CHANGES OBSERVED	GROSS:ADRENAL GLANDS	AORTA	STERNUM	FEMUR
ADRENAL GLANDS	0.0058	0.017		JOINT	BRAIN	CECUM	COLON
FINAL BODY WT(G)	33.6			DUODENUM	EPIDIDYMIDES	ESOPHAGUS	EYES/OPTIC N.
				GALLBLADDER	HEART	ILEUM	JEJUNUM
				KIDNEYS	LYMPH NODE, MAND	LIVER	LYMPH NODE, MES
				NERVE, SCIATIC	PANCREAS	PITUITARY	PROSTATE
				RECTUM	SPINAL CORD	SAL. GLAND MAND	STOMACH
				SKELETAL MUSCLE	SKIN	SPLEEN	SEMINAL VESICLES
				TESTES	THYROID GLANDS	THYMUS	TRACHEA
				URINARY BLADDER	PEYER'S PATCHES		
				MICRO:ADRENAL CORTEX	ADRENAL MEDULLA	AORTA	STERNUM
				MARROW, STERN	FEMUR	MARROW, FEMUR	JOINT
				BRAIN	CECUM	COLON	DUODENUM
				EPIDIDYMIDES	ESOPHAGUS	EYES/OPTIC N.	GALLBLADDER
				HEART	ILEUM	JEJUNUM	KIDNEYS
				LYMPH NODE, MAND	LIVER	LYMPH NODE, MES	LUNGS
				NERVE, SCIATIC	PANCREAS	PITUITARY	PROSTATE
				RECTUM	SPINAL CORD	SAL. GLAND MAND	STOMACH, GLAN
				STOMACH, NON	SKELETAL MUSCLE	SKIN	SPLEEN
				SEMINAL VESICLES	TESTES	THYROID GLANDS	THYMUS
				TRACHEA	URINARY BLADDER	PEYER'S PATCHES	

NOT PRESENT FOR EXAMINATION

MICRO:PARATHYROIDS

PROJECT NO.:WIL-639011
SPONSOR:SYNGENTA

TABLE A12
A SINGLE ORAL DOSE OF PMI-0105 WITH A 14-DAY RECOVERY IN MICE
INDIVIDUAL MACROSCOPIC AND MICROSCOPIC FINDINGS

PAGE 12

ANIMAL NO. 1649 GROUP 2: 2000 MG/KG MALE SCHEDULED EUTH 12/26/07 DATE OF DEATH: 12/26/07 STUDY DAY: 14
GRADE

GROSS/MICRO CORRELATIONS

GROSS FINDING

<====> CONFIRMING MICROSCOPIC FINDING

LUNGS: NOT FULLY COLLAPSED

<====>GROSS UNCONFIRMED

GROSS GRADE CODE: 1-SLIGHT, 2-MODERATE, 3-MARKED, P-PRESENT

MICRO GRADE CODE: 1-MINIMAL, 2-MILD, 3-MODERATE, 4-SEVERE, P-PRESENT

PROJECT NO.:WIL-639011
 SPONSOR:SYNGENTA

TABLE A12
 A SINGLE ORAL DOSE OF PMI-0105 WITH A 14-DAY RECOVERY IN MICE
 INDIVIDUAL MACROSCOPIC AND MICROSCOPIC FINDINGS

PAGE 13

ANIMAL NO. 1650 GROUP 2: 2000 MG/KG MALE SCHEDULED EUTH 12/26/07 DATE OF DEATH: 12/26/07 STUDY DAY: 14
 GRADE

ORGAN WEIGHT	ABS.(G)	REL.	PARATHYROIDS	MICRO: NOT PRESENT FOR EXAMINATION			
BRAIN	0.4753	1.415		PARATHYROIDS NOT IN PLANE OF SECTION.			
LIVER/GB	1.6362	4.870	NO SIGNIFICANT				
KIDNEYS	0.5573	1.659	CHANGES OBSERVED	GROSS:ADRENAL GLANDS	AORTA	STERNUM	FEMUR
SPLEEN	0.0918	0.273		JOINT	BRAIN	CECUM	COLON
HEART	0.2277	0.678		DUODENUM	EPIDIDYMIDES	ESOPHAGUS	EYES/OPTIC N.
EPIDIDYMIDES	0.0912	0.271		GALLBLADDER	HEART	ILEUM	JEJUNUM
TESTES	0.2227	0.663		KIDNEYS	LYMPH NODE, MAND	LIVER	LYMPH NODE, MES
ADRENAL GLANDS	0.0053	0.016		LUNGS	NERVE, SCIATIC	PANCREAS	PITUITARY
FINAL BODY WT(G)	33.6			PROSTATE	RECTUM	SPINAL CORD	SAL. GLAND MAND
				STOMACH	SKELETAL MUSCLE	SKIN	SPLEEN
				SEMINAL VESICLES	TESTES	THYROID GLANDS	THYMUS
				TRACHEA	URINARY BLADDER	PEYER'S PATCHES	
				MICRO:ADRENAL CORTEX	ADRENAL MEDULLA	AORTA	STERNUM
				MARROW, STERN	FEMUR	MARROW, FEMUR	JOINT
				BRAIN	CECUM	COLON	DUODENUM
				EPIDIDYMIDES	ESOPHAGUS	EYES/OPTIC N.	GALLBLADDER
				HEART	ILEUM	JEJUNUM	KIDNEYS
				LYMPH NODE, MAND	LIVER	LYMPH NODE, MES	LUNGS
				NERVE, SCIATIC	PANCREAS	PITUITARY	PROSTATE
				RECTUM	SPINAL CORD	SAL. GLAND MAND	STOMACH, GLAN
				STOMACH, NON	SKELETAL MUSCLE	SKIN	SPLEEN
				SEMINAL VESICLES	TESTES	THYROID GLANDS	THYMUS
				TRACHEA	URINARY BLADDER	PEYER'S PATCHES	

NOT PRESENT FOR EXAMINATION

MICRO:PARATHYROIDS

GROSS GRADE CODE: 1-SLIGHT, 2-MODERATE, 3-MARKED, P-PRESENT

MICRO GRADE CODE: 1-MINIMAL, 2-MILD, 3-MODERATE, 4-SEVERE, P-PRESENT

PROJECT NO.:WIL-639011
 SPONSOR:SYNGENTA

TABLE A12
 A SINGLE ORAL DOSE OF PMI-0105 WITH A 14-DAY RECOVERY IN MICE
 INDIVIDUAL MACROSCOPIC AND MICROSCOPIC FINDINGS

PAGE 14

ANIMAL NO. 1656 GROUP 1: 0 MG/KG FEMALE SCHEDULED EUTH 12/26/07 DATE OF DEATH: 12/26/07 STUDY DAY: 14
 GRADE

ORGAN WEIGHT	ABS.(G)	REL.	PARATHYROIDS	MICRO: NOT PRESENT FOR EXAMINATION			
BRAIN	0.5132	1.944		PARATHYROIDS NOT IN PLANE OF SECTION.			
LIVER/GB	1.2538	4.749	NO SIGNIFICANT				
KIDNEYS	0.3740	1.417	CHANGES OBSERVED	GROSS:ADRENAL GLANDS	AORTA	STERNUM	FEMUR
SPLEEN	0.0973	0.369		JOINT	BRAIN	CECUM	COLON
HEART	0.1470	0.557		DUODENUM	ESOPHAGUS	EYES/OPTIC N.	GALLBLADDER
OVARIES/OVIDUCTS	0.0222	0.084		HEART	ILEUM	JEJUNUM	KIDNEYS
ADRENAL GLANDS	0.0109	0.041		LYMPH NODE, MAND	LIVER	LYMPH NODE, MES	LUNGS
FINAL BODY WT(G)	26.4			MAMMARY GLAND	NERVE, SCIATIC	OVIDUCTS	OVARIES
				PANCREAS	PITUITARY	RECTUM	SPINAL CORD
				SAL. GLAND MAND	STOMACH	SKELETAL MUSCLE	SKIN
				SPLEEN	THYROID GLANDS	THYMUS	TRACHEA
				URINARY BLADDER	UTERUS	VAGINA	CERVIX
				PEYER'S PATCHES			
				MICRO:ADRENAL CORTEX	ADRENAL MEDULLA	AORTA	STERNUM
				MARROW, STERN	FEMUR	MARROW, FEMUR	JOINT
				BRAIN	CECUM	COLON	DUODENUM
				ESOPHAGUS	EYES/OPTIC N.	GALLBLADDER	HEART
				ILEUM	JEJUNUM	KIDNEYS	LYMPH NODE, MAND
				LIVER	LYMPH NODE, MES	LUNGS	MAMMARY GLAND
				NERVE, SCIATIC	OVIDUCTS	OVARIES	PANCREAS
				PITUITARY	RECTUM	SPINAL CORD	SAL. GLAND MAND
				STOMACH, GLAN	STOMACH, NON	SKELETAL MUSCLE	SKIN
				SPLEEN	THYROID GLANDS	THYMUS	TRACHEA
				URINARY BLADDER	UTERUS	VAGINA	CERVIX
				PEYER'S PATCHES			

NOT PRESENT FOR EXAMINATION

MICRO:PARATHYROIDS

GROSS GRADE CODE: 1-SLIGHT, 2-MODERATE, 3-MARKED, P-PRESENT

MICRO GRADE CODE: 1-MINIMAL, 2-MILD, 3-MODERATE, 4-SEVERE, P-PRESENT

PROJECT NO.:WIL-639011
 SPONSOR:SYNGENTA

TABLE A12
 A SINGLE ORAL DOSE OF PMI-0105 WITH A 14-DAY RECOVERY IN MICE
 INDIVIDUAL MACROSCOPIC AND MICROSCOPIC FINDINGS

PAGE 15

ANIMAL NO. 1658 GROUP 1: 0 MG/KG FEMALE SCHEDULED EUTH 12/26/07 DATE OF DEATH: 12/26/07 STUDY DAY: 14
 GRADE

ORGAN WEIGHT	ABS.(G)	REL.	ADRENAL MEDULLA	MICRO: NO SIGNIFICANT CHANGES OBSERVED			
BRAIN	0.4812	1.917		ONE MEDULLA LOST DURING MICROTOMY.			
LIVER/GB	1.2275	4.890	OVARIES	GROSS: CYST(S)			P
KIDNEYS	0.3489	1.390		ONE, 3 MM IN DIAMETER, RIGHT			
SPLEEN	0.0943	0.376	SKELETAL MUSCLE	MICRO: NO SIGNIFICANT CHANGES OBSERVED			
HEART	0.1503	0.599		SKELETAL MUSCLE IS PRESENT IN SLIDE.			
OVARIES/OVIDUCTS	0.0264	0.105	PARATHYROIDS	MICRO: NOT PRESENT FOR EXAMINATION			
ADRENAL GLANDS	0.0077	0.031		PARATHYROIDS NOT IN PLANE OF SECTION.			
FINAL BODY WT(G)	25.1		NO SIGNIFICANT CHANGES OBSERVED				
			GROSS:ADRENAL GLANDS	AORTA	STERNUM	FEMUR	
			JOINT	BRAIN	CECUM	COLON	
			DUODENUM	ESOPHAGUS	EYES/OPTIC N.	GALLBLADDER	
			HEART	ILEUM	JEJUNUM	KIDNEYS	
			LYMPH NODE, MAND	LIVER	LYMPH NODE, MES	LUNGS	
			MAMMARY GLAND	NERVE, SCIATIC	OVIDUCTS	PANCREAS	
			PITUITARY	RECTUM	SPINAL CORD	SAL. GLAND MAND	
			STOMACH	SKELETAL MUSCLE	SKIN	SPLEEN	
			THYROID GLANDS	THYMUS	TRACHEA	URINARY BLADDER	
			UTERUS	VAGINA	CERVIX	PEYER'S PATCHES	
			MICRO:ADRENAL CORTEX	ADRENAL MEDULLA	AORTA	STERNUM	
			MARROW, STERN	FEMUR	MARROW, FEMUR	JOINT	
			BRAIN	CECUM	COLON	DUODENUM	
			ESOPHAGUS	EYES/OPTIC N.	GALLBLADDER	HEART	
			ILEUM	JEJUNUM	KIDNEYS	LYMPH NODE, MAND	
			LIVER	LYMPH NODE, MES	LUNGS	MAMMARY GLAND	
			NERVE, SCIATIC	OVIDUCTS	OVARIES	PANCREAS	
			PITUITARY	RECTUM	SPINAL CORD	SAL. GLAND MAND	
			STOMACH, GLAN	STOMACH, NON	SKELETAL MUSCLE	SKIN	
			SPLEEN	THYROID GLANDS	THYMUS	TRACHEA	

PROJECT NO.:WIL-639011
SPONSOR:SYNGENTA

TABLE A12
A SINGLE ORAL DOSE OF PMI-0105 WITH A 14-DAY RECOVERY IN MICE
INDIVIDUAL MACROSCOPIC AND MICROSCOPIC FINDINGS

PAGE 16

ANIMAL NO. 1658 GROUP 1: 0 MG/KG FEMALE SCHEDULED EUTH 12/26/07 DATE OF DEATH: 12/26/07 STUDY DAY: 14
GRADE

URINARY BLADDER UTERUS VAGINA CERVIX
PEYER'S PATCHES

NOT PRESENT FOR EXAMINATION

MICRO:PARATHYROIDS

GROSS/MICRO CORRELATIONS
GROSS FINDING

<====> CONFIRMING MICROSCOPIC FINDING

OVARIES: CYST(S)

<====>GROSS UNCONFIRMED

GROSS GRADE CODE: 1-SLIGHT, 2-MODERATE, 3-MARKED, P-PRESENT

MICRO GRADE CODE: 1-MINIMAL, 2-MILD, 3-MODERATE, 4-SEVERE, P-PRESENT

PROJECT NO.:WIL-639011
 SPONSOR:SYNGENTA

TABLE A12
 A SINGLE ORAL DOSE OF PMI-0105 WITH A 14-DAY RECOVERY IN MICE
 INDIVIDUAL MACROSCOPIC AND MICROSCOPIC FINDINGS

PAGE 17

ANIMAL NO. 1659 GROUP 1: 0 MG/KG FEMALE SCHEDULED EUTH 12/26/07 DATE OF DEATH: 12/26/07 STUDY DAY: 14
 GRADE

ORGAN WEIGHT	ABS.(G)	REL.	PARATHYROIDS	MICRO: NOT PRESENT FOR EXAMINATION			
BRAIN	0.4704	1.823		PARATHYROIDS NOT IN PLANE OF SECTION.			
LIVER/GB	1.3059	5.062	NO SIGNIFICANT				
KIDNEYS	0.3694	1.432	CHANGES OBSERVED	GROSS:ADRENAL GLANDS	AORTA	STERNUM	FEMUR
SPLEEN	0.0860	0.333		JOINT	BRAIN	CECUM	COLON
HEART	0.1574	0.610		DUODENUM	ESOPHAGUS	EYES/OPTIC N.	GALLBLADDER
OVARIES/OVIDUCTS	0.0231	0.090		HEART	ILEUM	JEJUNUM	KIDNEYS
ADRENAL GLANDS	0.0104	0.040		LYMPH NODE, MAND	LIVER	LYMPH NODE, MES	LUNGS
FINAL BODY WT(G)	25.8			MAMMARY GLAND	NERVE, SCIATIC	OVIDUCTS	OVARIES
				PANCREAS	PITUITARY	RECTUM	SPINAL CORD
				SAL. GLAND MAND	STOMACH	SKELETAL MUSCLE	SKIN
				SPLEEN	THYROID GLANDS	THYMUS	TRACHEA
				URINARY BLADDER	UTERUS	VAGINA	CERVIX
				PEYER'S PATCHES			
				MICRO:ADRENAL CORTEX	ADRENAL MEDULLA	AORTA	STERNUM
				MARROW, STERN	FEMUR	MARROW, FEMUR	JOINT
				BRAIN	CECUM	COLON	DUODENUM
				ESOPHAGUS	EYES/OPTIC N.	GALLBLADDER	HEART
				ILEUM	JEJUNUM	KIDNEYS	LYMPH NODE, MAND
				LIVER	LYMPH NODE, MES	LUNGS	MAMMARY GLAND
				NERVE, SCIATIC	OVIDUCTS	OVARIES	PANCREAS
				PITUITARY	RECTUM	SPINAL CORD	SAL. GLAND MAND
				STOMACH, GLAN	STOMACH, NON	SKELETAL MUSCLE	SKIN
				SPLEEN	THYROID GLANDS	THYMUS	TRACHEA
				URINARY BLADDER	UTERUS	VAGINA	CERVIX
				PEYER'S PATCHES			

NOT PRESENT FOR EXAMINATION

MICRO:PARATHYROIDS

GROSS GRADE CODE: 1-SLIGHT, 2-MODERATE, 3-MARKED, P-PRESENT

MICRO GRADE CODE: 1-MINIMAL, 2-MILD, 3-MODERATE, 4-SEVERE, P-PRESENT

PROJECT NO.:WIL-639011
 SPONSOR:SYNGENTA

TABLE A12
 A SINGLE ORAL DOSE OF PMI-0105 WITH A 14-DAY RECOVERY IN MICE
 INDIVIDUAL MACROSCOPIC AND MICROSCOPIC FINDINGS

PAGE 18

ANIMAL NO. 1665 GROUP 1: 0 MG/KG FEMALE SCHEDULED EUTH 12/26/07 DATE OF DEATH: 12/26/07 STUDY DAY: 14
 GRADE

ORGAN WEIGHT	ABS.(G)	REL.	MARROW, STERN	MICRO: HYPERPLASIA, MYELOID	2
BRAIN	0.4539	2.073	MARROW, FEMUR	MICRO: HYPERPLASIA, MYELOID	2
LIVER/GB	1.1414	5.212	ESOPHAGUS	GROSS: NODULE(S)	P
KIDNEYS	0.3306	1.510		FEW, 1 TO 4 MM IN DIAMETER	
SPLEEN	0.1727	0.789	ESOPHAGUS	MICRO: INFLAMMATION, GRANULOMATOUS	4
HEART	0.1371	0.626		FOCAL; CONSISTENT WITH GAVAGE ACCIDENT.	
OVARIES/OVIDUCTS	0.0201	0.092	PARATHYROIDS	MICRO: NOT PRESENT FOR EXAMINATION	
ADRENAL GLANDS	0.0095	0.043		PARATHYROIDS NOT IN PLANE OF SECTION.	
FINAL BODY WT(G)	21.9		THYMUS	MICRO: NO SIGNIFICANT CHANGES OBSERVED	
				THYMUS LARGELY EFFACED BY INFLAMMATION FROM GAVAGE ACCIDENT.	
			PEYER'S PATCHES	MICRO: NOT PRESENT FOR EXAMINATION	
				PEYER'S PATCH NOT IN PLANE; RECUT MADE AND EXAMINED.	
			NO SIGNIFICANT CHANGES OBSERVED	GROSS:ADRENAL GLANDS	
				AORTA	STERNUM
				JOINT	FEMUR
				BRAIN	CECUM
				DUODENUM	GALLBLADDER
				EYES/OPTIC N.	HEART
				JEJUNUM	KIDNEYS
				KIDNEYS	LYMPH NODE, MAND
				LIVER	MAMMARY GLAND
				LYMPH NODE, MES	LUNGS
				LUNGS	PANCREAS
				OVARIES	SAL. GLAND MAND
				RECTUM	SPINAL CORD
				SPINAL CORD	SKIN
				SKIN	SPLEEN
				SKELETAL MUSCLE	TRACHEA
				THYROID GLANDS	URINARY BLADDER
				THYMUS	PEYER'S PATCHES
				UTERUS	VAGINA
				VAGINA	CERVIX
				ADRENAL CORTEX	AORTA
				ADRENAL MEDULLA	STERNUM
				ADRENAL MEDULLA	BRAIN
				FEMUR	CECUM
				JOINT	GALLBLADDER
				DUODENUM	EYES/OPTIC N.
				DUODENUM	KIDNEYS
				COLON	LYMPH NODE, MES
				HEART	LUNGS
				HEART	
				ILEUM	
				LYMPH NODE, MAND	
				LIVER	

PROJECT NO.:WIL-639011
SPONSOR:SYNGENTA

TABLE A12
A SINGLE ORAL DOSE OF PMI-0105 WITH A 14-DAY RECOVERY IN MICE
INDIVIDUAL MACROSCOPIC AND MICROSCOPIC FINDINGS

PAGE 19

ANIMAL NO. 1665 GROUP 1: 0 MG/KG FEMALE SCHEDULED EUTH 12/26/07 DATE OF DEATH: 12/26/07 STUDY DAY: 14
GRADE

MAMMARY GLAND	NERVE, SCIATIC	OVIDUCTS	OVARIES
PANCREAS	PITUITARY	RECTUM	SPINAL CORD
SAL. GLAND MAND	STOMACH, GLAN	STOMACH, NON	SKELETAL MUSCLE
SKIN	SPLEEN	THYROID GLANDS	THYMUS
TRACHEA	URINARY BLADDER	UTERUS	VAGINA
CERVIX			

NOT PRESENT FOR EXAMINATION

MICRO:PARATHYROIDS PEYER'S PATCHES

GROSS/MICRO CORRELATIONS
GROSS FINDING

<====> CONFIRMING MICROSCOPIC FINDING

ESOPHAGUS: NODULE(S)

<====>ESOPHAGUS: INFLAMMATION, GRANULOMATOUS

GROSS GRADE CODE: 1-SLIGHT, 2-MODERATE, 3-MARKED, P-PRESENT

MICRO GRADE CODE: 1-MINIMAL, 2-MILD, 3-MODERATE, 4-SEVERE, P-PRESENT

PROJECT NO.:WIL-639011
 SPONSOR:SYNGENTA

TABLE A12
 A SINGLE ORAL DOSE OF PMI-0105 WITH A 14-DAY RECOVERY IN MICE
 INDIVIDUAL MACROSCOPIC AND MICROSCOPIC FINDINGS

PAGE 20

ANIMAL NO. 1666 GROUP 1: 0 MG/KG FEMALE SCHEDULED EUTH 12/26/07 DATE OF DEATH: 12/26/07 STUDY DAY: 14
 GRADE

ORGAN WEIGHT	ABS.(G)	REL.	GENERAL COMMENT	GROSS: ORGAN DAMAGED AT NECROPSY	P
BRAIN	0.4896	1.855		FEMUR, RIGHT	
LIVER/GB	1.3010	4.928	OVARIES	MICRO: NO SIGNIFICANT CHANGES OBSERVED	
KIDNEYS	0.3379	1.280		ONE OF PAIR PRESENT; RECUT MADE AND EXAMINED.	
SPLEEN	0.0947	0.359	THYROID GLANDS	MICRO: NO SIGNIFICANT CHANGES OBSERVED	
HEART	0.1453	0.550		ONE OF PAIR PRESENT; RECUT MADE AND EXAMINED.	
OVARIES/OVIDUCTS	0.0215	0.081	PEYER'S PATCHES	MICRO: NOT PRESENT FOR EXAMINATION	
ADRENAL GLANDS	0.0094	0.036		PEYER'S PATCH NOT IN PLANE; RECUT MADE AND EXAMINED.	
FINAL BODY WT(G)	26.4		NO SIGNIFICANT CHANGES OBSERVED		
			GROSS:ADRENAL GLANDS	AORTA	STERNUM
			JOINT	BRAIN	FEMUR
			DUODENUM	ESOPHAGUS	CECUM
			HEART	ILEUM	EYES/OPTIC N.
			LYMPH NODE, MAND	LIVER	JEJUNUM
			MAMMARY GLAND	NERVE, SCIATIC	LYMPH NODE, MES
			PANCREAS	PITUITARY	OVIDUCTS
			SAL. GLAND MAND	STOMACH	RECTUM
			SPLEEN	THYROID GLANDS	SKELETAL MUSCLE
			URINARY BLADDER	UTERUS	SKIN
			PEYER'S PATCHES		THYMUS
			MICRO:ADRENAL CORTEX	ADRENAL MEDULLA	TRACHEA
			MARROW, STERN	FEMUR	CERVIX
			BRAIN	CECUM	STERNUM
			ESOPHAGUS	EYES/OPTIC N.	JOINT
			ILEUM	JEJUNUM	DUODENUM
			LIVER	LYMPH NODE, MES	COLON
			NERVE, SCIATIC	OVIDUCTS	GALLBLADDER
			PITUITARY	RECTUM	HEART
			STOMACH, GLAN	STOMACH, NON	KIDNEYS
					LYMPH NODE, MAND
					MAMMARY GLAND
					PANCREAS
					SPINAL CORD
					SAL. GLAND MAND
					SKIN

PROJECT NO.:WIL-639011
SPONSOR:SYNGENTA

TABLE A12
A SINGLE ORAL DOSE OF PMI-0105 WITH A 14-DAY RECOVERY IN MICE
INDIVIDUAL MACROSCOPIC AND MICROSCOPIC FINDINGS

PAGE 21

ANIMAL NO. 1666 GROUP 1: 0 MG/KG FEMALE SCHEDULED EUTH 12/26/07 DATE OF DEATH: 12/26/07 STUDY DAY: 14
GRADE

SPLEEN THYROID GLANDS PARATHYROIDS THYMUS
TRACHEA URINARY BLADDER UTERUS VAGINA
CERVIX

NOT PRESENT FOR EXAMINATION

MICRO:PEYER'S PATCHES

GROSS GRADE CODE: 1-SLIGHT, 2-MODERATE, 3-MARKED, P-PRESENT

MICRO GRADE CODE: 1-MINIMAL, 2-MILD, 3-MODERATE, 4-SEVERE, P-PRESENT

TABLE A12

PROJECT NO.:WIL-639011
 SPONSOR:SYNGENTA

A SINGLE ORAL DOSE OF PMI-0105 WITH A 14-DAY RECOVERY IN MICE
 INDIVIDUAL MACROSCOPIC AND MICROSCOPIC FINDINGS

PAGE 22

ANIMAL NO. 1655 GROUP 2: 2000 MG/KG FEMALE SCHEDULED EUTH 12/26/07 DATE OF DEATH: 12/26/07 STUDY DAY: 14
 GRADE

ORGAN WEIGHT	ABS. (G)	REL.	EYES/OPTIC N.	MICRO: NO SIGNIFICANT CHANGES OBSERVED
BRAIN	0.5057	1.880		BOTH OPTIC NERVES NOT IN PLANE; RECUTS MADE AND EXAMINED.
LIVER/GB	1.3701	5.093	LIVER	MICRO: INFLAMMATION, CHRONIC
KIDNEYS	0.3676	1.367	THYROID GLANDS	MICRO: NO SIGNIFICANT CHANGES OBSERVED
SPLEEN	0.0944	0.351		ONE OF PAIR PRESENT; RECUT MADE AND EXAMINED.
HEART	0.1500	0.558	PARATHYROIDS	MICRO: NOT PRESENT FOR EXAMINATION
OVARIES/OVIDUCTS	0.0248	0.092		PARATHYROIDS NOT IN PLANE OF SECTION.
ADRENAL GLANDS	0.0123	0.046	NO SIGNIFICANT	
FINAL BODY WT(G)	26.9		CHANGES OBSERVED	
			GROSS:ADRENAL GLANDS	AORTA
			JOINT	BRAIN
			DUODENUM	ESOPHAGUS
			HEART	ILEUM
			LYMPH NODE, MAND	LIVER
			MAMMARY GLAND	NERVE, SCIATIC
			PANCREAS	PITUITARY
			SAL. GLAND MAND	STOMACH
			SPLEEN	THYROID GLANDS
			URINARY BLADDER	UTERUS
			PEYER'S PATCHES	
			MICRO:ADRENAL CORTEX	ADRENAL MEDULLA
			MARROW, STERN	FEMUR
			BRAIN	CECUM
			ESOPHAGUS	EYES/OPTIC N.
			ILEUM	JEJUNUM
			LYMPH NODE, MES	LUNGS
			OVIDUCTS	OVARIES
			RECTUM	SPINAL CORD
			STOMACH, NON	SKELETAL MUSCLE
			THYROID GLANDS	THYMUS
				AORTA
				MARROW, FEMUR
				COLON
				GALLBLADDER
				KIDNEYS
				MAMMARY GLAND
				PANCREAS
				SAL. GLAND MAND
				STOMACH, GLAN
				SKIN
				TRACHEA
				STERNUM
				JOINT
				DUODENUM
				HEART
				LYMPH NODE, MAND
				NERVE, SCIATIC
				PITUITARY
				SPLEEN
				URINARY BLADDER

1

PROJECT NO.:WIL-639011
SPONSOR:SYNGENTA

TABLE A12
A SINGLE ORAL DOSE OF PMI-0105 WITH A 14-DAY RECOVERY IN MICE
INDIVIDUAL MACROSCOPIC AND MICROSCOPIC FINDINGS

PAGE 23

ANIMAL NO. 1655 GROUP 2: 2000 MG/KG FEMALE SCHEDULED EUTH 12/26/07 DATE OF DEATH: 12/26/07 STUDY DAY: 14
GRADE

UTERUS VAGINA CERVIX PEYER'S PATCHES

NOT PRESENT FOR EXAMINATION

MICRO:PARATHYROIDS

GROSS GRADE CODE: 1-SLIGHT, 2-MODERATE, 3-MARKED, P-PRESENT

MICRO GRADE CODE: 1-MINIMAL, 2-MILD, 3-MODERATE, 4-SEVERE, P-PRESENT

PROJECT NO.:WIL-639011 A SINGLE ORAL DOSE OF PMI-0105 WITH A 14-DAY RECOVERY IN MICE PAGE 24
 SPONSOR:SYNGENTA INDIVIDUAL MACROSCOPIC AND MICROSCOPIC FINDINGS

ANIMAL NO. 1662 GROUP 2: 2000 MG/KG FEMALE SCHEDULED EUTH 12/26/07 DATE OF DEATH: 12/26/07 STUDY DAY: 14

 GRADE

ORGAN WEIGHT	ABS.(G)	REL.	GENERAL COMMENT	GROSS: ORGAN DAMAGED AT NECROPSY				P
BRAIN	0.5203	1.949		FEMUR, RIGHT				
LIVER/GB	1.4006	5.246	NO SIGNIFICANT					
KIDNEYS	0.4086	1.530	CHANGES OBSERVED	GROSS:ADRENAL GLANDS	AORTA	STERNUM	FEMUR	
SPLEEN	0.1125	0.421		JOINT	BRAIN	CECUM	COLON	
HEART	0.1972	0.739		DUODENUM	ESOPHAGUS	EYES/OPTIC N.	GALLBLADDER	
OVARIES/OVIDUCTS	0.0255	0.096		HEART	ILEUM	JEJUNUM	KIDNEYS	
ADRENAL GLANDS	0.0130	0.049		LYMPH NODE, MAND	LIVER	LYMPH NODE, MES	LUNGS	
FINAL BODY WT(G)	26.7			MAMMARY GLAND	NERVE, SCIATIC	OVIDUCTS	OVARIES	
				PANCREAS	PITUITARY	RECTUM	SPINAL CORD	
				SAL. GLAND MAND	STOMACH	SKELETAL MUSCLE	SKIN	
				SPLEEN	THYROID GLANDS	THYMUS	TRACHEA	
				URINARY BLADDER	UTERUS	VAGINA	CERVIX	
				PEYER'S PATCHES				
				MICRO:ADRENAL CORTEX	ADRENAL MEDULLA	AORTA	STERNUM	
				MARROW, STERN	FEMUR	MARROW, FEMUR	JOINT	
				BRAIN	CECUM	COLON	DUODENUM	
				ESOPHAGUS	EYES/OPTIC N.	GALLBLADDER	HEART	
				ILEUM	JEJUNUM	KIDNEYS	LYMPH NODE, MAND	
				LIVER	LYMPH NODE, MES	LUNGS	MAMMARY GLAND	
				NERVE, SCIATIC	OVIDUCTS	OVARIES	PANCREAS	
				PITUITARY	RECTUM	SPINAL CORD	SAL. GLAND MAND	
				STOMACH, GLAN	STOMACH, NON	SKELETAL MUSCLE	SKIN	
				SPLEEN	THYROID GLANDS	PARATHYROIDS	THYMUS	
				TRACHEA	URINARY BLADDER	UTERUS	VAGINA	
				CERVIX	PEYER'S PATCHES			

GROSS GRADE CODE: 1-SLIGHT, 2-MODERATE, 3-MARKED, P-PRESENT

MICRO GRADE CODE: 1-MINIMAL, 2-MILD, 3-MODERATE, 4-SEVERE, P-PRESENT

PROJECT NO.:WIL-639011 A SINGLE ORAL DOSE OF PMI-0105 WITH A 14-DAY RECOVERY IN MICE PAGE 25
 SPONSOR:SYNGENTA INDIVIDUAL MACROSCOPIC AND MICROSCOPIC FINDINGS

ANIMAL NO. 1663 GROUP 2: 2000 MG/KG FEMALE SCHEDULED EUTH 12/26/07 DATE OF DEATH: 12/26/07 STUDY DAY: 14
 GRADE

ORGAN WEIGHT	ABS.(G)	REL.	THYROID GLANDS	MICRO: NO SIGNIFICANT CHANGES OBSERVED
BRAIN	0.5013	1.928		ONE OF PAIR PRESENT; RECUT MADE AND EXAMINED.
LIVER/GB	1.0666	4.102	PARATHYROIDS	MICRO: NOT PRESENT FOR EXAMINATION
KIDNEYS	0.3269	1.257		PARATHYROIDS NOT IN PLANE OF SECTION.
SPLEEN	0.1012	0.389	NO SIGNIFICANT	
HEART	0.1509	0.580	CHANGES OBSERVED	GROSS:ADRENAL GLANDS AORTA STERNUM FEMUR
OVARIES/OVIDUCTS	0.0234	0.090		JOINT BRAIN CECUM COLON
ADRENAL GLANDS	0.0116	0.045		DUODENUM ESOPHAGUS EYES/OPTIC N. GALLBLADDER
FINAL BODY WT(G)	26.0			HEART ILEUM JEJUNUM KIDNEYS
				LYMPH NODE, MAND LIVER LYMPH NODE, MES LUNGS
				MAMMARY GLAND NERVE, SCIATIC OVIDUCTS OVARIES
				PANCREAS PITUITARY RECTUM SPINAL CORD
				SAL. GLAND MAND STOMACH SKELETAL MUSCLE SKIN
				SPLEEN THYROID GLANDS THYMUS TRACHEA
				URINARY BLADDER UTERUS VAGINA CERVIX
				PEYER'S PATCHES
				MICRO:ADRENAL CORTEX ADRENAL MEDULLA AORTA STERNUM
				MARROW, STERN FEMUR MARROW, FEMUR JOINT
				BRAIN CECUM COLON DUODENUM
				ESOPHAGUS EYES/OPTIC N. GALLBLADDER HEART
				ILEUM JEJUNUM KIDNEYS LYMPH NODE, MAND
				LIVER LYMPH NODE, MES LUNGS MAMMARY GLAND
				NERVE, SCIATIC OVIDUCTS OVARIES PANCREAS
				PITUITARY RECTUM SPINAL CORD SAL. GLAND MAND
				STOMACH, GLAN STOMACH, NON SKELETAL MUSCLE SKIN
				SPLEEN THYROID GLANDS THYMUS TRACHEA
				URINARY BLADDER UTERUS VAGINA CERVIX
				PEYER'S PATCHES

NOT PRESENT FOR EXAMINATION

MICRO:PARATHYROIDS

PROJECT NO.:WIL-639011
SPONSOR:SYNGENTA

TABLE A12
A SINGLE ORAL DOSE OF PMI-0105 WITH A 14-DAY RECOVERY IN MICE
INDIVIDUAL MACROSCOPIC AND MICROSCOPIC FINDINGS

PAGE 26

ANIMAL NO. 1663 GROUP 2: 2000 MG/KG FEMALE SCHEDULED EUTH 12/26/07 DATE OF DEATH: 12/26/07 STUDY DAY: 14
GRADE

GROSS GRADE CODE: 1-SLIGHT, 2-MODERATE, 3-MARKED, P-PRESENT

MICRO GRADE CODE: 1-MINIMAL, 2-MILD, 3-MODERATE, 4-SEVERE, P-PRESENT

PROJECT NO.:WIL-639011
 SPONSOR:SYNGENTA

TABLE A12
 A SINGLE ORAL DOSE OF PMI-0105 WITH A 14-DAY RECOVERY IN MICE
 INDIVIDUAL MACROSCOPIC AND MICROSCOPIC FINDINGS

PAGE 27

ANIMAL NO. 1664 GROUP 2: 2000 MG/KG FEMALE SCHEDULED EUTH 12/26/07 DATE OF DEATH: 12/26/07 STUDY DAY: 14
 GRADE

ORGAN WEIGHT	ABS.(G)	REL.	ADRENAL GLANDS	GROSS: ENLARGED					
BRAIN	0.4858	2.041		BILATERAL					P
LIVER/GB	1.1092	4.661	HEART	MICRO: INFLAMMATION, CHRONIC					1
KIDNEYS	0.3423	1.438		MINIMAL INFLAMMATION PRESENT IN RIGHT ATRIUM.					
SPLEEN	0.0727	0.305	OVARIES	GROSS: CYST(S)					P
HEART	0.1356	0.570		ONE, 4 MM IN DIAMETER, LEFT					
OVARIES/OVIDUCTS	0.0540	0.227	OVARIES	MICRO: CYST, BURSAL					P
ADRENAL GLANDS	0.0149	0.063	NO SIGNIFICANT						
FINAL BODY WT(G)	23.8		CHANGES OBSERVED	GROSS:AORTA	STERNUM	FEMUR	JOINT		
				BRAIN	CECUM	COLON	DUODENUM		
				ESOPHAGUS	EYES/OPTIC N.	GALLBLADDER	HEART		
				ILEUM	JEJUNUM	KIDNEYS	LYMPH NODE, MAND		
				LIVER	LYMPH NODE, MES	LUNGS	MAMMARY GLAND		
				NERVE, SCIATIC	OVIDUCTS	PANCREAS	PITUITARY		
				RECTUM	SPINAL CORD	SAL. GLAND MAND	STOMACH		
				SKELETAL MUSCLE	SKIN	SPLEEN	THYROID GLANDS		
				THYMUS	TRACHEA	URINARY BLADDER	UTERUS		
				VAGINA	CERVIX	PEYER'S PATCHES			
				MICRO:ADRENAL CORTEX	ADRENAL MEDULLA	AORTA	STERNUM		
				MARROW, STERN	FEMUR	MARROW, FEMUR	JOINT		
				BRAIN	CECUM	COLON	DUODENUM		
				ESOPHAGUS	EYES/OPTIC N.	GALLBLADDER	ILEUM		
				JEJUNUM	KIDNEYS	LYMPH NODE, MAND	LIVER		
				LYMPH NODE, MES	LUNGS	MAMMARY GLAND	NERVE, SCIATIC		
				OVIDUCTS	PANCREAS	PITUITARY	RECTUM		
				SPINAL CORD	SAL. GLAND MAND	STOMACH, GLAN	STOMACH, NON		
				SKELETAL MUSCLE	SKIN	SPLEEN	THYROID GLANDS		
				PARATHYROIDS	THYMUS	TRACHEA	URINARY BLADDER		
				UTERUS	VAGINA	CERVIX	PEYER'S PATCHES		

PROJECT NO.:WIL-639011
SPONSOR:SYNGENTA

TABLE A12
A SINGLE ORAL DOSE OF PMI-0105 WITH A 14-DAY RECOVERY IN MICE
INDIVIDUAL MACROSCOPIC AND MICROSCOPIC FINDINGS

PAGE 28

ANIMAL NO. 1664 GROUP 2: 2000 MG/KG FEMALE SCHEDULED EUTH 12/26/07 DATE OF DEATH: 12/26/07 STUDY DAY: 14
GRADE

GROSS/MICRO CORRELATIONS
GROSS FINDING

<====> CONFIRMING MICROSCOPIC FINDING

ADRENAL GLANDS: ENLARGED
OVARIES: CYST(S)

<====>GROSS UNCONFIRMED
<====>OVARIES: CYST, BURSAL

GROSS GRADE CODE: 1-SLIGHT, 2-MODERATE, 3-MARKED, P-PRESENT

MICRO GRADE CODE: 1-MINIMAL, 2-MILD, 3-MODERATE, 4-SEVERE, P-PRESENT

PROJECT NO.:WIL-639011
 SPONSOR:SYNGENTA

TABLE A12
 A SINGLE ORAL DOSE OF PMI-0105 WITH A 14-DAY RECOVERY IN MICE
 INDIVIDUAL MACROSCOPIC AND MICROSCOPIC FINDINGS

PAGE 29

ANIMAL NO. 1667 GROUP 2: 2000 MG/KG FEMALE SCHEDULED EUTH 12/26/07 DATE OF DEATH: 12/26/07 STUDY DAY: 14
 GRADE

ORGAN WEIGHT	ABS.(G)	REL.	KIDNEYS	MICRO: VACUOLATION, TUBULAR EPITHELIUM	1
BRAIN	0.4449	1.758		VACUOLATION CONSISTENT WITH PROCESSING ARTIFACT.	
LIVER/GB	1.1311	4.471	OVARIES	GROSS: CYST(S)	P
KIDNEYS	0.3503	1.385		ONE, 3 MM IN DIAMETER, RED FLUID FILLED, LEFT	
SPLEEN	0.1072	0.424	PITUITARY	MICRO: NOT PRESENT FOR EXAMINATION	
HEART	0.1310	0.518		NOT IN PLANE OF SECTION; RECUT MADE AND EXAMINED.	
OVARIES/OVIDUCTS	0.0291	0.115	PARATHYROIDS	MICRO: NOT PRESENT FOR EXAMINATION	
ADRENAL GLANDS	0.0106	0.042		PARATHYROIDS NOT IN PLANE OF SECTION.	
FINAL BODY WT(G)	25.3		NO SIGNIFICANT CHANGES OBSERVED	GROSS:ADRENAL GLANDS AORTA STERNUM FEMUR JOINT BRAIN CECUM COLON DUODENUM ESOPHAGUS EYES/OPTIC N. GALLBLADDER HEART ILEUM JEJUNUM KIDNEYS LYMPH NODE, MAND LIVER LYMPH NODE, MES LUNGS MAMMARY GLAND NERVE, SCIATIC OVIDUCTS PANCREAS PITUITARY RECTUM SPINAL CORD SAL. GLAND MAND STOMACH SKELETAL MUSCLE SKIN SPLEEN THYROID GLANDS THYMUS TRACHEA URINARY BLADDER UTERUS VAGINA CERVIX PEYER'S PATCHES MICRO:ADRENAL CORTEX ADRENAL MEDULLA AORTA STERNUM MARROW, STERN FEMUR MARROW, FEMUR JOINT BRAIN CECUM COLON DUODENUM ESOPHAGUS EYES/OPTIC N. GALLBLADDER HEART ILEUM JEJUNUM LYMPH NODE, MAND LIVER LYMPH NODE, MES LUNGS MAMMARY GLAND NERVE, SCIATIC OVIDUCTS OVARIES PANCREAS RECTUM SPINAL CORD SAL. GLAND MAND STOMACH, GLAN STOMACH, NON SKELETAL MUSCLE SKIN SPLEEN THYROID GLANDS THYMUS TRACHEA URINARY BLADDER UTERUS	

PROJECT NO.:WIL-639011
SPONSOR:SYNGENTA

TABLE A12
A SINGLE ORAL DOSE OF PMI-0105 WITH A 14-DAY RECOVERY IN MICE
INDIVIDUAL MACROSCOPIC AND MICROSCOPIC FINDINGS

PAGE 30

ANIMAL NO. 1667 GROUP 2: 2000 MG/KG FEMALE SCHEDULED EUTH 12/26/07 DATE OF DEATH: 12/26/07 STUDY DAY: 14
GRADE

VAGINA CERVIX PEYER'S PATCHES
NOT PRESENT FOR EXAMINATION
MICRO:PITUITARY PARATHYROIDS
GROSS/MICRO CORRELATIONS
GROSS FINDING <====> CONFIRMING MICROSCOPIC FINDING

OVARIES: CYST(S) <====>GROSS UNCONFIRMED

GROSS GRADE CODE: 1-SLIGHT, 2-MODERATE, 3-MARKED, P-PRESENT

MICRO GRADE CODE: 1-MINIMAL, 2-MILD, 3-MODERATE, 4-SEVERE, P-PRESENT

PGRHv4.59
02/27/2008
R:03/20/2009

PROJECT NO.:WIL-639011
 SPONSOR:SYNGENTA

TABLE A13
 A SINGLE ORAL DOSE OF PMI-0105 WITH A 14-DAY RECOVERY IN MICE
 INDIVIDUAL ORGAN WEIGHTS AND FINAL BODY WEIGHTS [G]

PAGE 1
 DAY 14

MALE GROUP: 0 MG/KG

ANIMAL	FBW(G)	BRAIN	LIVE R/GB	KIDNEYS	SPLEEN	HEART	EPIDID YMIDES	TESTES	ADRENAL GLANDS
1639	32.9	0.4465	1.6142	0.6976	0.1008	0.1859	0.1039	0.2966	0.0044
1642	36.0	0.4787	1.6734	0.6315	0.0889	0.1752	0.1135	0.2798	0.0102
1645	35.9	0.4736	1.5842	0.5776	0.0766	0.1745	0.1220	0.2516	0.0062
1651	34.7	0.5121	1.7326	0.5707	0.0981	0.1872	0.1204	0.2735	0.0083
1652	35.1	0.5170	1.7701	0.6298	0.1044	0.2110	0.0942	0.2449	0.0052
MEAN	34.9	0.4856	1.6749	0.6214	0.0938	0.1868	0.1108	0.2693	0.0069
S.D.	1.25	0.02919	0.07795	0.05116	0.01118	0.01477	0.01171	0.02111	0.00237
S.E.	0.56	0.01305	0.03486	0.02288	0.00500	0.00660	0.00523	0.00944	0.00106
N	5	5	5	5	5	5	5	5	5

FBW = FINAL BODY WEIGHT

PROJECT NO.:WIL-639011
 SPONSOR:SYNGENTA

TABLE A13
 A SINGLE ORAL DOSE OF PMI-0105 WITH A 14-DAY RECOVERY IN MICE
 INDIVIDUAL ORGAN WEIGHTS AND FINAL BODY WEIGHTS [G]

PAGE 2
 DAY 14

MALE GROUP: 2000 MG/KG

ANIMAL	FBW(G)	BRAIN	LIVE R/GB	KIDNEYS	SPLEEN	HEART	EPIDID YMIDES	TESTES	ADRENAL GLANDS
1638	35.3	0.4644	1.7010	0.5654	0.0852	0.1914	0.0854	0.1824	0.0052
1641	30.9	0.5102	1.5105	0.5230	0.0641	0.1547	0.0762	0.2012	0.0064
1648	35.6	0.4916	1.7352	0.6111	0.0796	0.1839	0.0791	0.1587	0.0040
1649	33.6	0.4854	1.6695	0.6281	0.0681	0.2189	0.0876	0.1923	0.0058
1650	33.6	0.4753	1.6362	0.5573	0.0918	0.2277	0.0912	0.2227	0.0053
MEAN	33.8	0.4854	1.6505	0.5770	0.0778	0.1953	0.0839	0.1915	0.0053
S.D.	1.87	0.01730	0.08644	0.04246	0.01157	0.02916	0.00616	0.02359	0.00089
S.E.	0.84	0.00773	0.03866	0.01899	0.00518	0.01304	0.00275	0.01055	0.00040
N	5	5	5	5	5	5	5	5	5

FBW = FINAL BODY WEIGHT

PROJECT NO.:WIL-639011
 SPONSOR:SYNGENTA

TABLE A13
 A SINGLE ORAL DOSE OF PMI-0105 WITH A 14-DAY RECOVERY IN MICE
 INDIVIDUAL ORGAN WEIGHTS AND FINAL BODY WEIGHTS [G]

PAGE 3
 DAY 14

FEMALE GROUP: 0 MG/KG

ANIMAL	FBW(G)	BRAIN	LIVE R/GB	KIDNEYS	SPLEEN	HEART	OVARIES/OVIDUCTS	ADRENAL GLANDS
1656	26.4	0.5132	1.2538	0.3740	0.0973	0.1470	0.0222	0.0109
1658	25.1	0.4812	1.2275	0.3489	0.0943	0.1503	0.0264	0.0077
1659	25.8	0.4704	1.3059	0.3694	0.0860	0.1574	0.0231	0.0104
1665	21.9	0.4539	1.1414	0.3306	0.1727	0.1371	0.0201	0.0095
1666	26.4	0.4896	1.3010	0.3379	0.0947	0.1453	0.0215	0.0094
MEAN	25.1	0.4817	1.2459	0.3522	0.1090	0.1474	0.0227	0.0096
S.D.	1.88	0.02211	0.06700	0.01906	0.03586	0.00740	0.00236	0.00122
S.E.	0.84	0.00989	0.02996	0.00852	0.01604	0.00331	0.00106	0.00055
N	5	5	5	5	5	5	5	5

FBW = FINAL BODY WEIGHT

PROJECT NO.:WIL-639011
 SPONSOR:SYNGENTA

TABLE A13
 A SINGLE ORAL DOSE OF PMI-0105 WITH A 14-DAY RECOVERY IN MICE
 INDIVIDUAL ORGAN WEIGHTS AND FINAL BODY WEIGHTS [G]

PAGE 4
 DAY 14

FEMALE GROUP: 2000 MG/KG

ANIMAL	FBW(G)	BRAIN	LIVE R/GB	KIDNEYS	SPLEEN	HEART	OVARIES/OVIDUCTS	ADRENAL GLANDS
1655	26.9	0.5057	1.3701	0.3676	0.0944	0.1500	0.0248	0.0123
1662	26.7	0.5203	1.4006	0.4086	0.1125	0.1972	0.0255	0.0130
1663	26.0	0.5013	1.0666	0.3269	0.1012	0.1509	0.0234	0.0116
1664	23.8	0.4858	1.1092	0.3423	0.0727	0.1356	0.0540	0.0149
1667	25.3	0.4449	1.1311	0.3503	0.1072	0.1310	0.0291	0.0106
MEAN	25.7	0.4916	1.2155	0.3591	0.0976	0.1529	0.0314	0.0125
S.D.	1.25	0.02886	0.15713	0.03130	0.01547	0.02624	0.01283	0.00162
S.E.	0.56	0.01291	0.07027	0.01400	0.00692	0.01173	0.00574	0.00072
N	5	5	5	5	5	5	5	5

FBW = FINAL BODY WEIGHT

POFBWv4.14
 02/27/2008
 R:03/20/2009

PROJECT NO.:WIL-639011
 SPONSOR:SYNGENTA

TABLE A14
 A SINGLE ORAL DOSE OF PMI-0105 WITH A 14-DAY RECOVERY IN MICE
 INDIVIDUAL ORGAN WTS. RELATIVE TO FINAL BODY WTS. [G/100 G]

PAGE 1
 DAY 14

MALE GROUP: 0 MG/KG

ANIMAL	FBW(G)	BRAIN	LIVE R/GB	KIDNEYS	SPLEEN	HEART	EPIDID YMIDES	TESTES	ADRENAL GLANDS
1639	32.9	1.357	4.906	2.120	0.306	0.565	0.316	0.902	0.013
1642	36.0	1.330	4.648	1.754	0.247	0.487	0.315	0.777	0.028
1645	35.9	1.319	4.413	1.609	0.213	0.486	0.340	0.701	0.017
1651	34.7	1.476	4.993	1.645	0.283	0.539	0.347	0.788	0.024
1652	35.1	1.473	5.043	1.794	0.297	0.601	0.268	0.698	0.015
MEAN	34.9	1.391	4.801	1.784	0.269	0.536	0.317	0.773	0.019
S.D.	1.25	0.0775	0.2648	0.2024	0.0386	0.0499	0.0310	0.0832	0.0063
S.E.	0.56	0.0346	0.1184	0.0905	0.0173	0.0223	0.0138	0.0372	0.0028
N	5	5	5	5	5	5	5	5	5

FBW = FINAL BODY WEIGHT

PROJECT NO.:WIL-639011
 SPONSOR:SYNGENTA

TABLE A14
 A SINGLE ORAL DOSE OF PMI-0105 WITH A 14-DAY RECOVERY IN MICE
 INDIVIDUAL ORGAN WTS. RELATIVE TO FINAL BODY WTS. [G/100 G]

PAGE 2
 DAY 14

MALE GROUP: 2000 MG/KG

ANIMAL	FBW(G)	BRAIN	LIVE R/GB	KIDNEYS	SPLEEN	HEART	EPIDID YMIDES	TESTES	ADRENAL GLANDS
1638	35.3	1.316	4.819	1.602	0.241	0.542	0.242	0.517	0.015
1641	30.9	1.651	4.888	1.693	0.207	0.501	0.247	0.651	0.021
1648	35.6	1.381	4.874	1.717	0.224	0.517	0.222	0.446	0.011
1649	33.6	1.445	4.969	1.869	0.203	0.651	0.261	0.572	0.017
1650	33.6	1.415	4.870	1.659	0.273	0.678	0.271	0.663	0.016
MEAN	33.8	1.442	4.884	1.708	0.230	0.578	0.249	0.570	0.016
S.D.	1.87	0.1265	0.0542	0.0998	0.0286	0.0810	0.0188	0.0914	0.0036
S.E.	0.84	0.0566	0.0243	0.0446	0.0128	0.0362	0.0084	0.0409	0.0016
N	5	5	5	5	5	5	5	5	5

FBW = FINAL BODY WEIGHT

PROJECT NO.:WIL-639011
 SPONSOR:SYNGENTA

TABLE A14
 A SINGLE ORAL DOSE OF PMI-0105 WITH A 14-DAY RECOVERY IN MICE
 INDIVIDUAL ORGAN WTS. RELATIVE TO FINAL BODY WTS. [G/100 G]

PAGE 3
 DAY 14

FEMALE GROUP: 0 MG/KG

ANIMAL	FBW(G)	BRAIN	LIVE R/GB	KIDNEYS	SPLEEN	HEART	OVARIES/OVIDUCTS	ADRENAL GLANDS
1656	26.4	1.944	4.749	1.417	0.369	0.557	0.084	0.041
1658	25.1	1.917	4.890	1.390	0.376	0.599	0.105	0.031
1659	25.8	1.823	5.062	1.432	0.333	0.610	0.090	0.040
1665	21.9	2.073	5.212	1.510	0.789	0.626	0.092	0.043
1666	26.4	1.855	4.928	1.280	0.359	0.550	0.081	0.036
MEAN	25.1	1.922	4.968	1.406	0.445	0.588	0.090	0.038
S.D.	1.88	0.0970	0.1761	0.0833	0.1929	0.0334	0.0093	0.0048
S.E.	0.84	0.0434	0.0787	0.0372	0.0863	0.0149	0.0042	0.0021
N	5	5	5	5	5	5	5	5

FBW = FINAL BODY WEIGHT

PROJECT NO.:WIL-639011
 SPONSOR:SYNGENTA

TABLE A14
 A SINGLE ORAL DOSE OF PMI-0105 WITH A 14-DAY RECOVERY IN MICE
 INDIVIDUAL ORGAN WTS. RELATIVE TO FINAL BODY WTS. [G/100 G]

PAGE 4
 DAY 14

FEMALE GROUP: 2000 MG/KG

ANIMAL	FBW(G)	BRAIN	LIVE R/GB	KIDNEYS	SPLEEN	HEART	OVARIES/OVIDUCTS	ADRENAL GLANDS
1655	26.9	1.880	5.093	1.367	0.351	0.558	0.092	0.046
1662	26.7	1.949	5.246	1.530	0.421	0.739	0.096	0.049
1663	26.0	1.928	4.102	1.257	0.389	0.580	0.090	0.045
1664	23.8	2.041	4.661	1.438	0.305	0.570	0.227	0.063
1667	25.3	1.758	4.471	1.385	0.424	0.518	0.115	0.042
MEAN	25.7	1.911	4.715	1.395	0.378	0.593	0.124	0.049
S.D.	1.25	0.1037	0.4645	0.1000	0.0504	0.0849	0.0584	0.0082
S.E.	0.56	0.0464	0.2077	0.0447	0.0225	0.0380	0.0261	0.0037
N	5	5	5	5	5	5	5	5

FBW = FINAL BODY WEIGHT

POFBWv4.14
 02/27/2008
 R:03/20/2009

PROJECT NO.:WIL-639011
 SPONSOR:SYNGENTA

TABLE A15
 A SINGLE ORAL DOSE OF PMI-0105 WITH A 14-DAY RECOVERY IN MICE
 INDIVIDUAL ORGAN WEIGHTS RELATIVE TO BRAIN WEIGHTS [G/100 G]

PAGE 1
 DAY 14

MALE GROUP: 0 MG/KG

ANIMAL	FBW(G)	BRAIN WT (GRAMS)	LIVE R/GB	KIDNEYS	SPLEEN	HEART	EPIDID YMIDES	TESTES	ADRENAL GLANDS
1639	32.9	0.4465	361.523	156.237	22.576	41.635	23.270	66.428	0.985
1642	36.0	0.4787	349.572	131.920	18.571	36.599	23.710	58.450	2.131
1645	35.9	0.4736	334.502	121.959	16.174	36.845	25.760	53.125	1.309
1651	34.7	0.5121	338.332	111.443	19.156	36.555	23.511	53.408	1.621
1652	35.1	0.5170	342.379	121.818	20.193	40.812	18.221	47.369	1.006
MEAN	34.9	0.4856	345.262	128.675	19.334	38.489	22.894	55.756	1.410
S.D.	1.25	0.02919	10.6666	17.0239	2.3371	2.5154	2.7946	7.1401	0.4792
S.E.	0.56	0.01305	4.7702	7.6133	1.0452	1.1249	1.2498	3.1932	0.2143
N	5	5	5	5	5	5	5	5	5

FBW = FINAL BODY WEIGHT

PROJECT NO.:WIL-639011
 SPONSOR:SYNGENTA

TABLE A15
 A SINGLE ORAL DOSE OF PMI-0105 WITH A 14-DAY RECOVERY IN MICE
 INDIVIDUAL ORGAN WEIGHTS RELATIVE TO BRAIN WEIGHTS [G/100 G]

PAGE 2
 DAY 14

MALE GROUP: 2000 MG/KG

ANIMAL	FBW(G)	BRAIN WT (GRAMS)	LIVE R/GB	KIDNEYS	SPLEEN	HEART	EPIDID YMIDES	TESTES	ADRENAL GLANDS
1638	35.3	0.4644	366.279	121.749	18.346	41.214	18.389	39.276	1.120
1641	30.9	0.5102	296.060	102.509	12.564	30.321	14.935	39.436	1.254
1648	35.6	0.4916	352.970	124.308	16.192	37.408	16.090	32.282	0.814
1649	33.6	0.4854	343.943	129.398	14.030	45.097	18.047	39.617	1.195
1650	33.6	0.4753	344.246	117.252	19.314	47.907	19.188	46.855	1.115
MEAN	33.8	0.4854	340.700	119.043	16.089	40.389	17.330	39.493	1.100
S.D.	1.87	0.01730	26.5549	10.2329	2.8359	6.8851	1.7579	5.1542	0.1697
S.E.	0.84	0.00773	11.8757	4.5763	1.2683	3.0791	0.7862	2.3050	0.0759
N	5	5	5	5	5	5	5	5	5

FBW = FINAL BODY WEIGHT

PROJECT NO.:WIL-639011
 SPONSOR:SYNGENTA

TABLE A15
 A SINGLE ORAL DOSE OF PMI-0105 WITH A 14-DAY RECOVERY IN MICE
 INDIVIDUAL ORGAN WEIGHTS RELATIVE TO BRAIN WEIGHTS [G/100 G]

PAGE 3
 DAY 14

FEMALE GROUP: 0 MG/KG

ANIMAL	FBW(G)	BRAIN WT (GRAMS)	LIVE R/GB	KIDNEYS	SPLEEN	HEART	OVARIES/ OVIDUCTS	ADRENAL GLANDS
1656	26.4	0.5132	244.310	72.876	18.959	28.644	4.326	2.124
1658	25.1	0.4812	255.091	72.506	19.597	31.234	5.486	1.600
1659	25.8	0.4704	277.615	78.529	18.282	33.461	4.911	2.211
1665	21.9	0.4539	251.465	72.835	38.048	30.205	4.428	2.093
1666	26.4	0.4896	265.727	69.016	19.342	29.677	4.391	1.920
MEAN	25.1	0.4817	258.842	73.152	22.846	30.644	4.708	1.990
S.D.	1.88	0.02211	13.0337	3.4137	8.5128	1.8311	0.4928	0.2421
S.E.	0.84	0.00989	5.8288	1.5266	3.8071	0.8189	0.2204	0.1083
N	5	5	5	5	5	5	5	5

FBW = FINAL BODY WEIGHT

PROJECT NO.:WIL-639011
 SPONSOR:SYNGENTA

TABLE A15
 A SINGLE ORAL DOSE OF PMI-0105 WITH A 14-DAY RECOVERY IN MICE
 INDIVIDUAL ORGAN WEIGHTS RELATIVE TO BRAIN WEIGHTS [G/100 G]

PAGE 4
 DAY 14

FEMALE GROUP: 2000 MG/KG

ANIMAL	FBW(G)	BRAIN WT (GRAMS)	LIVE R/GB	KIDNEYS	SPLEEN	HEART	OVARIES/ OVIDUCTS	ADRENAL GLANDS
1655	26.9	0.5057	270.931	72.691	18.667	29.662	4.904	2.432
1662	26.7	0.5203	269.191	78.532	21.622	37.901	4.901	2.499
1663	26.0	0.5013	212.767	65.210	20.188	30.102	4.668	2.314
1664	23.8	0.4858	228.324	70.461	14.965	27.913	11.116	3.067
1667	25.3	0.4449	254.237	78.737	24.095	29.445	6.541	2.383
MEAN	25.7	0.4916	247.090	73.126	19.907	31.005	6.426	2.539
S.D.	1.25	0.02886	25.6815	5.7154	3.4103	3.9423	2.7268	0.3028
S.E.	0.56	0.01291	11.4851	2.5560	1.5251	1.7631	1.2195	0.1354
N	5	5	5	5	5	5	5	5

FBW = FINAL BODY WEIGHT

POFBWv4.14
 02/27/2008
 R:03/20/2009